
<html lang="en"     class="pb-page"  data-request-id="e085cae9-7c62-4588-a87a-110a7bf4ce7b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c01484;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue" /></meta><meta name="dc.Creator" content="Yang  Liu" /></meta><meta name="dc.Creator" content="Hanying  Ruan" /></meta><meta name="dc.Creator" content="Ying  Li" /></meta><meta name="dc.Creator" content="Guoliang  Sun" /></meta><meta name="dc.Creator" content="Xiao  Liu" /></meta><meta name="dc.Creator" content="Wenhui  He" /></meta><meta name="dc.Creator" content="Fengfeng  Mao" /></meta><meta name="dc.Creator" content="Miaomiao  He" /></meta><meta name="dc.Creator" content="Liwei  Yan" /></meta><meta name="dc.Creator" content="Guocai  Zhong" /></meta><meta name="dc.Creator" content="Huan  Yan" /></meta><meta name="dc.Creator" content="Wenhui  Li" /></meta><meta name="dc.Creator" content="Zhiyuan  Zhang" /></meta><meta name="dc.Description" content="Analogues of the natural product cyclosporine A (CsA) were developed and assessed as antivirals against infection of hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). An analogue t..." /></meta><meta name="Description" content="Analogues of the natural product cyclosporine A (CsA) were developed and assessed as antivirals against infection of hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). An analogue t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 28, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01484" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01484" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01484" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01484" /></link>
        
    
    

<title>Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01484" /></meta><meta property="og:title" content="Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0013.jpeg" /></meta><meta property="og:description" content="Analogues of the natural product cyclosporine A (CsA) were developed and assessed as antivirals against infection of hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). An analogue termed 27A exhibits potent inhibition of HBV/HDV infection by specifically blocking viral engagement to its cellular receptor NTCP, while it lacks immunosuppressive activity found in natural CsA. Intraperitoneal injection or oral intake of 27A protects HDV-susceptible mouse model from HDV infection. 27A serves as a promising lead for the development of novel anti-HDV/HBV agents." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01484"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01484">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01484&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01484&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01484&amp;href=/doi/10.1021/acs.jmedchem.0c01484" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 543-565</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01477" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01522" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div><div class="loa-info-affiliations-info">Graduate Program, Tsinghua University, Beijing 100084, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Liu">Yang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hanying Ruan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hanying Ruan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hanying++Ruan">Hanying Ruan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ying Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ying Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ying++Li">Ying Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guoliang Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guoliang Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div><div class="loa-info-affiliations-info">Graduate Program, Peking University, Beijing 100080, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guoliang++Sun">Guoliang Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiao Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiao Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiao++Liu">Xiao Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenhui He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenhui He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenhui++He">Wenhui He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fengfeng Mao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fengfeng Mao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fengfeng++Mao">Fengfeng Mao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Miaomiao He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Miaomiao He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div><div class="loa-info-affiliations-info">Graduate Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Miaomiao++He">Miaomiao He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liwei Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liwei Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liwei++Yan">Liwei Yan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guocai Zhong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guocai Zhong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guocai++Zhong">Guocai Zhong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huan Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huan Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huan++Yan">Huan Yan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenhui Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenhui Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e5898c92808b8d908ca58b8c8796cb8486cb868b"><span class="__cf_email__" data-cfemail="6e0207190b00061b072e00070c1d400f0d400d00">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenhui++Li">Wenhui Li</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Zhiyuan Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiyuan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Biological Sciences, Beijing 102206, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#205a48414e475a48495955414e604e4942530e41430e434e"><span class="__cf_email__" data-cfemail="4c36242d222b36242535392d220c22252e3f622d2f622f22">[email protected]</span></a>. Tel: +86-10-80726688-8575.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiyuan++Zhang">Zhiyuan Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2910-1986" title="Orcid link">http://orcid.org/0000-0002-2910-1986</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01484&amp;href=/doi/10.1021%2Facs.jmedchem.0c01484" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 543–565</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 28, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 August 2020</li><li><span class="item_label"><b>Published</b> online</span>28 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01484" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01484</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D543%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYang%2BLiu%252C%2BHanying%2BRuan%252C%2BYing%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D1%26contentID%3Dacs.jmedchem.0c01484%26title%3DPotent%2Band%2BSpecific%2BInhibition%2Bof%2BNTCP-Mediated%2BHBV%252FHDV%2BInfection%2Band%2BSubstrate%2BTransporting%2Bby%2Ba%2BNovel%252C%2BOral-Available%2BCyclosporine%2BA%2BAnalogue%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D565%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01484"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">876</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01484" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Hanying&quot;,&quot;last_name&quot;:&quot;Ruan&quot;},{&quot;first_name&quot;:&quot;Ying&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Guoliang&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Xiao&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Wenhui&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Fengfeng&quot;,&quot;last_name&quot;:&quot;Mao&quot;},{&quot;first_name&quot;:&quot;Miaomiao&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Liwei&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Guocai&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Huan&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Wenhui&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhiyuan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;543-565&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01484&quot;},&quot;abstract&quot;:&quot;Analogues of the natural product cyclosporine A (CsA) were developed and assessed as antivirals against infection of hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). An analogue termed 27A exhibits potent inhibition of HBV/HDV infection by specifically blocking viral engagement to its cellular receptor NTCP, while it lacks immunosuppressive activity found in natural CsA. Intraperitoneal injection or oral intake of 27A protects HDV-susceptible mouse model from HDV infection. 27A serves as a promising lead for the development of novel anti-HDV/HBV agents.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01484&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01484" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01484&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01484" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01484&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01484" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01484&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01484&amp;href=/doi/10.1021/acs.jmedchem.0c01484" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01484" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01484" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01484%26sid%3Dliteratum%253Aachs%26pmid%3D33369415%26genre%3Darticle%26aulast%3DLiu%26date%3D2021%26atitle%3DPotent%2Band%2BSpecific%2BInhibition%2Bof%2BNTCP-Mediated%2BHBV%252FHDV%2BInfection%2Band%2BSubstrate%2BTransporting%2Bby%2Ba%2BNovel%252C%2BOral-Available%2BCyclosporine%2BA%2BAnalogue%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D1%26spage%3D543%26epage%3D565%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/jmcmar.2021.64.issue-1/20210114/jmcmar.2021.64.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Analogues of the natural product cyclosporine A (CsA) were developed and assessed as antivirals against infection of hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). An analogue termed <b>27A</b> exhibits potent inhibition of HBV/HDV infection by specifically blocking viral engagement to its cellular receptor NTCP, while it lacks immunosuppressive activity found in natural CsA. Intraperitoneal injection or oral intake of <b>27A</b> protects HDV-susceptible mouse model from HDV infection. <b>27A</b> serves as a promising lead for the development of novel anti-HDV/HBV agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43607" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43607" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatitis B virus (HBV) infection remains a major global public health problem; chronic HBV infection and related diseases cause around 1 million deaths annually worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> HDV is a satellite virus of HBV and replicates only in the presence of envelope proteins of HBV.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Co-infection of HBV with HDV represents the most severe viral hepatitis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Identification of sodium taurocholate co-transporting peptide (NTCP, encoded by the <i>SLC10A1</i> gene) as a cellular receptor for both HBV and HDV significantly advanced our understanding of the viral infections.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> NTCP is a bile acid transporter that predominantly expressed on the sinusoidal membrane of hepatocytes, and its expression is subjected to complicated regulation of liver-specific transcription factors and microenvironment.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> NTCP-mediated HBV infection initiates from the specific interaction between the HBV Pre-S1 domain of the large envelope protein (L) and NTCP.<a onclick="showRef(event, 'ref5 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref5 ref8 ref9">(5,8,9)</a> A small motif of NTCP-containing residues 157–165 is essential for HBV Pre-S1 binding, and it is responsible for the species specificity of HBV infection between human and nonhuman primates.<a onclick="showRef(event, 'ref5 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref5 ref10 ref11">(5,10,11)</a> Moreover, residues required for NTCP uptake of its substrates are also employed by HBV and HDV entry.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Consistent with this, bile acids, the natural substrates of NTCP, and their derivatives were demonstrated to reduce Pre-S1-NTCP binding and viral infection.<a onclick="showRef(event, 'ref10 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref12 ref13">(10,12,13)</a> Furthermore, NTCP variant rs2296651 (Ser267Phe), which loses taurocholate transport activity and the ability to support HBV infection <i>in vitro</i>,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> was reported to be inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Collectively, these studies indicate that NTCP is a promising therapeutic target for antivirals against the viral infection.</div><div class="NLM_p">To date, several classes of small-molecular inhibitors targeting NTCP have been identified. A structure–activity relationship study using computational analysis and pharmacophore characteristics of NTCP substrates estimated 31 FDA-approved drugs as potential NTCP inhibitors.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Some of those drugs, including cyclosporine A,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> irbesartan, ritonavir,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and ezetimibe,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> have been tested for their activity against HBV/HDV infection on cell cultures. Bile acid derivatives and cholesterol derivatives<a onclick="showRef(event, 'ref10 ref12 ref13 ref20'); return false;" href="javascript:void(0);" class="ref ref10 ref12 ref13 ref20">(10,12,13,20)</a> that have similar structures to substrates of NTCP were also reported as HBV entry inhibitors. However, none of these compounds were tested <i>in vivo</i> against HBV.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Myrcludex B, the first-in-class and only NTCP inhibitor under clinical development, is a synthetic lipopeptide derived from the Pre-S1 domain of the HBV envelope protein.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Its safety and effectiveness in patients co-infected with HBV and HDV have been confirmed in Phase II clinical trial.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> However, Myrcludex B needs to be administrated via subcutaneous injection, developing novel and oral-available NTCP inhibitor is desirable.</div><div class="NLM_p last">Cyclosporine A (CsA) is a cyclic peptide comprising 11 amino acids that was originally isolated from the ascomycete fungus <i>Tolypocladium inflatum</i>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> It is widely used in the clinic as an immunosuppressive drug for organ transplantation patients. Previous work has shown that CsA inhibits bile acids uptake by NTCP<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> and NTCP-mediated HBV and HDV entry.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> In this study, we report the synthesis of a large series of CsA analogues. We also used NTCP-complemented HepG2 cells, which are susceptible to HBV and HDV infection, to assess the antiviral activities of these analogues using <i>in vitro</i> HBV/HDV infection assays. We ultimately obtained a highly potent and very specific compound that targets NTCP, and we used multiple approaches to assess its antiviral mechanism and to verify its activity <i>in vivo</i>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87048" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87048" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The synthesis route for the five-membered ring series of CsA analogues is depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>,<a class="ref internalNav" href="#sch2" aria-label="2">2</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. The olefinic bond of CsA <b>1</b> was broken down to form an aldehyde by ozone, which then self-cyclized to give compound <b>2</b>. A methylated product compound <b>3</b> was synthesized from compound <b>2</b> by carrying out a reaction in methanol in the presence of <i>p</i>-toluenesulfonic acid. Another analogue compound <b>4</b> was prepared through three steps: reduction of hemiacetal <b>2</b> in methanol in the presence of reducing reagent NaBH<sub>4</sub> gave the ring-opening product compound <b>5</b>, which was then reacted with MsCl and triethylamine (TEA) and instinctively self-cyclized to give target compound <b>4</b>. The ketone analogue <b>6</b> was obtained by treating compound <b>1</b> with Jones reagent. Compound <b>6</b> was converted to compound <b>7</b> via a Witting reaction. Hydrogenation of compound <b>7</b> using 10% Pd/C in MeOH gave compound <b>8</b>.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>3</b>, <b>4</b>, <b>7</b>, and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) O<sub>3</sub>, Me<sub>2</sub>S, dichloromethane (DCM), −78 °C, 30 min; (b) MeOH, <i>p</i>-TsOH, room temperature (RT), 16 h; (c) NaBH<sub>4</sub>, MeOH, RT, 16 h; (d) MsCl, triethylamine (TEA), DCM, 0 °C then RT, overnight; (e) Jones reagent, acetone, 0 °C then RT, overnight; (f) <i>t</i>-BuOK, methyltriphenylphosphonium bromide, tetrahydrofuran (THF), −78 °C then 0 °C, 3 h; (g) 10% Pd/C, MeOH, H<sub>2</sub>, 1 atm, RT, 16 h.</p></p></figure><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>10</b>–<b>52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) acetic anhydride (Ac<sub>2</sub>O), pyridine (Py), RT, overnight; (b) appropriate mercapto heterocyclic and aromatic, trimethylsilyl trifluoromethanesulfonate (TMSOTf), <i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide (BSA), acetonitrile (ACN), 50 °C, 90 min; (c) methyl 2-hydroxyacetate or methyl 3-hydroxypropanoate, silver trifluoromethanesulfonate, activated 3 Å molecular sieves, DCM, RT, 2 h; NIS, activated 3 Å molecular sieves, ACN, RT, 2 h; (d) 1 N NaOH, MeOH, RT, 4.5 h; (e) 3-(benzyloxy)phenol or 3,5-dimethoxyphenol, FeCl<sub>3</sub>, 3 Å molecular sieves, DCM, RT, 16 h.</p></p></figure><div class="NLM_p">The synthetic routes for compounds <b>10</b>–<b>52</b> are illustrated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. We started from preparing a common intermediate compound <b>9</b> by acetylation of compound <b>2</b> with acetic anhydride in pyridine. The designed five-membered ring analogues of CsA, compound <b>10</b>, and compounds <b>14</b>–<b>42</b> and <b>45</b>–<b>52</b> were synthesized by treating the intermediate <b>9</b> with various mercapto heterocyclics and mercapto aromatics together with trimethylsilyl trifluoromethanesulfonate (TMSOTf) and <i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide (BSA) in acetonitrile (CH<sub>3</sub>CN), as a mixture of α,β racemic. Normally, the major product (isoform A) could be separated and defined by a typical double-doublets peak with J-coupling constants of 6.4 and 8.8 Hz around δ 4.2–4.4 ppm in the <sup>1</sup>H NMR spectrum as a character signal. The isoform B could be isolated as a minor product (dd, <i>J</i> = 6.0, 8.0 Hz, δ around 4.0–4.15 Hz) occasionally.</div><div class="NLM_p last">Compound <b>10</b> was also used as a starting material for the synthesis of the O-linked compounds <b>11</b>–<b>12</b> by reacting with methyl 2-hydroxyacetate or methyl 3-hydroxypropanoate, respectively. Hydrolysis of <b>12</b> gave the acid derivative <b>13</b>. Other O-linked CsA analogue compounds <b>43</b> and <b>44</b> were prepared via treating compound <b>2</b> with 3,5-dimethoxyphenol or 3-(benzyloxy) phenol catalyzed by Lewis acid FeCl<sub>3</sub> in the presence of dry 3 Å molecular sieves. Both of isomers <b>43A</b> and <b>43B</b> were separated through diligent chromatography. Unfortunately, we could not distinguish the α or β isomers from the NMR-<sup>1</sup>H spectrum. Attempts of characterization by X-ray crystal structure to find the right configuration failed, as we could not obtain either crystal form of two isomers.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Rational Design of an NTCP Inhibitor</h3><div class="NLM_p">Since NTCP was discovered as the key receptor for HBV and HDV infection, a few research groups have reported a number of small-molecule NTCP inhibitors, such as bile acid analogues and CsA derivatives,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> that are able to block virus infection. In our hands, the natural product CsA showed inhibition at IC<sub>50</sub> of 5.8 and 1 μM against HBV and HDV infection in cell assays, respectively, indicating a good starting hit to continue medicinal chemist effort to improve its potency. We noted that previously reported CsA-based structures, which were generated by replacing or modifying some residues on the cyclic peptide macrocycle, did not have much potency improvement, even though intensive effort had been made toward compound synthesis. Our attention then focused on the unusual butenyl-methyl-threonine (BMT) amino acid as it has two workable (olefin and hydroxyl) functional groups for further derivatizing.</div><div class="NLM_p">As we have little structure–activity relationship (SAR) information about CsA against HBV and HDV interaction with NTCP, we started with design and synthesis of a few long-chain analogues by manipulating the olefin functional group. However, these analogues did not show any potency improvement at all (data not shown). Having been inspired by sugar structures and chemistry, we came up with an idea of five-membered ring structure that would give us a larger working space for expending the medicinal chemistry effort.</div><div class="NLM_p">Following the design strategy outlined in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, we initialized our synthetic efforts based on a scaffold-hopping approach by breaking the carbon–carbon double bond to form a hemiacetal ring system and generate the bicyclic skeleton. A first set of testing compounds, compounds <b>2</b>–<b>13</b>, were synthesized (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), while hemiacetal <b>2</b> and thioglycoside <b>10</b> were common intermediates used for the synthesis of <i>S</i>-glycoside and <i>O</i>-glycoside analogues, while <i>C</i>-glycoside analogues were synthesized starting from original CsA. All newly synthesized compounds were tested in HBV infection assays with the HepG2-NTCP cells to determine the IC<sub>50</sub> of their antiviral activity. Surprisingly, all compounds of the first set of cyclic CsA analogues did not show good inhibition even at a 10 μM compound concentration with an exception that <i>p</i>-thiocreasol <b>10A</b> showed IC<sub>50</sub> at 281 nM, which is a 20-fold improvement compared to the initial hit CsA. According to the encouraging result, compound <b>10</b> seems to be a decent hit that sets up a new direction for further SAR development.</div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Strategy for developing NTCP inhibitor from CsA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Alkyl Substitutions at the C-5 Position of the Five-Membered Ring of CsA Derivative</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CsA</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5.784 ± 1.122</td><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">11.913 ± 1.914</td><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">ethan-1-one</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">13.504 ± 8.126</td><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">prop-1-en-2-yl</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">methyl acetate</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">methyl propionate</td><td class="colsep0 rowsep0" align="left">9.260 ± 1.952</td><td class="colsep0 rowsep0" align="left"><b>10A</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.281 ± 0.149</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">propionic acid</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"><b>10m</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (1:3.3)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.523 ± 0.260</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">HBV infection of HepG2-NTCP cells assay. Mean values from a minimum of three experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">A mixture of two isomers. Ratio of main product to minor product (A/B).</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Lead Optimization</h3><div class="NLM_p">On the basis of the above findings, considering synthesis accessibility, we deployed a design strategy focusing on further modifications on the mercapto aromatic ring of compound <b>10</b>. Therefore, compound <b>10A</b> (IC<sub>50</sub> = 0.281 μM) was used as a starting point for extending the structure–activity relationship (SAR) studies. We first explored a set of compounds to obtain an SAR on the 4-position of the phenyl ring (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <b>14B</b>, removing the methyl group on phenyl ring from compound <b>10</b>, had sharply decreased inhibition activity (IC<sub>50</sub> = 5.3 μM). Similar activity was observed on the pyrimidyl compound <b>15A</b> (IC<sub>50</sub> = 5.0 μM). However, a pair of separated racemic 4-methoxyl compounds <b>16A</b> and <b>16B</b> also lost 3.5-fold and 6-fold activity, respectively, indicating that α-isomer and β-isomer might follow a different SAR. 4-Butyl compound <b>17A</b>, extending the carbon chain at 4-position, maintained its inhibitory activity. Substitution with polar functional groups like methylpiperazine (compound <b>18A</b>) and morpholine (compound <b>19A</b>) also caused 5.5-fold and 4.5-fold activity loss. Interestingly, the 4-<i>O</i>-benzyl compound <b>20A</b> maintained the inhibition activity at the same level as compound <b>10A</b>, which indicates that the extended phenyl group might form a new interaction with the binding protein.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Optimizing the Monosubstituted Benzene Ring in the Structure of Compound <b>10</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0010.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14B</b></td><td class="colsep0 rowsep0" align="char" char="±">5.329 ± 1.053</td><td class="colsep0 rowsep0" align="left"><b>23A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.181 ± 0.045</td><td class="colsep0 rowsep0" align="left"><b>31A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.269 ± 0.073</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15A</b></td><td class="colsep0 rowsep0" align="char" char="±">4.955 ± 0.952</td><td class="colsep0 rowsep0" align="left"><b>24A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.223 ± 0.038</td><td class="colsep0 rowsep0" align="left"><b>31m</b><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (1:1.5)</td><td class="colsep0 rowsep0" align="char" char="±">0.253 ± 0.096</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.990 ± 0.331</td><td class="colsep0 rowsep0" align="left"><b>25A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.365 ± 0.066</td><td class="colsep0 rowsep0" align="left"><b>32A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.382 ± 0.079</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16B</b></td><td class="colsep0 rowsep0" align="char" char="±">1.700 ± 0.960</td><td class="colsep0 rowsep0" align="left"><b>26A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.249 ± 0.082</td><td class="colsep0 rowsep0" align="left"><b>33A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.480 ± 0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.262 ± 0.148</td><td class="colsep0 rowsep0" align="left"><b>27A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.110 ± 0.015</td><td class="colsep0 rowsep0" align="left"><b>34A</b></td><td class="colsep0 rowsep0" align="char" char="±">1.199 ± 0.554</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18A</b></td><td class="colsep0 rowsep0" align="char" char="±">1.541 ± 0.316</td><td class="colsep0 rowsep0" align="left"><b>27B</b></td><td class="colsep0 rowsep0" align="char" char="±">0.013 ± 0.002</td><td class="colsep0 rowsep0" align="left"><b>35A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.206 ± 0.061</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19A</b></td><td class="colsep0 rowsep0" align="char" char="±">1.266 ± 0.355</td><td class="colsep0 rowsep0" align="left"><b>28A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.172 ± 0.039</td><td class="colsep0 rowsep0" align="left"><b>36A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.171 ± 0.152</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.256 ± 0.026</td><td class="colsep0 rowsep0" align="left"><b>29A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.354 ± 0.038</td><td class="colsep0 rowsep0" align="left"><b>43A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.344 ± 0.058</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21A</b></td><td class="colsep0 rowsep0" align="char" char="±">1.650 ± 1.320</td><td class="colsep0 rowsep0" align="left"><b>30A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.317 ± 0.075</td><td class="colsep0 rowsep0" align="left"><b>43B</b></td><td class="colsep0 rowsep0" align="char" char="±">0.681 ± 0.097</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22A</b></td><td class="colsep0 rowsep0" align="char" char="±">0.530 ± 0.152</td><td class="colsep0 rowsep0" align="left"><b>30m</b><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (1:1)</td><td class="colsep0 rowsep0" align="char" char="±">0.261 ± 0.077</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">HBV infection of HepG2-NTCP cells assay. Mean values from a minimum of three experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">A mixture of two isomers. Ratio of main product to minor product (A/B, A is the α-isoform, and B is the β-isoform).</p></div></div></div><div class="NLM_p">To investigate whether the substituent at the C-3 position affects anti-HBV activity, we synthesized compounds <b>21A</b>–<b>26A</b>, <b>27A</b>, <b>27B</b>, <b>28A</b>, and <b>29A</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <b>21A</b>, with a hydroxyl group introduced at the C-3 position, was 3.2-fold more potent than the original phenyl compound <b>14B</b>. The extension of the side chain from the 4-oxygen atom resulted in a notable increase in potency based on inhibition testing results, such as compound <b>22A</b> (IC<sub>50</sub> = 0.530 μM, 3-fold vs <b>21A</b>), compound <b>23A</b> (IC<sub>50</sub> = 0.181 μM, 9-fold vs <b>21A</b>) and compound <b>24A</b> (IC<sub>50</sub> = 0.223 μM, 7.4-fold vs <b>21A</b>). Further extending the carbon chain or adding a larger alkyl group did not further improve the anti-HBV infection activity (<b>25A</b>–<b>26A</b>, <b>28A</b>–<b>29A</b>). One pair of 4-<i>O</i>-benzyl compound <b>27A</b> and <b>27B</b> gave the best inhibition activities. The isomeric activity of 4-<i>O</i>-benzyl compounds <b>27A</b> gave anti-HBV infection power at an IC<sub>50</sub> of 0.110 μM. Surprisingly, another isolated isomer <b>27B</b> showed excellent inhibition potency with IC<sub>50</sub> = 0.013 μM, 9-fold more potent than compound <b>27A</b>. The pyridinyl analogues <b>30A</b>, <b>31A</b>, <b>32A</b>, and 3-<i>N</i>-methylpyridone <b>33A</b> were slightly less active than <b>27A</b>; however, those B isoforms seemed having similar potency to their A isoforms based on the inhibition results of the mixtures of <b>30m</b> and <b>31m</b>. In addition, we found that 3-<i>N</i>-substituted compounds (<b>34A</b>–<b>36A</b>) had slightly reduced inhibition activity compared to the 3-<i>O</i>-substituted compounds (<b>22A</b>-<b>24A</b>). Even though compound <b>27B</b> showed the profound inhibition potency, many reaction methods had been tried to reverse the α,β selectivity during the synthesis of <b>27B</b> isomer. Unfortunately, the B isoform was always 10 times less than the A isoform in the mixture and difficult to be separated. We have devoted much effort toward crystallization of these isomers to identify their conformation, but we did not obtain any crystal. We then conducted a two-dimensional (2D) NMR study on <b>27A</b> and <b>27B</b>. The data from a series of 2D NMR experiments seem to support β-configuration for compound <b>27B</b> as we see long-distance coupling between the Me group on the five-membered ring with the anomeric hydrogen Ha, also coupling between the anomeric hydrogen Ha and the hydrogen Hb on the five-membered ring. Instead, from the NOE data of compound <b>27A</b>, we did not see the long-distance coupling between the Me group and Ha, and the coupling between Ha and Hb (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Supplemental Figure 1</a>). These data may help denote <b>27A</b> as the α-isoform and <b>27B</b> as the β-isoform. This general pattern should apply to other compounds, <b>A</b> isoform should be the α-isoform and <b>B</b> isoform should be the β-isoform.</div><div class="NLM_p">To further investigate whether the double-substituent benzene ring would affect the anti-HBV infection activity, a set of disubstituted compounds were synthesized and tested via anti-HBV infection assay (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compared with the 3-methoxyl parent compound <b>22A</b> (IC<sub>50</sub> = 0.530 μM), the 3,4-di-OMe compound <b>37A</b> (IC<sub>50</sub> = 0.346 μM) had a slight potency increase; however, the 3,5-di-OMe compound <b>38A</b> (IC<sub>50</sub> = 0.117 μM), 3-Cl-5-OMe compound <b>39A</b> (IC<sub>50</sub> = 0.116 μM), and 3-OMe-4-Cl compound <b>40A</b> (IC<sub>50</sub> = 0.101 μM) showed 5-fold activity enhancement. Compound <b>41A</b>, the 3-OBn-4-Cl analogue, had about 2-fold activity increase. Surprisingly, the 2,6-di-OMe compound <b>42A</b> dramatically lost the inhibition potency, presumably owing to a torsional angle change along the C–S–Ar bonds. We next synthesized a few <i>O</i>-glycoside compounds (<b>43A</b>, <b>43B</b>, and <b>44A</b>) to compare with their S-glycoside analogues (<b>27A</b>, <b>27B</b>, and <b>38A</b>). The <i>O</i>-glycoside compounds had about 3- to 5-fold activity loss compared with their S-glycoside analogues, indicating that the <i>S</i>-glycoside analogues may be better inhibitors for anti-HBV infection.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Optimizing the Disubstituted Benzene Ring in the Structure of Compound <b>10</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0011.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37A</b></td><td class="colsep0 rowsep0" align="left">3-OMe, 4-OMe</td><td class="colsep0 rowsep0" align="char" char="±">0.346 ± 0.069</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38A</b></td><td class="colsep0 rowsep0" align="left">3-OMe, 5-OMe</td><td class="colsep0 rowsep0" align="char" char="±">0.117 ± 0.042</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39A</b></td><td class="colsep0 rowsep0" align="left">3-Cl, 5-OMe</td><td class="colsep0 rowsep0" align="char" char="±">0.116 ± 0.059</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40A</b></td><td class="colsep0 rowsep0" align="left">3-OMe, 4-Cl</td><td class="colsep0 rowsep0" align="char" char="±">0.101 ± 0.057</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41A</b></td><td class="colsep0 rowsep0" align="left">3-O-Bn, 4-Cl</td><td class="colsep0 rowsep0" align="char" char="±">0.215 ± 0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42A</b></td><td class="colsep0 rowsep0" align="left">2-OMe, 6-OMe</td><td class="colsep0 rowsep0" align="char" char="±">2.169 ± 0.832</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44A</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">0.689 ± 0.340</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">HBV infection of HepG2-NTCP cells assay. Mean values from a minimum of three experiments.</p></div></div></div><div class="NLM_p">Building from these SAR findings, we further focused on halogen modification on the second benzyl ring of <b>27A</b> (<b>45A</b>–<b>50A</b>), hoping to get structures with improved potency or metabolic stability (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Unfortunately, no significant activity improvement was achieved. These compounds retained similar or slightly decreased activity compared to compound <b>27A</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). A slight modification on both phenyl rings (compounds <b>51A</b> and <b>52A</b>) did not improve the potency either, indicating little opportunity to achieve further enhancement on the potency. Having successfully improved the potency from the low micromolar initial hit CsA to a low nanomolar compound based on HBV infection assays with HepG2-NTCP cells, we next assessed metabolic stability of selected compounds (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). According to their liver microsomal stability, compounds <b>27A</b>, <b>27B</b>, <b>32A</b>, and <b>47A</b> were selected for basic pharmacokinetics (PK) analysis in a preliminary oral mouse PK study, while plasma samples were collected and tested at 8 and 24 h time points to monitor the drug concentration (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Table S1</a>; Supporting Information). The plasma protein binding (PPB) of compound <b>27A</b> in mouse and human was detected (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Table S2</a>; Supporting Information). Overall, compound <b>27A</b> exhibited the most attractive combination of better potency and PK profile; therefore, it was selected for full PK profiling study, which gave a very long half-life in mouse plasma and good bioavailability in both oral administration or IP dosing (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>); thereafter, it was selected as a potential candidate for further evaluation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Further Optimization of Compound <b>27A</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0012.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45A</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="char" char="±">0.318 ± 0.104</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46A</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="char" char="±">0.197 ± 0.029</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47A</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="char" char="±">0.206 ± 0.050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48A</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-Cl, 4-F</td><td class="colsep0 rowsep0" align="char" char="±">0.403 ± 0.195</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49A</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-Cl, 4-F</td><td class="colsep0 rowsep0" align="char" char="±">0.335 ± 0.111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50A</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-Me, 4-F</td><td class="colsep0 rowsep0" align="char" char="±">0.122 ± 0.030</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51A</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="char" char="±">0.417 ± 0.112</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52A</b></td><td class="colsep0 rowsep0" align="left">MeO</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="char" char="±">0.216 ± 0.082</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52m</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (1:1.4)</td><td class="colsep0 rowsep0" align="left">MeO</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="char" char="±">0.132 ± 0.004</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">HBV infection of HepG2-NTCP cells assay. Mean values from a minimum of three experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">A mixture of two isomers. Ratio of main product to minor product (A/B).</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Human/Rat/Mouse Liver Microsome Stability Detection</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">HLM CL<sub>int</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">RLM CL<sub>int</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">MLM CL<sub>int</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17A</b></td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23A</b></td><td class="colsep0 rowsep0" align="char" char=".">18.5</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27A</b></td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27B</b></td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36A</b></td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38A</b></td><td class="colsep0 rowsep0" align="char" char=".">10.2</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39A</b></td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40A</b></td><td class="colsep0 rowsep0" align="char" char=".">14.8</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47A</b></td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50A</b></td><td class="colsep0 rowsep0" align="char" char=".">13.0</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">CLint: μL/(min mg protein), determined in human/rat/mouse microsomes.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters for Intravenous (IV), Intraperitoneal (IP), and Oral (PO) Administration of <b>27A</b> in C57BL/6 Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">AUCInf (h*ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">39 673</td><td class="colsep0 rowsep0" align="char" char=".">6.027</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IP<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">87 351</td><td class="colsep0 rowsep0" align="char" char=".">5.683</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">12399</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">14 518</td><td class="colsep0 rowsep0" align="char" char=".">5.651</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2287</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">IV dose: 5 mg/kg.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">IP dose: 10 mg/kg.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">PO dose: 10 mg/kg. All administrated with dimethyl sulfoxide (DMSO):cremophor:0.9%NaCl = 5:5:90. Values were the mean values of male for mouse (<i>n</i> = 3).</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Antiviral Activity</h3><div class="NLM_p">After <b>27A</b> being selected as an advanced compound, we then carried out more detailed antiviral activity tests around compound <b>27A</b>. We tested <b>27A</b> on primary human hepatocytes (PHH) and found that <b>27A</b> could inhibit HBV infection on PHH cells (estimated IC<sub>50</sub> = 59 nM) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Supplement Figure 2</a>). We then found that <b>27A</b> could reduce the infection of HBV genotypes B and C (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), which differ in sequence from the genotype D virus strain used in the IC<sub>50</sub> determination. These results indicate that <b>27A</b> exerts pan-genotypic anti-HBV effects. We next investigated the anti-HBV mechanism of <b>27A</b>. Southern blotting of HBV DNA, which was extracted from infected HepG2-NTCP cells, indicated that <b>27A</b> could significantly decrease the HBV cccDNA level compared to the DMSO control upon addition of the HBV inoculum, in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Consistent with this, viral transcription was also dramatically decreased by <b>27A</b>, as revealed in a Northern blot assay targeting HBV RNAs (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C, left and middle panels). In contrast, when <b>27A</b> was added on day 3 post infection, the transcription level of HBV virus was not affected (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C, right panel), implying that <b>27A</b> inhibits HBV infection at an early stage of HBV life cycle.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Antiviral activity of <b>27A</b>. (A) <b>27A</b> inhibits genotype B and genotype C HBV virus infection of HepG2-NTCP cells. HBeAg and HBsAg titers that secreted in the medium were determined at dpi 5 by commercial ELISA kits. The concentration of the compounds used in the assay was 2 μM for <b>27A</b> and 200 nM for Myr47. (B) Southern blot assay on HBV DNA extracted from HBV-infected HepG2-NTCP cells. HBV DNA was extracted on dpi 5 by Hirt methods. Southern blotting was conducted with DIG-labeled probe that targeting full-length HBV genome (DIG-high prime DNA-labeling and detection starter kit II, Roche, cat. No. 11585614910). (C) Northern blot assay on RNAs extracted from HBV-infected HepG2-NTCP cells. <b>27A</b> was added to the cells with the inoculum of the virus (lanes 3 and 4) or at dpi 3–5 (lanes 5 and 6). The blotting was procedure was similar to that of Southern blot except for the additional DIG-labeled glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probe. (D) <b>27A</b> inhibits HDV infection of HepG2-NTCP cells. HDV delta antigen was stained by a homemade FITC-labeled antidelta antigen antibody at dpi 5. The pictures were captured by an Opera High Content Screening System (PerkinElmer). Blue: 4′,6-diamidino-2-phenylindole (DAPI) stain, green: HDV delta antigen. (E) HDV infection ratio calculation of (D) was conducted by Columbus Image Analysis System (PerkinElmer).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, <b>27A</b> inhibits the infection of Hepatitis D virus, which is an accepted surrogate for HBV entry into HepG2-NTCP cells.<a onclick="showRef(event, 'ref3 ref4 ref28'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref28">(3,4,28)</a> Specifically, treatment with 200 nM <b>27A</b> significantly decreased the infection ratio of HDV to 50% of the DMSO control, with the decrease rising to over 95% at a concentration of 5 μM, in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D). Collectively, these results indicate that <b>27A</b> blocks HBV and HDV entry into hepatocytes, demonstrating the strong potential of <b>27A</b> as an anti-HBV and HDV agent with apparently attractive potency.</div><div class="NLM_p">Having investigated the <i>in vitro</i> efficacy of <b>27A</b>, we then focused on verifying its antiviral efficiency <i>in vivo</i>. hNTCP-tg mice, which are susceptible to HDV infection,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> were divided into three groups and administrated through intraperitoneal injection: the mice in group A were injected <b>27A</b> at dose of 40 mg/kg before HDV challenge (<i>n</i> = 4); the mice in group B were dosed <b>27A</b> at 40 mg/kg for two consecutive days (<i>n</i> = 4); and the mice in group C were dosed with vehicle (<i>n</i> = 5). All of the mice in each group were challenged with HDV virus at a dose of 5 × 10<sup>9</sup> genome equivalents and then sacrificed on the 7th day to determine the virus infection efficiency. Group A with a single dose of <b>27A</b> given before HDV infection significantly decreased the HDV RNA levels in the liver compared to the vehicle control (<i>n</i> = 4). Group B with an additional dose of <b>27A</b> further enhanced its antiviral efficacy (<i>n</i> = 4) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). As compound <b>27A</b> was designed as an oral drug, we wanted to know if oral administration would also work well. Given that adult hNTCP-tg mice are not susceptible to HDV infection, while oral administration to neonatal mice is not easy to conduct, we decided to orally dose compound <b>27A</b> to adult HDV-susceptible mice model: the NTCP-edited FVB mice that was previously reported.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The results, shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C, indicated that an oral gavage dose of 30 mg/kg <b>27A</b> prior to HDV infection efficiently decreased the HDV RNA levels in the liver (<i>n</i> = 4) compared to the vehicle control group (<i>n</i> = 4) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Collectively, these <i>in vivo</i> study results revealed that both intraperitoneal injection and oral administration of compound <b>27A</b> can achieve promising antiviral efficacy.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>27A</b> inhibits HDV infection <i>in vivo</i>. (A) Experimental scheme of <i>in vivo</i> HDV infection of mice models. (B) Intraperitoneal injection (I.P.) of <b>27A</b> inhibits HDV infection in mice. hNTCP-Tg-C57B/L mice were challenged with HDV by intraperitoneal injection of 5 × 10<sup>9</sup> Geq of HDV on day 9 after birth and sacrificed on day 15 after birth. <b>27A</b> was administrated once (Group A, <i>n</i> = 4), twice (Group B, <i>n</i> = 4), or vehicle (Group C, <i>n</i> = 5) to mice through I.P. before HDV inoculation. HDV RNA levels were assessed by quantitative polymerase chain reaction (qPCR) of the RNA extracted from the liver of challenged mice; the levels of NTCP mRNA were also determined. The RNA copy numbers from 20 ng of liver RNA are presented. The bars indicate the median of each group. (C) Oral intake of <b>27A</b> inhibits HDV infection in the mice. <b>27A</b> (<i>n</i> = 4) or vehicle (<i>n</i> = 4) were administrated to adult NTCP-edited FVB mice for 8 days through gavage. The mice were challenged with HDV on the 2nd day by intraperitoneal injection of 5 × 10<sup>9</sup> Geq of HDV with 50 mg/kg dexamethasone. HDV RNA level and edited NTCP mRNA level were determined in the same way as in (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Mode-of-Action Study</h3><div class="NLM_p">Encouraged by the good results of <i>in vivo</i> efficacy studies, we then moved to investigate the mode of action of compound <b>27A</b> to understand how it interrupts the HBV infection process. Considering NTCP on the hepatocyte cell surface is the key receptor protein utilized by the virus for entry into cell causing infection, whereas CsA is known to inhibit NTCP function, we assessed that <b>27A</b> may act as a blocker to prevent the initial interaction between virus and NTCP by sitting on a certain site or act as a modulator to interfere with NTCP surface localization. During our <i>in vivo</i> animal efficacy study, we have observed that the taurocholic acid level in the mice was increased (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Supplement Figure 4</a>). Given that NTCP is a cholic acid transporter, over all of these observations, it is implied that NTCP seems to be a suspectable target of <b>27A</b>. Therefore, we tested <b>27A</b> in <sup>3</sup>H-taurocholic acid (<sup>3</sup>H-TCA) uptake assays using HepG2-NTCP cells. <b>27A</b> can inhibit NTCP-mediated uptake of its substrate <sup>3</sup>H-TCA with an IC<sub>50</sub> value of 0.066 ± 0.031 μM (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), similar to the IC<sub>50</sub> value of <b>27A</b> in the inhibition of HBV infection assay, but showed no cytotoxicity at 100 μM. This result supported that the antiviral activity of <b>27A</b> may associate with the inhibition of NTCP function.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mechanism studies of <b>27A</b>. (A) IC<sub>50</sub> determination of <b>27A</b> on inhibiting NTCP uptake of <sup>3</sup>H-taurocholic acid (<sup>3</sup>H-TCA). (B) NTCP (green) and cell nucleus (blue) staining using anti-NTCP antibody and DAPI, respectively. HepG2-NTCP cells were stained after 2 h treatment of DMSO, <b>27A</b>, or taurolithocholic acid (TLCA). The compounds were used at 2 μM. (C) Myr59F (green) staining on HepG2-NTCP cells in the presence of DMSO, <b>27A</b> (1 μM), or Myr47 (200 nM). The fluorescence intensity analysis is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Supplement Figure 3</a>. (D) NTCP uptake inhibition assay. <b>27A</b> (2 μM) inhibits NTCP from multiple species (hNTCP: human-NTCP; mNTCP: mouse-NTCP; mkNTCP: monkey-NTCP; tsNTCP: treeshrew-NTCP; hASBT: human-ASBT) uptake of <sup>3</sup>H-TCA on transfected HepG2 cells, compared with tauroursodeoxycholic acid (TUDCA, 20 μM) and Myr47 (200 nM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is known that HepG2-NTCP cells under treatment with taurolithocholic acid (TLCA) can induce NTCP endocytosis.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> We want to know if <b>27A</b> plays the same action or through a different mechanism. We then measured NTCP distribution by performing immunostaining of NTCP after treating the HepG2-NTCP cells with <b>27A</b> or without. The cells treated with <b>27A</b> showed a similar surface expression level of NTCP to cells treated with DMSO, whereas the cells treated with taurolithocholic acid (TLCA) showed decreased NTCP staining intensity at the cell surface (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). These results clearly indicated that the mode of action of <b>27A</b> is through blocking taurocholic acid transporting function of NTCP function rather than through inducing NTCP endocytosis.</div><div class="NLM_p">We next used Myr59F, an FITC-labeled polypeptide derived from HBV Pre-S1 polypeptide used as a surrogative indicator, to visualize the binding between HBV and NTCP of HepG2-NTCP cells. Myr47, a nonlabeled Pre-S1-derived peptide, is known as a competitive inhibitor of Myr59F-NTCP interaction. Notably, we found that both <b>27A</b> and Myr47 significantly blocked Myr59F binding to NTCP, which is revealed by decreased cell membrane staining compared with DMSO control (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Myr47 inhibition has been studied in NTCP-mediated TCA uptake assay using HepG2 cells expressing NTCP from multiple species and found similarly high-affinity inhibition among human-NTCP, mouse-NTCP, and treeshrew-NTCP but not monkey-NTCP (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D), owing to the sequence difference in the binding motif residues 157–165, whereas <b>27A</b> can block NTCP-mediated TCA uptake in all species. We also tested both inhibitors against another bile acid transporter protein ASBT, which is localized in the terminal ileum, and found that both compounds had no inhibition to ASBT’s function.</div><div class="NLM_p last">We then compared Alisporivir, a cyclophilin inhibitor, which was previously reported to suppress HBV replication with <b>27A</b> in HBV infection assays. Alisporivir inhibits HBV infection at 10 μM that is about 100-fold higher than <b>27A</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Supplement Figure 5</a>), indicating that the mechanism of <b>27A</b> inhibiting HBV early infection is not related to cyclophilin inhibition. Collectively, these results support a conclusion that <b>27A</b> inhibits HBV infection by disrupting the interaction between NTCP and HBV Pre-S1 polypeptide, while stressing that <b>27A</b> may target a site on NTCP, which is distinct from the site targeted by the HBV Pre-S1 polypeptide.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Biological Evaluation</h3><div class="NLM_p">We next evaluate the drug potential of <b>27A</b>. Given the knowledge that CsA has been reported as an inhibitor for another liver-tropism bile acid transporters—organic anion-transporting polypeptide (OATP) family transporters—contributes to a multitude of transporter-mediated drug–drug interactions in clinical situations.<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31−33)</a> We therefore investigated the OATP inhibition activity of <b>27A</b> via uptake assay on OATP1B1 overexpressing HepG2 cells using its natural substrate <sup>3</sup>H-estrone sulfate. CsA, as expected, significantly inhibits OATP1B1-mediated uptake of estrone sulfate (estimated IC<sub>50</sub> = 0.75 μM). In contrast, <b>27A</b> inhibits OATP1B1 at a much lower level compared with CsA (estimated IC<sub>50</sub> = 2.27 μM) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A), indicating that <b>27A</b> has lost affinity to OATP1B1 of its original structure CsA. These results support that <b>27A</b> has better selectively on NTCP over OATP1B1 compared with CsA.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Biological evaluation of <b>27A</b>. (A) OATP1B1 uptake inhibition assay. <b>27A</b> inhibits OATP1B1 uptake of <sup>3</sup>H-estrone sulfate on transfected HepG2 cells, compared with CsA. (B, C) Immunosuppressive effect of <b>27A</b>: (B) FACS analysis of mouse primary spleen T cells stained by CSFE. The cells were stimulated by anti-CD3 antibody in the presence of indicated compounds for 48 h before analysis. Pos. control: cells stimulated by antibody and no other treatment. (C) NF-AT luciferase assay in Jurkat T cells stimulated by PMA (10 ng/mL) and ionomycin (500 nM) in the presence of indicated compounds for 48 h before analysis. The concentration of the compounds used in this assay is 2 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recall that CsA is widely used as an immunosuppressive agent in the clinic, for example, in patients undergoing organ transplantation. Considering the impressive results as an antiviral agent, its potential development as an antiviral drug would be aided by a lack of immunosuppressive activity. We therefore investigated whether <b>27A</b> retains any immunosuppressive activity. We separated primary spleen T cells from adult C57B/L mouse spleens and stained them with CFSE—a fluorescent dye that diffuses equally into daughter cells, enabling tracing of the proliferation of T cells.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> After stimulating with anti-CD3 antibody in the presence or absence of <b>27A</b> or controls (CsA, DMSO) for 2 days, the cells were then analyzed via FACS. The anti-CD3-stimulated primary spleen T cells exhibited proliferation, which, as expected, was totally abolished in the presence of CsA. In contrast, we found that neither <b>27A</b> nor DMSO abolished the proliferation of the T cells, indicating that <b>27A</b> has apparently lost the immunosuppressive activity of its parent compound CsA (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).</div><div class="NLM_p last">We further verified this loss of immunosuppressive activity by investigating the impacts of <b>27A</b> on the calcineurin/NF-AT pathway in Jurkat cells using a previously described pGL3-NFAT-luc reporter assay.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> After stimulating cells with PMA and ionomycin in the presence or absence of CsA or <b>27A</b> (2 μM) for 24 h, the cells were then lysed, and the luciferase activity was measured. CsA dramatically decreased the luciferase activity compared to the DMSO control. In contrast, the luciferase activity in <b>27A</b>-treated cells was about 25 times higher than that in CsA-treated cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). These results showed that the immunosuppressive effect of <b>27A</b> is largely blunted compared to its original structure.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, we have completed the synthesis of cyclosporine A analogues <b>1</b>–<b>53</b>, all of which were screened using anti-HBV infection assays with HepG2-NTCP cells. We ultimately identified a highly potent and specific NTCP inhibitor, <b>27A</b>, which has a (3-(benzyloxy)phenyl)(methyl)sulfane group at the C-5 position of the five-membered ring that contributes to its low nanomolar potency. Virological studies indicated that <b>27A</b> exerts pan-genomic HBV inhibition activity and HDV inhibition activity <i>in vitro</i>. Supporting and extending these findings, a series of <i>in vivo</i> studies showed that <b>27A</b> can be used as a prophylaxis agent for HDV infection and highlighted a favorable pharmacokinetics profile and efficacy via oral dosage. Subsequently, biochemical experiments showed that the antiviral mechanism of <b>27A</b> may be due to the inhibition of the binding between HBV Pre-S1 peptide and NTCP, while revealing that this mode of action does not rely on alteration of the normal membrane localization of NTCP. In addition, <b>27A</b> is superior to CsA not only with better selectivity on NTCP over OATP1B1 but also with the lack of immunosuppressive effect, on the aspect of being an antiviral agent. Thus, our results collectively support that a small molecule that specifically targets NTCP holds great promise for development as an anti-HBV/HDV drug candidate and as a chemical tool to study NTCP functions and the precise steps of the early phase of HBV/HDV infection.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Ethics Statement</h3><div class="NLM_p last">All animals were housed in the animal facility of the National Institute of Biological Sciences (NIBS), Beijing. Animal experiments were conducted following the National Guidelines for Housing and Care of Laboratory Animals and performed in accordance with NIBS institutional regulations after approved by the institution’s Institutional Animal Care and Use Committee (IACUC). The protocol number is NIBS-0012.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> IC<sub>50</sub> Determination Using <i>In Vitro</i> HBV Infection System</h3><div class="NLM_p last">HepG2-NTCP cells were seeded in a 96-well plate (Corning) for 4–6 h before the medium was changed to primary maintenance medium (PMM, formula previously reported<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a>) for 20–24 h. The cells were inoculated with HBV virus-containing medium in the presence of testing compounds at different concentrations for 4 h at room temperature and 37 °C afterward for 24 h. The inoculum medium was then changed to PMM with 2% fetal bovine serum (Gibco) for every 2 days till day 5 post infection. The titer of HBeAg secreted in the inoculum was tested by an ELISA kit (Wantai, Inc.) and read by a plate reader (Beijing Pulang New Tech, Inc.). IC<sub>50</sub> values (mean ± standard deviation calculated from six or more measuring points in three duplicate repeats) were determined using nonlinear regression analysis by GraphPad software.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> HBV Nucleic Acid Extraction, Southern and Northern Blotting Assays</h3><div class="NLM_p">HBV cccDNA from HBV-infected cells was extracted according to a modified Hirt method, as previously described.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Briefly, the infected cells from one well of six-well plates were lysed in Hirt lysis buffer (10 mM Tris-HCl, 10 mM ethylenediamine tetraacetic acid (EDTA), 0.6% sodium dodecyl sulfate (SDS), pH 7.4) for 30 min at room temperature. After adding 5 M NaCl, the cell lysate was vigorously mixed and incubated at 4 °C overnight. After centrifugation at 10 000 rpm for 30 min at 4 °C, the supernatant was extracted twice with saturated Tris-phenol (pH 8.0) and once with phenol-chloroform. The extracted DNA was precipitated with equal volumes of isopropanol at −20 °C overnight. The DNA pellet was washed with 70% ethanol and dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) to be analyzed.</div><div class="NLM_p">HBV RNA from HBV-infected cells was extracted by TRIzol reagent (Thermo Fisher) according to the manufacturer’s guide. The infected cells from one well of a 24-well plate were lysed in TRIzol reagent. After adding 1/5 volume of chloroform, the cell lysate was mixed thoroughly and incubated for 5 min at room temperature. After centrifugation at 12 000 rpm and 4 °C for 15 min, the supernatant was transferred into a new tube, mixed with an equal volume of isopropanol, and incubated for 5 min before centrifuged at 12 000 rpm and 4 °C for 10 min to get an RNA pellet. The pellet was then washed with 70% ethanol and dissolved in DEPC-treated water.</div><div class="NLM_p">For detection of cccDNA by Southern blot, the extracted HBV cccDNA samples were subjected to 1.2% agarose gel electrophoresis. For detection of RNA by Northern blot, the extracted RNA samples were subjected to 1.0% agarose gel supplemented with MOPs buffer and formaldehyde.</div><div class="NLM_p last">The blotting procedures for Southern blot and Northern blot are identical. After electrophoresis, the nuclei acid stayed in the gel was transferred onto Amersham Hybond-N<sup>+</sup> membrane (GE Healthcare). The Hybond-N<sup>+</sup> membrane was cross-linked in a UV cross-linker chamber with a UV energy dosage of 1200 mJ and followed by probing with DiG-labeled HBV genotype D (accession number: U95551.1) linear full-length genomic DNA that was prepared by a DiG High Prime DNA Labeling and Detection Kit (Roche). Hybridization was performed in PerfectHyb plus hybridization buffer (Sigma) with prehybridization for 1 h at 50 °C and overnight hybridization at 50 °C, followed by two washes in two kinds of wash buffers (0.5 × SSC, 0.1% SDS, room temperature and 0.1 × SSC, 0.1% SDS, 65 °C, respectively). Chemiluminescence excitation on the membrane was conducted according to the manufacturer’s guide (Roche). The membrane was blocked by a blocking buffer for 30 min followed by incubation with Anti-DiG-AP antibody (Roche) for 30 min. The membrane was then treated by CSPD solution (Roche) for 5 min and exposed to Carestream X-OMAT BT Film (XBT-1, Carestream). For Southern blot assay, 100 pg each of 3.2, 2.1, and 1.7 kb HBV DNA fragments prepared by PCR amplification of a plasmid containing 1.0 copies of linear HBV genotype D genome was used as a DNA marker.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Liver Microsome Stability Assay</h3><div class="NLM_p last">Commercial human/mouse liver microsome was diluted to a final concentration of 1 mg/mL in fresh 0.05 M phosphate buffer (the buffer was prepared by dissolving 8.7 g of K<sub>2</sub>HPO<sub>4</sub> in 1000 mL of H<sub>2</sub>O; pH was adjusted to 7.4 using H<sub>3</sub>PO<sub>4</sub>). Testing compounds were added to the liver microsome at a final concentration of 1 μM, mixed well, and the mixture was then preincubated at 37 °C for 5 min. The enzyme activity was initiated by adding 1 mM NADPH. A small volume of the mixture (20 μL) was collected at different time points (0, 5, 15, 30, and 60 min) and quenched by adding 300 μL of methanol. The samples were vigorously vortexed for 1 min and then placed at −20 °C for 1 h. The samples were then centrifuged at 3500 rpm for 15 min, and the supernatant was collected for liquid chromatography–mass spectrometry (LC–MS) analysis.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> HDV Production, Mouse Viral Inoculation, and Quantification of HDV RNA Assays</h3><div class="NLM_p last">HDV was produced as previously described via transfection of two plasmids in Huh-7 cells.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The mice were inoculated with purified HDV by intraperitoneal injection. Mouse liver samples were homogenized in liquid nitrogen immediately after collection, and then lysed by TRIzol reagent (Thermo Fisher) and RNA was extracted as described earlier. The total RNA was reverse-transcribed into cDNA with PrimeScriptTM RT-PCR Kit (Takara), and cDNA from 20 ng of RNA was used for qPCR assay.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <sup>3</sup>H-TCA Uptake Assays</h3><div class="NLM_p last">HepG2-NTCP cells were seeded in 96-well plates for 4–6 h before the medium was changed to PMM for 20–24 h. The cells were then treated with test compounds for 2 h, then the culture medium was changed to 100 μL of Na<sup>+</sup> Ringer’s buffer supplemented with 2 μM <sup>3</sup>H-TCA (PerkinElmer). The uptake procedure was conducted at 37 °C for 10 min before the buffer was removed, and the cells were then washed by phosphate-buffered saline (PBS) twice. The cells were then treated with 50 μL of 1% Triton-X100 (Sigma) in PBS to release the isotype labeled TCA. The supernatant was then transferred to a reading plate with 200 μL of Ultima Gold XR LSC-cocktail (PerkinElmer), and the plate was then read by a MicroBeta TriLux LSC Counter (PerkinElmer).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Immunosuppression Assays</h3><div class="NLM_p last">Spleen T cells from a mature C57B/L mouse were separated and cultured in complete RPMI-1640 medium (Thermo Fisher). The cells were primarily stained by CFSE (Thermo Fisher) following manufacturer’s guide and then cultured in 96-well plates coated by anti-CD3 antibody for 72 h in the presence of CsA, <b>27A</b>, and DMSO control. Before testing, the cells were stained with PE-anti-CD4 antibody (BD Biosciences). T cell proliferation was determined by FACS (BD FACS Arial II). For NF-AT signaling pathway assay, Jurkat cells were cultured in complete RPMI-1640 supplemented with 10% FBS (Gibco) and Glutamax (Thermo Fisher). pGL3-NFAT-LUC plasmid was purchased from Addgene. The plasmid was transfected into Jurkat cells by electroporation conducted by a Neon Transfection system (Thermo Fisher) with parameters following manufacturer’s instructions (pulse voltage: 1350 V, pulse width: 10 ms, pulse number: 3). Twenty-four hours after transfection, the cells were stimulated with 10 ng/mL PMA (Sigma) and 500 nM ionomycin (Beyotime Biotechnology) with testing compounds or control for 48 h. After stimulation, the cells were then lysed by passive lysis buffer (Promega) and the luciferase activity in the cell lysis was determined by a Centro LB960 plate reader (Berthold Tech).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry</h3><div class="NLM_p">All solvents and reagents were used directly as obtained commercially unless otherwise noted (the synthesis methods of mercapto heterocyclic and aromatic intermediates are shown in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Supporting Information</a>). All air- and moisture-sensitive reactions were carried out under an atmosphere of dry argon with heat-dried glassware and standard syringe techniques. LC–mass spectrometry (MS) system: Waters 2545 (XBridge C18)/3100 mass detector. <sup>1</sup>H NMR spectra were recorded on a Varian 400 MHz spectrometer (Varian, Inc., Palo Alto, CA) at ambient temperature with tetramethylsilane as an internal standard. <sup>13</sup>C NMR spectra were recorded on a Varian 100 MHz spectrometer (with complete proton decoupling) at ambient temperature. Chemical shifts are reported in ppm. Data for <sup>1</sup>H NMR are reported as follows: chemical shift (δ) in ppm, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants, and integration. High-resolution mass spectra were obtained by Agilent Technologies 6540UHDAccurate-Mass Q-TOF LC/MS (Santa Clara, CA). The samples were analyzed by high-performance liquid chromatography (HPLC)/MS on a Waters Auto Purification LC/MS system (3100 mass detector, 2545 binary gradient module, 2767 sample manager, and 2998 photodiode array detector), which was purchased from Waters (Milford, MA). The system was equipped with a Waters C18 5 μm SunFire separation column (150 × 4.6 mm<sup>2</sup>), equilibrated with HPLC-grade water (solvent A) and HPLC-grade acetonitrile (solvent B) with a flow rate of 0.3 mL/min. Thin-layer chromatography was carried out using HS-GF 254 silica plates; TLC spots were visualized under UV light; chromatographic purification was carried out using silica gel (Yan Tai Mou Ping Yuan Bo Jing Xi Silica Gel Plant). The purity of all final compounds was confirmed to be >95% by HPLC.</div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-33-((2<i>R</i>,3<i>R</i>)-5-hydroxy-3-methyltetrahydrofuran-2-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>2</b>)</h4><div class="NLM_p last">To a well-stirred solution of cyclosporine A (0.12 g, 0.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was bubbled a flow of O<sub>3</sub> at −78 °C. After 5 min, the solvent turned out blue, which indicated complete consumption of starting material, 0.3 mL of Me<sub>2</sub>S was added to quench the reaction; the system was warmed to r.t. and stirred for another 2 h. The solvent was evaporated to dryness under vacuum to give 0.12 g of a white solid, and the crude product was used directly for the next step without further purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.61 (d, <i>J</i> = 8.8 Hz, 1H), 8.27 (d, <i>J</i> = 10.0 Hz, 1H), 8.05 (d, <i>J</i> = 7.6 Hz, 1H), 7.33 (d, <i>J</i> = 7.6 Hz, 1H), 5.64–5.66 (m, 1H), 5.43–5.47 (m, 1H), 5.33–5.36 (m, 1H), 5.13–5.15 (m, 2H), 5.05–5.09 (m, 1H), 4.77–4.83 (m, 2H), 4.71–4.73 (m, 2H), 4.60–4.62 (m, 1H), 4.49–4.52(m, 1H), 4.14–4.19 (m, 1H), 3.97–3.98 (m, 1H), 3.47 (s, 3H), 3.39 (s, 3H), 3.29 (s, 3H), 3.10 (s, 3H), 3.06 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.48–2.55 (m, 1H), 2.29–2.33 (m, 1H), 2.11–2.16 (m, 3H), 2.01–2.05 (m, 3H), 1.62–1.68 (m, 5H), 1.42–1.44 (m, 3H), 1.27–1.31 (m, 9H), 1.23–1.25 (m, 5H), 1.15–1.17 (m, 4H), 1.04–1.07 (m, 3H), 0.97–0.99 (m, 8H), 0.88–0.89 (m, 6H), 0.81–0.83 (m, 8H), 0.71–0.74 (m, 4H), 0.63–0.65 (m, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 175.3, 172.8, 171.9, 171.4, 170.8, 170.7, 170.1, 170.0, 168.7, 168.0, 167.5, 97.0, 81.4, 77.3, 77.0, 76.7, 61.9, 59.3, 56.8, 54.2, 53.7, 50.1, 48.6, 48.5, 48.1, 45.8, 43.5, 41.4, 39.6, 39.1, 37.9, 36.8, 36.2, 35.4, 31.3, 30.8, 30.4, 30.4, 30.1, 29.9, 29.7, 26.4, 26.1, 25.4, 25.0, 24.8, 24.7, 24.2, 23.6, 23.2, 23.0, 22.2, 22.0, 21.8, 20.8, 20.0, 19.4, 18.2, 17.5, 17.3, 17.1, 16.7, 9.6. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>60</sub>H<sub>108</sub>N<sub>11</sub>O<sub>13</sub> 1190.8128, found 1190.8034.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-33-((2<i>R</i>,3<i>R</i>)-5-methoxy-3-methyltetrahydrofuran-2-yl)-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>3</b>)</h4><div class="NLM_p last">Compound <b>2</b> (50 mg, 0.042 mmol) was dissolved in MeOH (5 mL), <i>p</i>-TsOH (7 mg, 0.042 mmol) was added to the above solution at 0 °C, then the whole system was stirred at r.t. overnight. The solvent was concentrated; the residue was dissolved in ethyl acetate (5 mL); the organic layer was washed with saturated aq. NaCl (3 mL) and was separated, dried and concentrated; and the crude product was purified by prep. HPLC to afford 36 mg of a white solid. Yield: 72%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.33 (d, <i>J</i> = 9.6 Hz, 1H), 8.04 (d, <i>J</i> = 7.2 Hz, 1H), 7.62 (d, <i>J</i> = 8.8 Hz, 1H), 7.47 (d, <i>J</i> = 8.0 Hz, 1H). 5.66 (dd, <i>J</i> = 4.4, 10.8 Hz, 1H), 5.31 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.19–5.23 (m, 1H), 5.13–5.17 (m, 1H), 5.07–5.10 (m, 2H), 4.95–5.01 (m, 1H), 4.84–4.87 (m, 2H), 4.76–4.81 (m, 1H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.39 (t, <i>J</i> = 7.2 Hz, 1H), 4.28 (t, <i>J</i> = 6.8 Hz, 1H), 4.13 (dd, <i>J</i> = 4.8, 9.6 Hz, 1H), 3.47 (s, 3H), 3.38 (s, 3H), 3.27 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.04 (s, 3H), 2.69 (s, 3H), 2.67 (s, 3H), 2.28–2.35 (m, 1H), 2.11–2.18 (m, 1H), 2.01–2.07 (m, 3H), 1.88–1.97 (m, 3H), 1.60–1.72 (m, 5H), 1.44–1.52 (m, 3H), 1.31–1.34 (m, 3H), 1.24–1.26 (m, 4H), 1.12–1.16 (m, 3H), 0.96–0.98 (m, 6H), 0.92–0.95 (m, 6H), 0.90–0.91 (m, 6H), 0.85–0.88(m, 14H), 0.79–0.81 (m, 5H), 0.72–0.75 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.6, 173.2, 173.1, 172.7, 171.5, 171.2, 170.8, 170.8, 170.4, 169.8, 168.8, 130.9, 128.8, 105.3, 81.7, 65.5, 60.4, 57.9, 57.0, 55.4, 54.9, 54.8, 54.7, 54.6, 54.2, 50.0, 48.5, 48.4, 48.0, 44.7, 40.7, 40.2, 39.2, 39.1, 37.2, 36.2, 34.3, 32.4, 31.5, 31.3, 31.1, 30.5, 30.0, 29.9, 29.7, 29.6, 25.9, 24.8, 24.8, 24.7, 24.5, 23.7, 23.7, 23.5, 23.4, 21.9, 21.4, 21.3, 21.2, 20.1, 19.0, 18.6, 17.7, 15.0, 13.7, 9.9. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>61</sub>H<sub>110</sub>N<sub>11</sub>O<sub>13</sub> 1204.8285, found 1204.8281.</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>)-3-methyltetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>4</b>)</h4><div class="NLM_p">Step 1: (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((1R,2R)-1,4-dihydroxy-2-methylbutyl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>5</b>)</div><div class="NLM_p">Compound <b>2</b> (0.3 g, 0.24 mmol) was dissolved in 5 mL of MeOH. NaBH<sub>4</sub> (45 g, 1.22 mmol) was added slowly to the solution at 0 °C. It was stirred at r.t for 16 h. Water was added to quench the reaction and extracted with EtOAc (10 mL × 3). The organic layers were combined and evaporated to dryness and purified by prep-HPLC to give 200 mg of a white solid. Yield: 69.9%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.20 (d, <i>J</i> = 10.0 Hz, 1H), 7.85 (d, <i>J</i> = 6.8 Hz, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 5.69 (dd, <i>J</i> = 4.0, 11.6 Hz, 1H), 5.33 (d, <i>J</i> = 7.2 Hz, 1H), 5.29 (dd, <i>J</i> = 3.6, 11.6 Hz, 1H), 5.12–5.16 (m, 1H), 5.03–5.10 (m, 2H), 4.94–5.00 (m, 1H), 4.79–4.92 (m, 2H), 4.70 (d, <i>J</i> = 14.0 Hz, 1H), 4.65 (t, <i>J</i> = 9.2 Hz, 1H), 4.41–4.51 (m, 1H), 3.95 (t, <i>J</i> = 6.4 Hz, 1H), 3.61–3.67 (m, 1H), 3.53 (s, 3H), 3.45–3.51 (m, 1H), 3.39 (s, 3H), 3.28 (s, 3H), 3.15 (s, 3H), 3.14 (s, 3H), 2.68(s, 3H), 2.67 (s, 3H), 2.38–2.48 (m, 1H), 2.08–2.20 (m, 4H), 1.95–2.04 (m, 2H), 1.77–1.87 (m, 3H), 1.56–1.66 (m, 5H), 1.40–1.48 (m, 3H), 1.31–1.34 (m, 4H), 1.25–1.27 (m, 3H), 1.01–1.06 (m, 7H), 0.97–1.01 (m, 6H), 0.92–0.96 (m, 11H), 0.88–0.91 (m, 4H), 0.84–0.87 (m, 11H), 0.76 (d, <i>J</i> = 6.8 Hz, 3H). Mass (ESI): <i>m</i>/<i>z</i> calcd for C<sub>60</sub>H<sub>109</sub>N<sub>11</sub>O<sub>13</sub> 1192.60, found 1193.80 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><b>Step 2</b>: To a cooled mixture of compound <b>5</b> (0.1 g, 0.084 mmol) and Et<sub>3</sub>N (13 mg, 18 μL) was added MsCl (11 mg, 7 μL) and stirred at 0 °C to r.t. overnight. The reaction was quenched with water; the organic layer was separated; the aqueous layer was extracted with ethyl acetate (3 × 3 mL); the organic phase was combined, dried, and filtered; and the solvent was evaporated under vacuum. The residue was purified by prep. HPLC, and 50 mg of a white solid was obtained, total yield: 50%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.41 (d, <i>J</i> = 9.2 Hz, 1H), 8.07 (d, <i>J</i> = 6.0 Hz, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 1H), 7.48 (d, <i>J</i> = 7.6 Hz, 1H), 5.66 (d, <i>J</i> = 8.0 Hz, 1H), 5.32 (d, <i>J</i> = 10.4 Hz, 1H), 5.19 (d, <i>J</i> = 10.8 Hz, 1H), 5.06–5.13 (m, 2H), 5.02 (d, <i>J</i> = 8.8 Hz, 1H), 4.92–4.98 (m, 1H), 4.77–4.84 (m, 2H), 4.68 (d, <i>J</i> = 14.0 Hz, 1H), 4.38 (t, <i>J</i> = 6.4 Hz, 1H), 3.97 (d, <i>J</i> = 6.8 Hz, 1H), 3.67–3.73 (m, 3H), 3.46 (s, 3H), 3.38 (s, 3H), 3.23 (s, 3H), 3.16 (s, 3H), 3.06 (s, 3H), 2.67(s, 3H), 2.66 (s, 3H), 2.28–2.38 (m, 1H), 1.92–2.19 (m, 6H), 1.54–1.80 (m, 6H), 1.38–1.48 (m, 3H), 1.31 (d, <i>J</i> = 6.8 Hz, 4H), 1.24 (d, <i>J</i> = 6.4 Hz, 3H), 1.10–1.190 (m, 2H), 0.96–1.04 (m, 11H), 0.83–0.93 (m, 25H), 0.78 (d, <i>J</i> = 6.0 Hz, 3H), 0.68 (d, <i>J</i> = 6.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.61, 173.36, 173.17, 173.11, 171.36, 171.19, 170.85, 170.78, 170.68, 169.89, 169.37, 82.70, 67.08, 60.25, 57.86, 57.08, 54.84, 54.72, 54.18, 49.91, 48.54, 48.24, 47.86, 44.64, 40.61, 39.14, 37.29, 36.16, 34.94, 33.34, 32.63, 31.56, 31.22, 31.14, 29.94, 29.86, 29.60, 25.43, 24.75, 24.64, 24.50, 24.21, 23.76, 23.74, 23.71, 23.64, 23.43, 21.81, 21.21, 20.76, 20.38, 20.21, 19.22, 19.22, 18.50, 18.35, 17.64, 14.93, 9.84. Mass (ESI): <i>m</i>/<i>z</i> calcd for C<sub>60</sub>H<sub>107</sub>N<sub>11</sub>O<sub>12</sub> 1173.81, found 1174.80 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>)-3-methyl-5-(prop-1-en-2-yl)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>7</b>)</h4><div class="NLM_p">Step 1: (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>)-5-acetyl-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>6</b>)</div><div class="NLM_p">Cyclosporin A (100 mg, 0.083 mmol) was dissolved in 1 mL of acetone. Jones reagent (0.3 mL) was added slowly to the solution and stirred at r.t for 16 h. MeOH was added to quench the reaction. The solvent was evaporated to dryness and purified by prep-TLC (DCM/MeOH = 15/1) to give 25 mg of a brown solid. Yield: 24.6%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.24 (d, <i>J</i> = 10.0 Hz, 1H), 7.95 (d, <i>J</i> = 7.2 Hz, 1H), 7.51 (d, <i>J</i> = 8.8 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.28 (dd, <i>J</i> = 8.0, 10.8 Hz, 1H), 5.16–5.21 (m, 2H), 5.07–5.15 (m, 2H), 4.95–5.01 (m, 1H), 4.80–4.89 (m, 3H), 4.69 (d, <i>J</i> = 14.0 Hz, 1H), 4.37–4.44 (m, 1H), 4.21 (dd, <i>J</i> = 5.2, 8.8 Hz, 1H), 4.04–4.11 (m, 1H), 3.48 (s, 3H), 3.37 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.04 (s, 3H), 2.68 (s, 3H), 2.66 (s, 3H), 2.28–2.35 (m, 1H), 2.22–2.25 (m, 1H), 2.19 (s, 3H), 1.91–2.13 (m, 6H), 1.54–1.77 (m, 6H), 1.39–1.48 (m, 2H), 1.29–1.34 (m, 4H), 1.22–1.26 (m, 5H), 0.97–1.02 (m, 10H), 0.91–0.94(m, 8H), 0.84–0.88 (m, 16H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.69 (d, <i>J</i> = 6.4 Hz, 4H). Mass (ESI): <i>m</i>/<i>z</i> calcd for C<sub>62</sub>H<sub>109</sub>N<sub>11</sub>O<sub>13</sub> 1216.62, found 1217.80 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><b>Step 2</b>: To a cooled solution of Ph<sub>3</sub>P<sup>+</sup>-CH<sub>3</sub>Br<sup>–</sup> (71.2 mg, 0.2 mmol) in THF (3 mL) was added <i>t</i>-BuOK (18 mg, 0.16 mmol) in THF (2 mL). The suspension was stirred at −78 °C for 10 min and then warmed to 0 °C for 30 min. The obtained orange solution was cooled to −78 °C again, and a solution of compound <b>5</b> (100 mg, 0.082 mmol) in THF (2 mL) was added. The obtained mixture was stirred at 0 °C for 3 h. The reaction was quenched with H<sub>2</sub>O; the organic layer was separated; the aqueous phase was extracted with ethyl acetate with three times (3 × 5 mL); and the organic phase was combined, dried, filtered, and evaporated under vacuo. The residue was purified by prep. HPLC. A white solid (23 mg) was obtained, yield: 23%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.42 (d, <i>J</i> = 9.6 Hz, 1H), 8.05 (d, <i>J</i> = 7.2 Hz, 1H), 7.64 (d, <i>J</i> = 9.2 Hz, 1H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 5.67 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.34 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.22 (d, <i>J</i> = 11.2 Hz, 1H), 5.11–5.18 (m, 2H), 5.07 (t, <i>J</i> = 6.8 Hz, 1H), 4.93–5.02 (m, 2H), 4.89 (s, 1H), 4.85 (t, <i>J</i> = 7.2 Hz, 1H), 4.73 (s, 1H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.40 (t, <i>J</i> = 7.2 Hz, 1H), 4.29 (t, <i>J</i> = 6.8 Hz, 1H), 4.02–4.08 (m, 2H), 3.48 (s, 3H), 3.37 (s, 3H), 3.22 (s, 3H), 3.16 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 2.24–2.33 (m, 1H), 1.95–2.16 (m, 8H), 1.65–1.75 (m, 3H), 1.64 (s, 3H), 1.54–1.60 (m, 2H), 1.40–1.47 (m, 3H), 1.34 (d, <i>J</i> = 7.2 Hz, 4H), 1.25 (d, <i>J</i> = 6.8 Hz, 4H), 1.05 (d, <i>J</i> = 6.4 Hz, 3H), 0.98–1.01 (m, 9H), 0.92–0.96 (m, 9H), 0.85–0.88 (m, 14H), 0.79 (d, <i>J</i> = 6.8 Hz, 4H), 0.69 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.61, 173.30, 172.89, 172.85, 171.59, 171.17, 170.82, 170.72, 170.28, 169.89, 169.14, 145.36, 130.89, 128.79, 109.77, 82.55, 81.16, 65.54, 60.87, 57.86, 57.10, 54.89, 54.51, 54.33, 50.02, 48.58, 48.31, 47.94, 44.61, 40.53, 40.42, 39.21, 39.10, 37.16, 36.81, 36.32, 32.87, 31.57, 31.28, 31.26, 30.52, 29.93, 29.82, 29.61, 26.02, 24.79, 24.66, 24.63, 24.24, 23.71, 23.68, 23.47, 21.89, 21.36, 20.81, 20.16, 19.43, 19.16, 18.75, 18.70, 18.55, 18.16, 17.75, 14.97, 13.72, 9.84. Mass (ESI): <i>m</i>/<i>z</i> calcd for C<sub>63</sub>H<sub>111</sub>N<sub>11</sub>O<sub>12</sub> 1213.84, found 1214.81 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-33-((2<i>R</i>,3<i>R</i>)-5-isopropyl-3-methyltetrahydrofuran-2-yl)-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>8</b>)</h4><div class="NLM_p last">10% Pd/C (10 mg) and 6 N HCl (0.5 mL) were added to a solution of compound <b>7</b> (70 mg, 0.058 mmol) in MeOH (5 mL). The resulting suspension was stirred under an atmosphere of H<sub>2</sub> at room temperature overnight, and then Pd/C was filtered with celite. It was then concentrated and purified by prep. HPLC to obtain 8 mg of a white solid, yield: 11%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.43 (d, <i>J</i> = 9.6 Hz, 1H), 8.06 (d, <i>J</i> = 7.2 Hz, 1H), 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 7.47 (d, <i>J</i> = 8.0 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.35 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.24 (d, <i>J</i> = 11.2 Hz, 1H), 5.12–5.18 (m, 1H), 5.07 (t, <i>J</i> = 6.8 Hz, 1H), 4.91–5.03 (m, 2H), 4.87–4.89 (m, 1H), 4.84 (t, <i>J</i> = 7.2 Hz, 1H), 4.71–4.73 (m, 1H), 4.65 (d, <i>J</i> = 14.0 Hz, 1H), 4.40 (t, <i>J</i> = 7.2 Hz, 1H), 4.28 (t, <i>J</i> = 6.8 Hz, 1H), 4.02–4.08 (m, 1H), 3.47 (s, 3H), 3.36 (s, 3H), 3.22 (s, 3H), 3.16 (s, 3H), 3.04 (s, 3H), 2.68 (s, 3H), 2.66 (s, 3H), 2.25–2.34 (m, 1H), 1.96–2.18 (m, 8H), 1.65–1.76 (m, 3H), 1.62–1.64 (m, 3H), 1.55–1.61 (m, 2H), 1.41–1.47 (m, 5H), 1.33 (d, <i>J</i> = 7.2 Hz, 4H), 1.26 (d, <i>J</i> = 6.8 Hz, 4H), 1.04 (d, <i>J</i> = 6.4 Hz, 3H), 0.97–1.01 (m, 10H), 0.91–0.96 (m, 10H), 0.84–0.89 (m, 14H), 0.78 (d, <i>J</i> = 6.8 Hz, 4H), 0.68 (d, <i>J</i> = 6.4 Hz, 3H). Mass (ESI): <i>m</i>/<i>z</i> calcd for C<sub>63</sub>H<sub>113</sub>N<sub>11</sub>O<sub>12</sub> 1215.86, found 1217.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (4<i>R</i>,5<i>R</i>)-5-((2<i>S</i>,5<i>S</i>,11<i>S</i>,14<i>S</i>,17<i>S</i>,20<i>S</i>,23<i>R</i>,26<i>S</i>,29<i>S</i>,32<i>S</i>)-5-Ethyl-11,17,26,29-tetraisobutyl-14,32-diisopropyl-1,7,10,16,20,23,25,28,31-nonamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl)-4-methyltetrahydrofuran-2-yl acetate (<b>9</b>)</h4><div class="NLM_p last">Compound <b>2</b> (50 mg, 0.042 mmol) and acetic anhydride (0.3 mL) were dissolved in anhydrous pyridine (3 mL), and the solution was allowed to stand at r.t. for 12 h. The solvent was concentrated and purified by prep. HPLC to obtain 38 mg of a white solid, yield: 76%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.49 (d, <i>J</i> = 9.6 Hz, 1H), 8.33 (d, <i>J</i> = 9.6 Hz, 1H), 8.02 (d, <i>J</i> = 7.2 Hz, 1H), 7.91 (d, <i>J</i> = 6.8 Hz, 1H), 5.62–5.66 (m, 1H), 5.41–5.45 (m, 1H), 5.25–5.29 (m, 2H), 5.13–5.15 (m, 1H), 4.89–4.97 (m, 2H), 4.74–4.80 (m, 2H), 4.55–4.62 (m, 1H), 4.42–4.50 (m, 1H), 4.34–4.37 (m, 1H), 4.24–4.30 (m, 1H), 3.94–4.10 (m, 1H), 3.43 (s, 3H), 3.36 (s, 3H), 3.23 (s, 3H), 3.14 (s, 3H), 2.75 (s, 3H), 2.66 (s, 3H), 2.63 (s, 3H), 2.36–2.42 (m, 1H), 2.29–2.34 (m, 1H), 2.06–2.14 (m, 3H), 1.99 (s, 3H), 1.91–1.96 (m, 3H), 1.67–1.75 (m, 3H), 1.52–1.58 (m, 5H), 1.41–1.46 (m, 3H), 1.30–1.33 (m, 3H), 1.22–1.25 (m, 3H), 1.16–1.19 (m, 4H), 1.13–1.15 (m, 3H), 0.99–1.02 (m, 5H), 0.94–0.96 (m, 5H), 0.91–0.93 (m, 6H), 0.85–0.88 (m, 7H), 0.76–0.79 (m, 6H), 0.67–0.71 (m, 4H), 0.57–0.62 (m, 2H). Mass (ESI): <i>m</i>/<i>z</i> calcd for C<sub>62</sub>H<sub>109</sub>N<sub>11</sub>O<sub>14</sub> 1231.82, found 1232.86 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-(<i>p</i>-tolylthio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>10A</b>)</h4><div class="NLM_p last">To the solution of compound <b>9</b> (360.9 mg, 0.292 mmol) and <i>p</i>-toluenethiol (72.4 mg, 0.584 mmol) in 18 mL of acetonitrile were added <i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide (0.286 mL, 1.168 mmol) and trimethylsilyl trifluoromethanesulfonate (0.159 mL, 0.876 mmol). The solution was stirred at 50 °C under nitrogen for 90 min. The reaction mixture was evaporated to dryness and redissolved with DCM (20 mL). It was washed with sat. NaHCO<sub>3</sub> solution and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The brown residue was purified by prep. HPLC to give 140 mg of compound <b>10A</b> and 42.2 mg of compound <b>10m</b> (α,β-mixture, major:minor = 1:3.3) as a white solid. Total yield: 48.1%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.43 (d, <i>J</i> = 9.6 Hz, 1H), 8.07 (d, <i>J</i> = 6.8 Hz, 1H), 7.67 (d, <i>J</i> = 8.8 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.35 (d, <i>J</i> = 8.0 Hz, 2H), 7.10 (d, <i>J</i> = 8.4 Hz, 2H), 5.67 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.42 (dd, <i>J</i> = 3.6, 7.6 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.22 (d, <i>J</i> = 1.2 Hz, 1H), 5.08–5.14 (m, 3H), 4.97–5.01 (m, 1H), 4.90–4.95 (m, 1H), 4.81–4.88 (m, 2H), 4.65 (d, <i>J</i> = 13.6 Hz, 1H), 4.35–4.40 (m, 1H), 4.29 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.46 (s, 3H), 3.39 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.07 (s, 3H), 2.71 (s, 3H), 2.66 (s, 3H), 2.39–2.47 (m, 1H), 2.31 (s, 3H), 2.22–2.27 (m, 1H), 2.05–2.12 (m, 3H), 1.93–2.01 (m, 3H), 1.60–1.70 (m, 5H), 1.41–1.52 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.26 (d, <i>J</i> = 6.8 Hz, 3H), 1.16 (d, <i>J</i> = 6.8 Hz, 3H), 0.99–1.03 (m, 9H), 0.93–0.95 (m, 8H), 0.89–0.91 (m, 4H), 0.85–0.87 (m, 11H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.77 (d, <i>J</i> = 6.8 Hz, 3H), 0.64 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>67</sub>H<sub>114</sub>N<sub>11</sub>O<sub>12</sub>S 1296.8369, found 1296.8365.</div></div><div id="sec4_8_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Methyl 2-(((4<i>R</i>,5<i>R</i>)-5-((2<i>S</i>,5<i>S</i>,11<i>S</i>,14<i>S</i>,17<i>S</i>,20<i>S</i>,23<i>R</i>,26<i>S</i>,29<i>S</i>,32<i>S</i>)-5-ethyl-11,17,26,29-tetraisobutyl-14,32-diisopropyl-1,7,10,16,20,23,25,28,31-nonamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl)-4-methyltetrahydrofuran-2-yl)oxy)acetate (<b>11</b>)</h4><div class="NLM_p last">Compound <b>10</b> (50 mg, 0.039 mmol), methyl-2-hydroxyacetate (7 mg, 0.078 mmol), silver trifluoromethanesulfonate (10 mg, 0.078 mmol), and activated 3 Å molecular sieves (100 mg) were stirred in dry CH<sub>2</sub>Cl<sub>2</sub> (2 mL) for 2 h under a nitrogen atmosphere in a three-neck flask (10 mL). N-iodosuccinimide (17.6 mg, 0.078 mmol) and activated 3 Å molecular sieves (100 mg) in dry CH<sub>3</sub>CN (1 mL) in another three-neck flask (10 mL) were stirred at r.t. for 2 h. Then, the mixture in the second flask was added to the first one, stirred at r.t. for another 1 h to complete the reaction. The mixture was filtered and diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep. HPLC to give 24 mg of a colorless oil, yield: 48.8%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.35 (d, <i>J</i> = 10.0 Hz, 1H), 8.04 (d, <i>J</i> = 6.8 Hz, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 7.49 (d, <i>J</i> = 7.6 Hz, 1H), 5.67 (dd, <i>J</i> = 4.0, 10.4 Hz, 1H), 5.32 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.21 (d, <i>J</i> = 10.8 Hz, 1H), 5.15–5.07 (m, 4H), 5.02–4.96 (m, 2H), 4.87–4.82 (m, 2H), 4.67 (d, <i>J</i> = 13.6 Hz, 1H), 4.39 (t, <i>J</i> = 7.2 Hz, 1H), 4.22 (dd, <i>J</i> = 4.8, 9.6 Hz, 1H), 4.12 (s, 2H), 3.73 (s, 3H), 3.47 (s, 3H), 3.40 (s, 3H), 3.24 (s, 3H), 3.18 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 2.37–2.31 (m, 2H), 2.15–2.00 (m, 6H), 1.70–1.60 (m, 5H), 1.50–1.40 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.27 (m, 3H), 1.21 (d, <i>J</i> = 6.8 Hz, 3H), 1.03–1.00 (m, 8H), 0.95–0.92 (m, 8H), 0.89–0.88 (m, 4H), 0.87–0.84 (m, 15H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.70 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>63</sub>H<sub>112</sub>N<sub>11</sub>O<sub>15</sub> 1262.8339, found 1262.8299.</div></div><div id="sec4_8_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Methyl 3-(((4<i>R</i>,5<i>R</i>)-5-((2<i>S</i>,5<i>S</i>,11<i>S</i>,14<i>S</i>,17<i>S</i>,20<i>S</i>,23<i>R</i>,26<i>S</i>,29<i>S</i>,32<i>S</i>)-5-Ethyl-11,17,26,29-tetraisobutyl-14,32-diisopropyl-1,7,10,16,20,23,25,28,31-nonamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl)-4-methyltetrahydrofuran-2-yl)oxy)propanoate (<b>12</b>)</h4><div class="NLM_p last">The title compound was obtained as a yellow oil using a method similar to that described for compound <b>11</b> in 34.1% yield in one step. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.36 (d, <i>J</i> = 10.0 Hz, 1H), 8.05 (d, <i>J</i> = 6.8 Hz, 1H), 7.58 (d, <i>J</i> = 9.2 Hz, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 5.67 (dd, <i>J</i> = 4.4, 10.8 Hz, 1H), 5.32 (dd, <i>J</i> = 4.0, 11.6 Hz, 1H), 5.22 (d, <i>J</i> = 11.2 Hz, 1H), 5.15–5.07 (m, 3H), 5.01–4.95 (m, 1H), 4.91 (d, <i>J</i> = 4.8 Hz, 1H), 4.88–4.84 (m, 2H), 4.67 (d, <i>J</i> = 14.0 Hz, 1H), 4.39 (t, <i>J</i> = 7.2 Hz, 1H), 4.15 (dd, <i>J</i> = 4.8, 9.6 Hz, 1H), 3.92–3.86 (m, 1H), 3.68 (s, 3H), 3.49 (s, 3H), 3.40 (s, 3H), 3.23 (s, 3H), 3.18 (s, 3H), 3.06 (s, 3H), 2.79–2.77 (m, 2H), 2.70 (s, 3H), 2.67 (s, 3H), 2.56 (t, <i>J</i> = 7.2 Hz, 2H), 2.37–2.30 (m, 2H), 2.17–2.07 (m, 3H), 2.05–1.99 (m, 3H), 1.70–1.57 (m, 5H), 1.56–1.46 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.26 (m, 3H), 1.14 (d, <i>J</i> = 6.8 Hz, 3H), 1.02–1.00 (m, 8H), 0.95–0.92 (m, 8H), 0.89–0.88 (m, 4H), 0.87 (m, 5H), 0.87–0.84 (m, 10H), 0.81 (d, <i>J</i> = 6.8 Hz, 4H), 0.73 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]+ calcd for C64H114N11O15 1276.8496, found 1276.8472.</div></div><div id="sec4_8_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3-(((4<i>R</i>,5<i>R</i>)-5-((2<i>S</i>,5<i>S</i>,11<i>S</i>,14<i>S</i>,17<i>S</i>,20<i>S</i>,23<i>R</i>,26<i>S</i>,29<i>S</i>,32<i>S</i>)-5-ethyl-11,17,26,29-tetraisobutyl-14,32-diisopropyl-1,7,10,16,20,23,25,28,31-nonamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2-yl)-4-methyltetrahydrofuran-2-yl)oxy)propanoic Acid (<b>13</b>)</h4><div class="NLM_p last">To a well-stirred solution of compound <b>12</b> (145 mg, 0.114 mmol) in CH<sub>3</sub>OH (4 mL) was added 1 N NaOH (2 mL) at 0 °C. The mixture was stirred at r.t. for 4.5 h. Then, it was evaporated under a reduced pressure to give a yellow liquid. 1 N HCl was added until pH 1. Then, CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 mL) was added to the above system. The organic layers were combined and washed with saturated aqueous NaCl (50 mL), dried, and concentrated. The crude product was purified by prep. HPLC to afford 20 mg of a white solid. Yield: 14.0%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.28 (d, <i>J</i> = 6.8 Hz, 1H), 8.06 (d, <i>J</i> = 7.2 Hz, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 1H), 5.68 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.35 (dd, <i>J</i> = 3.6, 10.8 Hz, 1H), 5.16–5.09 (m, 4H), 5.01–4.97(m, 2H), 4.88 (t, <i>J</i> = 7.4 Hz, 1H), 4.80 (t, <i>J</i> = 8.8 Hz, 1H), 4.67 (d, <i>J</i> = 13.2 Hz, 1H), 4.41 (t, <i>J</i> = 7.2 Hz, 1H), 4.17 (dd, <i>J</i> = 4.8, 8.8 Hz, 1H), 3.98–3.93 (m, 2H), 3.79–3.74 (m, 1H), 3.50 (s, 3H), 3.41 (s, 3H), 3.25 (s, 3H), 3.18 (s, 3H), 3.07 (s, 3H), 2.81–2.74 (m, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.38- 2.36 (m, 2H), 2.20–2.04 (m, 4H), 1.67–1.58 (m, 3 H), 1.53–1.49 (m, 2H), 1.32–1.30 (m, 4H), 1.28–1.25 (m, 7H), 1.15 (d, <i>J</i> = 6.8 Hz, 3H), 1.06–1.03 (m, 4H), 1.01–0.99 (m, 4H), 0.96–0.94 (m, 6H), 0.93–0.92 (m, 3H), 0.90–0.87 (m, 13H), 0.85–0.83 (m, 9H), 0.73 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>63</sub>H<sub>112</sub>N<sub>11</sub>O<sub>15</sub> 1262.8339, found 1262.8309.</div></div><div id="sec4_8_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>R</i>)-3-methyl-5-(phenylthio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>14B</b>)</h4><div class="NLM_p last">The title compound was obtained as a colorless oil using a method similar to that described for compound <b>9</b> in 4.8% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.44 (d, <i>J</i> = 8.8 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.71 (d, <i>J</i> = 8.0 Hz, 1H), 7.55 (d, <i>J</i> = 7.6 Hz, 1H), 7.40–7.46 (m, 2H), 7.27–7.32 (m, 1H), 7.17–7.22 (m, 2H), 5.65–5.69 (m, 1H), 5.47–5.50 (m, 1H), 5.32–5.37 (m, 1H), 5.18–5.24 (m, 2H), 5.07–5.14 (m, 2H), 4.98–5.04 (m, 1H), 4.90–4.96 (m, 1H), 4.84–4.88 (m, 1H), 4.62–4.69 (m, 1H), 4.35–4.43 (m, 1H), 4.26–4.33 (m, 1H), 4.06–4.11 (m, 1H), 3.45 (s, 3H), 3.39 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.07 (s, 3H), 2.71 (s, 3H), 2.66 (s, 3H), 2.41–2.48 (m, 1H), 2.26–2.34 (m, 1H), 2.04–2.16 (m, 3H), 1.97–2.03 (m, 3H), 1.60–1.69 (m, 5H), 1.40–1.52 (m, 3H), 1.31–1.35 (m, 6H), 1.25–1.27 (m, 9H), 1.15–1.19 (m, 4H), 1.01–1.05 (m, 6H), 0.93–0.96 (m, 7H), 0.85–0.89 (m, 13H), 0.75–0.77 (m, 3H), 0.60–0.63 (m, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>66</sub>H<sub>112</sub>N<sub>11</sub>O<sub>12</sub>S 1282.8213, found 1282.8212.</div></div><div id="sec4_8_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((4-(trifluoromethyl)pyrimidin-2-yl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>15A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 1.8% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.74 (d, <i>J</i> = 5.2 Hz, 1H), 8.40 (d, <i>J</i> = 10.0 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.29 (d, <i>J</i> = 6.8 Hz, 1H), 5.68 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.33–5.36 (m, 2H), 5.16–5.21 (m, 3H), 4.95–5.01 (m, 2H), 4.89–4.92 (m, 1H), 4.84–4.87 (m, 2H), 4.68 (d, <i>J</i> = 13.6 Hz, 1H), 4.39–4.44 (m, 1H), 4.32–4.34 (m, 1H), 3.41 (s, 3H), 3.38 (s, 3H), 3.25 (s, 3H), 3.19 (s, 3H), 3.07 (s, 3H), 2.69 (s, 3H), 2.68 (s, 3H), 2.47–2.54 (m, 1H), 2.28–2.32 (m, 1H), 2.12–2.17 (m, 3H), 2.02–2.06 (m, 3H), 1.63–1.71 (m, 6H), 1.45–1.49 (m, 2H), 1.33–1.35 (m, 6H), 1.26–1.28 (m, 3H), 1.00–1.03 (m, 8H), 0.93–0.96 (m, 12H), 0.87–0.89 (m, 12H), 0.80–0.83 (m, 7H), 0.77 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>65</sub>H<sub>109</sub>F<sub>3</sub>N<sub>13</sub>O<sub>12</sub>S 1352.7991, found 1352.7955.</div></div><div id="sec4_8_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((4-methoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>16A</b>) (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-33-((2<i>R</i>,3<i>R</i>,5<i>R</i>)-5-((4-methoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>16B</b>)</h4><div class="NLM_p">The title compounds <b>16A</b> and <b>16B</b> were obtained as a white solid using a method similar to that described for compound <b>9</b> in 47.1 and 7.5% yields in one step, respectively.</div><div id="sec4_8_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Compound <b>16A</b></h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 9.6 Hz, 1H), 8.05 (d, <i>J</i> = 6.8 Hz, 1H), 7.64 (d, <i>J</i> = 9.2 Hz, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.8 Hz, 2H), 6.84 (d, <i>J</i> = 9.2 Hz, 2H), 5.65 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.32 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.27–5.31 (m, 1H), 5.19 (t, <i>J</i> = 9.2 Hz, 2H), 5.04–5.12 (m, 3H), 4.95–5.01 (m, 1H), 4.89–4.93 (m, 1H), 4.82–4.86 (m, 1H), 4.65 (d, <i>J</i> = 14.0 Hz, 1H), 4.34–4.41 (m, 1H), 4.26 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.78 (s, 3H), 3.46 (s, 3H), 3.38 (s, 3H), 3.21 (s, 3H), 3.17 (s, 3H), 3.05 (s, 3H), 2.70 (s, 3H), 2.65 (s, 3H), 2.34–2.41 (m, 1H), 2.25–2.31 (m, 1H), 2.07–2.15 (m, 3H), 1.93–1.98 (m, 3H), 1.59–1.68 (m, 5H), 1.41–1.47 (m, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.24 (d, <i>J</i> = 6.8 Hz, 3H), 1.14 (d, <i>J</i> = 6.8 Hz, 3H), 0.99–1.01 (m, 4H), 0.97–0.98 (m, 4H), 0.93–0.95 (m, 10H), 0.89–0.90 (m, 6H), 0.85–0.86 (m, 8H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.74 (d, <i>J</i> = 6.4 Hz, 3H), 0.59 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.64, 173.06, 172.86, 171.41, 171.32, 171.14, 170.86, 170.70, 170.24, 169.80, 168.62, 159.12, 134.67, 133.64(2C), 126.14, 114.39(5C), 87.71, 81.60, 59.96, 57.85, 57.01, 55.21, 54.91, 54.54, 54.20, 50.03, 48.66, 48.00, 44.64, 41.20, 40.67, 39.22, 39.01, 37.12, 36.28, 35.27, 32.59, 31.56, 31.24, 31.18, 29.88, 29.65, 25.95, 24.80, 24.67, 24.59, 24.43, 23.69, 23.62, 23.45, 23.29, 21.88, 21.39, 21.13, 20.10, 20.00, 18.81, 18.67, 18.59, 17.70, 15.06, 9.82. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>67</sub>H<sub>114</sub>N<sub>11</sub>O<sub>13</sub>S 1312.8318, found 1312.8287.</div></div><div id="sec4_8_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Compound <b>16B</b></h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (d, <i>J</i> = 9.6 Hz, 1H), 7.99 (d, <i>J</i> = 6.8 Hz, 1H), 7.45 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (d, <i>J</i> = 8.8 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 1H), 6.83 (d, <i>J</i> = 8.8 Hz, 2H), 5.68 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.31 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.18–5.24 (m, 3H), 5.07–5.16 (m, 3H), 4.92–4.98 (m, 1H), 4.83–4.88 (m, 2H), 4.67 (d, <i>J</i> = 14.0 Hz, 1H), 4.40–4.48 (m, 1H), 4.03 (dd, <i>J</i> = 5.6, 8.0 Hz, 1H), 3.79 (s, 3H), 3.54 (s, 3H), 3.27 (s, 3H), 3.25 (s, 3H), 3.17 (s, 3H), 3.07 (s, 3H), 2.70 (s, 6H), 2.30–2.39 (m, 1H), 2.20–2.27 (m, 1H), 2.10–2.16 (m, 3H), 1.93–2.01 (m, 3H), 1.78–1.90 (m, 4H), 1.58–1.70 (m, 4H), 1.40–1.49 (m, 3H), 1.34 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.03 (d, <i>J</i> = 6.8 Hz, 3H), 0.99 (d, <i>J</i> = 6.8 Hz, 3H), 0.95–0.97 (m, 5H), 0.92–0.95 (m, 13H), 0.87–0.89 (m, 8H), 0.82–0.85 (m, 7H), 0.74 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>67</sub>H<sub>114</sub>N<sub>11</sub>O<sub>13</sub>S 1312.8318, found 1312.8285.</div></div></div><div id="sec4_8_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((4-Butylphenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>17A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 9.2% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.41 (d, <i>J</i> = 9.6 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.35 (d, <i>J</i> = 8.0 Hz, 2H), 7.10 (d, <i>J</i> = 8.0 Hz, 2H), 5.68 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.44 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.22 (d, <i>J</i> = 6.4 Hz, 1H), 5.19 (d, <i>J</i> = 5.2 Hz, 1H), 5.08–5.15 (m, 2H), 4.97–5.02 (m, 1H), 4.91–4.95 (m, 1H), 4.83–4.87 (m, 2H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.35–4.43 (m, 1H), 4.29 (dd, <i>J</i> = 6.4, 9.6 Hz, 1H), 3.46 (s, 3H), 3.38 (s, 3H), 3.21 (s, 3H), 3.18 (s, 3H), 3.06 (s, 3H), 2.71 (s, 3H), 2.67 (s, 3H), 2.56 (t, <i>J</i> = 8.0 Hz, 2H), 2.41–2.45 (m, 1H), 2.26–2.29 (m, 2H), 2.06–2.18 (m, 5H), 1.93–2.02 (m, 3H), 1.55–1.65 (m, 7H), 1.34 (d, <i>J</i> = 6.8 Hz, 4H), 1.26 (d, <i>J</i> = 6.8 Hz, 4H), 1.16 (d, <i>J</i> = 6.8 Hz, 3H), 0.99–1.03 (m, 9H), 0.92–0.95 (m, 10H), 0.89–0.90 (m, 6H), 0.85–0.87 (m, 10H), 0.82 (d, <i>J</i> = 6.4 Hz, 4H), 0.78 (d, <i>J</i> = 6.4 Hz, 3H), 0.66 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup>calcd for C<sub>70</sub>H<sub>120</sub>N<sub>11</sub>O<sub>12</sub>S 1338.8839, found 1338.8806.</div></div><div id="sec4_8_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)phenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>18A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 21.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.41 (d, <i>J</i> = 9.2 Hz, 1H), 8.05 (d, <i>J</i> = 6.4 Hz, 1H), 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 7.52 (d, <i>J</i> = 7.6 Hz, 1H), 7.39 (m, 2H), 7.16–7.23 (m, 2H), 5.64–5.68 (m, 1H), 5.51–5.53 (m, 1H), 5.30–5.34 (m, 1H), 5.10–5.23 (m, 4H), 4.96–5.02 (m, 1H), 4.81–4.92 (m, 3H), 4.65 (d, <i>J</i> = 13.6 Hz, 1H), 4.37–4.42 (m, 1H), 4.29–4.31 (m, 1H), 3.54 (s, 2H), 3.42 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.06 (s, 3H), 2.94–2.99 (m, 2H), 2.82–2.92 (m, 6H), 2.77 (s, 3H), 2.70 (s, 3H), 2.67 (s, 3H), 2.41–2.49 (m, 1H), 2.27–2.34 (m, 1H), 2.09–2.18 (m, 3H), 1.92–2.06 (m, 3H), 1.57–1.74 (m, 6H), 1.45–1.55 (m, 2H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.26 (d, <i>J</i> = 7.2 Hz, 3H), 1.17 (d, <i>J</i> = 6.4 Hz, 3H), 0.99–1.04 (m, 8H), 0.93–0.95 (m, 10H), 0.84–0.90 (m, 14H), 0.79–0.83 (m, 7H), 0.69 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.72, 173.14, 173.03, 172.94, 171.39, 171.13, 170.82, 170.73, 170.29, 169.91, 168.56, 129.58, 86.22, 81.77, 61.36, 59.68, 57.89, 57.00, 54.91, 54.57, 54.11, 53.70, 50.03, 49.48, 48.65, 48.31, 47.99, 44.65, 43.55, 43.54, 41.31, 40.92, 39.21, 39.04, 37.20, 36.25, 35.24, 32.59, 31.56, 31.26, 31.19, 29.98, 29.92, 29.71, 29.66, 29.57, 25.88, 24.79, 24.68, 24.60, 24.45, 24.02, 23.69, 23.62, 23.46, 23.41, 23.36, 22.75, 21.88, 21.72, 21.35, 21.29, 21.24, 20.22, 20.07, 18.89, 18.60, 18.57, 18.50, 17.66, 15.02, 9.82. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>72</sub>H<sub>124</sub>N<sub>13</sub>O<sub>12</sub>S 1394.9213, found 1394.9305.</div></div><div id="sec4_8_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((4-morpholinophenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>19A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 28.9% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 9.6 Hz, 1H), 8.03 (d, <i>J</i> = 6.8 Hz, 1H), 7.63 (d, <i>J</i> = 9.2 Hz, 1H), 7.51 (d, <i>J</i> = 7.6 Hz, 1H), 7.38 (d, <i>J</i> = 8.8 Hz, 2H), 6.81–7.00 (m, 2H), 5.66 (dd, <i>J</i> = 4.4, 10.8 Hz, 1H), 5.34 (d, <i>J</i> = 4.0 Hz, 1H), 5.31 (d, <i>J</i> = 4.4 Hz, 1H), 5.21 (d, <i>J</i> = 8.8 Hz, 1H), 5.19 (d, <i>J</i> = 6.0 Hz, 1H), 5.06–5.14 (m, 2H), 4.98–5.02 (m, 1H), 4.81–4.96 (m, 3H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.35–4.42 (m, 1H), 4.25 (dd, <i>J</i> = 6.4, 8.8 Hz, 1H), 3.80–3.92 (m, 4H), 3.45 (s, 3H), 3.39 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.14–3.17 (m, 4H), 3.06 (s, 3H), 2.70 (s, 3H), 2.66 (s, 3H), 2.36–2.43 (m, 1H), 2.28–2.33 (m, 1H), 2.05–2.13 (m, 3H), 1.93–2.00 (m, 3H), 1.57–1.65 (m, 4H), 1.42–1.50 (m, 2H), 1.33 (d, <i>J</i> = 7.2 Hz, 4H), 1.25 (d, <i>J</i> = 6.8 Hz, 4H), 1.15 (d, <i>J</i> = 6.8 Hz, 3H), 0.97–1.02 (m, 8H), 0.92–0.96 (m, 9H), 0.87–0.90 (m, 8H), 0.85–0.86 (m, 8H), 0.81 (d, <i>J</i> = 6.4 Hz, 3H), 0.79 (d, <i>J</i> = 6.4 Hz, 3H), 0.66 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>70</sub>H<sub>119</sub>ClN<sub>12</sub>O<sub>13</sub>S 1367.8740, found 1367.8741.</div></div><div id="sec4_8_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((4-(Benzyloxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>20A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 14.8% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (d, <i>J</i> = 9.2 Hz, 1H), 8.03 (d, <i>J</i> = 6.8 Hz, 1H), 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 7.50 (d, <i>J</i> = 7.6 Hz, 1H), 7.36–7.41 (m, 7H), 6.92 (d, <i>J</i> = 8.8 Hz, 2H), 5.66 (dd, <i>J</i> = 3.6, 10.8 Hz, 1H), 5.30–5.36 (m, 2H), 5.21 (d, <i>J</i> = 8.8 Hz, 1H), 5.19 (d, <i>J</i> = 7.2 Hz, 1H), 5.05–5.13 (m, 3H), 5.04 (s, 2H), 4.99 (t, <i>J</i> = 7.2 Hz, 1H), 4.92 (t, <i>J</i> = 8.0 Hz, 1H), 4.85 (t, <i>J</i> = 7.2 Hz, 1H), 4.66 (d, <i>J</i> = 13.2 Hz, 1H), 4.36–4.42 (m, 1H), 4.27 (dd, <i>J</i> = 6.4, 8.8 Hz, 1H), 3.47 (s, 3H), 3.38 (s, 3H), 3.21 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.70 (s, 3H), 2.66 (s, 3H), 2.36–2.43 (m, 1H), 2.26–2.32 (m, 1H), 2.07–2.16 (m, 3H), 1.94–2.01 (m, 3H), 1.58–1.71 (m, 5H), 1.42–1.50 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25–1.28 (m, 3H), 1.14 (d, <i>J</i> = 6.4 Hz, 3H), 1.01 (d, <i>J</i> = 6.4 Hz, 3H), 0.93–0.97 (m, 13H), 0.89–0.90 (m, 4H), 0.84–0.87 (m, 12H), 0.81 (d, <i>J</i> = 6.0 Hz, 4H), 0.77 (d, <i>J</i> = 6.4 Hz, 3H), 0.63 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>118</sub>N<sub>11</sub>O<sub>13</sub>S 1388.8631, found 1388.8594.</div></div><div id="sec4_8_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-hydroxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>21A</b>)</h4><div class="NLM_p last">The title compound was obtained as a brown solid using a method similar to that described for compound <b>9</b> in 2.3% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.97 (brs, 1H), 8.44 (d, <i>J</i> = 9.2 Hz, 1H), 8.12 (d, <i>J</i> = 7.2 Hz, 1H), 7.74 (d, <i>J</i> = 9.2 Hz, 1H), 7.60 (d, <i>J</i> = 8.4 Hz, 1H), 7.29 (t, <i>J</i> = 2.0 Hz, 1H), 7.08 (t, <i>J</i> = 8.0 Hz, 1H), 6.74 (d, <i>J</i> = 8.0 Hz, 1H), 6.67–6.70 (m, 1H), 5.64 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.58 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.34–5.38 (m, 3H), 5.24 (dd, <i>J</i> = 6.8, 9.2 Hz, 1H), 5.18 (t, <i>J</i> = 6.8 Hz, 1H), 4.99–5.05 (m, 2H), 4.86–4.91 (m, 2H), 4.65 (d, <i>J</i> = 13.2 Hz, 1H), 4.38–4.45 (m, 1H), 4.28 (dd, <i>J</i> = 8.0, 9.6 Hz, 1H), 3.44 (s, 3H), 3.43 (s, 3H), 3.24 (s, 3H), 3.18 (s, 3H), 3.09 (s, 3H), 2.73 (s, 3H), 2.69 (s, 3H), 2.32–2.42 (m, 1H), 2.14–2.21 (m, 2H), 1.98–2.11 (m, 3H), 1.88–1.97 (m, 2H), 1.62–1.70 (m, 5H), 1.41–1.49 (m, 3H), 1.31 (d, <i>J</i> = 7.2 Hz, 3H), 1.27 (d, <i>J</i> = 7.2 Hz, 3H), 1.26 (d, <i>J</i> = 4.8 Hz, 3H), 1.12 (d, <i>J</i> = 6.8 Hz, 3H), 1.00–1.04 (m, 6H), 0.91–0.95 (m, 14H), 0.86–0.89 (m, 12H), 0.84 (d, <i>J</i> = 2.8 Hz, 4H), 0.76 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>66</sub>H<sub>112</sub>N<sub>11</sub>O<sub>13</sub>S 1298.8162, found 1298.8151.</div></div><div id="sec4_8_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-methoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>22A</b>)</h4><div class="NLM_p last">The title compound was obtained as a pale yellow solid using a method similar to that described for compound <b>9</b> in 28.3% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 9.6 Hz, 1H), 8.04 (d, <i>J</i> = 6.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 1H), 7.21 (t, <i>J</i> = 8.0 Hz, 1H), 7.07 (d, <i>J</i> = 8.0 Hz, 1H), 6.96 (t, <i>J</i> = 2.0 Hz, 1H), 6.74 (dd, <i>J</i> = 2.4, 8.0 Hz, 1H), 5.67 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.48 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.32 (dd, <i>J</i> = 3.6, 11.2 Hz, 1H), 5.16–5.20 (m, 2H), 5.06–5.12 (m, 3H), 4.95–5.01 (m, 1H), 4.92 (t, <i>J</i> = 8.0 Hz, 1H), 4.82–4.87 (m, 1H), 4.65 (d, <i>J</i> = 14.0 Hz, 1H), 4.36–4.43 (m, 1H), 4.32 (dd, <i>J</i> = 6.0, 9.2 Hz, 1H), 3.78 (s, 3H), 3.45 (s, 3H), 3.37 (s, 3H), 3.21 (s, 3H), 3.17 (s, 3H), 3.05 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.37–2.44 (m, 1H), 2.24–2.33 (m, 1H), 2.07–2.15 (m, 3H), 1.92–2.01 (m, 3H), 1.58–1.70 (m, 5H), 1.43–1.50 (m, 3H), 1.32 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 5.6 Hz, 3H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H), 0.99–1.01 (m, 8H), 0.93–0.94 (m, 9H), 0.88–0.90 (m, 4H), 0.84–0.86 (m, 11H), 0.80 (d, <i>J</i> = 6.4 Hz, 4H), 0.76 (d, <i>J</i> = 6.8 Hz, 3H), 0.60 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.70, 173.18, 173.10, 173.07, 171.48, 171.14, 170.85, 170.72, 170.33, 169.86, 168.66, 159.48, 137.41, 131.79, 129.72, 122.60, 115.16, 113.08, 87.00, 82.09, 60.09, 57.87, 57.03, 55.29, 54.88, 54.53, 54.20, 50.02, 48.62, 48.28, 47.96, 44.60, 41.14, 40.79, 39.22, 39.09, 37.21, 36.30, 35.04, 32.61, 31.63, 31.28, 31.20, 29.93,, 29.86, 29.64, 25.92, 24.82, 24.69, 24.55, 24.34, 23.84, 23.74, 23.61, 23.48, 23.35, 21.89, 21.39, 21.08, 20.50, 20.24, 18.81, 18.66, 18.58, 17.68, 14.95, 9.87. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>67</sub>H<sub>114</sub>N<sub>11</sub>O<sub>13</sub>S 1312.8318, found 1312.8298.</div></div><div id="sec4_8_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-Ethoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>23A</b>)</h4><div class="NLM_p last">The title compound was obtained as a light yellow solid using a method similar to that described for compound <b>9</b> in 17.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 9.6 Hz, 1H), 8.04 (d, <i>J</i> = 6.8 Hz, 1H), 7.61 (d, <i>J</i> = 8.8 Hz, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 7.21 (t, <i>J</i> = 8.0 Hz, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 6.91 (t, <i>J</i> = 1.6 Hz, 1H), 6.73 (dd, <i>J</i> = 1.6, 7.6 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.48 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.21 (d, <i>J</i> = 6.4 Hz, 1H), 5.18 (d, <i>J</i> = 4.4 Hz, 1H), 5.06–5.13 (m, 2H), 4.92–5.02 (m, 2H), 4.81–4.87 (m, 2H), 4.65 (d, <i>J</i> = 13.6 Hz, 1H), 4.36–4.43 (m, 1H), 4.31 (dd, <i>J</i> = 6.0, 9.2 Hz, 1H), 4.00 (q, <i>J</i> = 6.8 Hz, 2H), 3.45 (s, 3H), 3.37 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.37–2.45 (m, 1H), 2.26–2.34 (m, 1H), 2.08–2.16 (m, 3H), 1.94–2.04 (m, 3H), 1.53–1.70 (m, 6H), 1.44–1.51 (m, 2H), 1.40 (t, <i>J</i> = 6.8 Hz, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H), 0.97–1.01 (m, 8H), 0.93–0.95 (m, 9H), 0.89–0.91 (m, 4H), 0.84–0.88 (m, 11H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.78 (d, <i>J</i> = 6.8 Hz, 3H), 0.61 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup>calcd for C<sub>68</sub>H<sub>116</sub>N<sub>11</sub>O<sub>13</sub>S 1326.8475, found 1326.8461.</div></div><div id="sec4_8_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-propoxyphenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>24A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 21.5% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 9.6 Hz, 1H), 8.03 (d, <i>J</i> = 6.8 Hz, 1H), 7.61 (d, <i>J</i> = 8.8 Hz, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 1H), 7.20 (t, <i>J</i> = 8.0 Hz, 1H), 7.08 (d, <i>J</i> = 8.0 Hz, 1H), 6.90 (t, <i>J</i> = 1.6 Hz, 1H), 6.73 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 5.65 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.46 (dd, <i>J</i> = 3.2, 7.6 Hz, 1H), 5.32 (dd, <i>J</i> = 3.2, 10.8 Hz, 1H), 5.17–5.20 (m, 2H), 5.04–5.12 (m, 3H), 4.94–5.00 (m, 1H), 4.91 (t, <i>J</i> = 8.0 Hz, 1H), 4.83 (t, <i>J</i> = 7.2 Hz, 1H), 4.64 (d, <i>J</i> = 13.6 Hz, 1H), 4.35–4.42 (m, 1H), 4.30 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.88 (t, <i>J</i> = 6.4 Hz, 2H), 3.44 (s, 3H), 3.36 (s, 3H), 3.21 (s, 3H), 3.16 (s, 3H), 3.05 (s, 3H), 2.68 (s, 3H), 2.64 (s, 3H), 2.37–2.44 (m, 1H), 2.25–2.33 (m, 1H), 2.06–2.15 (m, 3H), 1.93–2.02 (m, 3H), 1.73–1.82 (m, 2H), 1.57–1.66 (m, 5H), 1.41–1.50 (m, 3H), 1.32 (d, <i>J</i> = 7.2 Hz, 3H), 1.24 (d, <i>J</i> = 6.0 Hz, 3H), 1.16 (d, <i>J</i> = 6.8 Hz, 3H), 0.97–1.02 (m, 12H), 0.92–0.94 (m, 8H), 0.88–0.89 (m, 4H), 0.83–0.86 (m, 11H), 0.79 (d, <i>J</i> = 6.8 Hz, 4H), 0.77 (d, <i>J</i> = 6.8 Hz, 3H), 0.61 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.65, 173.13, 173.08, 173.00, 171.45, 171.13, 170.82, 170.70, 170.30, 169.77, 168.65, 158.91, 137.09, 129.77, 122.52, 116.24, 113.35, 86.76, 81.95, 69.41, 59.90, 57.82, 57.01, 54.88, 54.53, 54.18, 50.00, 48.63, 48.30, 47.95, 44.60, 41.19, 40.77, 39.21, 39.03, 37.19, 36.26, 35.11, 32.61, 31.59, 31.25, 31.16, 29.89, 29.87, 29.74, 29.62, 25.88, 24.80, 24.66, 24.58, 24.37, 23.80, 23.70, 23.55, 23.44, 23.34, 22.51, 21.87, 21.37, 21.10, 20.21, 20.16, 18.82, 18.63, 18.56, 17.68, 14.97, 10.47, 9.82. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>69</sub>H<sub>118</sub>N<sub>11</sub>O<sub>13</sub>S 1340.8631, found 1340.8603.</div></div><div id="sec4_8_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-(Cyclopropylmethoxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>25A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 18.3% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.36 (d, <i>J</i> = 9.2 Hz, 1H), 8.05 (d, <i>J</i> = 6.4 Hz, 1H), 7.63 (d, <i>J</i> = 9.2 Hz, 1H), 7.49 (d, <i>J</i> = 7.6 Hz, 1H), 7.20 (t, <i>J</i> = 8.0 Hz, 1H), 7.08–7.11 (m, 1H), 6.89 (s, 1H), 6.74 (dd, <i>J</i> = 0.8, 8.0 Hz, 1H), 5.65 (dd, <i>J</i> = 3.2, 10.4 Hz, 1H), 5.46 (dd, <i>J</i> = 3.6, 7.6 Hz, 1H), 5.31 (dd, <i>J</i> = 3.2, 10.8 Hz, 1H), 5.16–5.19 (m, 2H), 5.05–5.12 (m, 2H), 4.93–4.99 (m, 2H), 4.89 (t, <i>J</i> = 8.4 Hz, 1H), 4.83 (t, <i>J</i> = 7.6 Hz, 1H), 4.64 (d, <i>J</i> = 14.0 Hz, 1H), 4.34–4.41 (m, 1H), 4.29 (dd, <i>J</i> = 6.4, 8.4 Hz, 1H), 3.76 (d, <i>J</i> = 6.8 Hz, 2H), 3.43 (s, 3H), 3.35 (s, 3H), 3.20 (s, 3H), 3.16 (s, 3H), 3.04 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.38–2.45 (m, 1H), 2.24–2.30 (m, 1H), 2.03–2.17 (m, 4H), 1.91–2.01 (m, 2H), 1.53–1.67 (m, 5H), 1.40–1.48 (m, 3H), 1.31 (d, <i>J</i> = 7.2 Hz, 3H), 1.24 (d, <i>J</i> = 6.4 Hz, 3H), 1.15 (d, <i>J</i> = 6.4 Hz, 3H), 0.96–1.00 (m, 8H), 0.92–0.93 (m, 8H), 0.87–0.89 (m, 4H), 0.83–0.86 (m, 11H), 0.80 (d, <i>J</i> = 6.4 Hz, 4H), 0.76 (d, <i>J</i> = 6.8 Hz, 4H), 0.67–0.68 (m, 1H), 0.60–0.62 (m, 4H), 0.32 (q, <i>J</i> = 4.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup>calcd for C<sub>70</sub>H<sub>118</sub>N<sub>11</sub>O<sub>13</sub>S 1352.8631, found 1352.8602.</div></div><div id="sec4_8_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-((tetrahydro-2<i>H</i>-pyran-4-yl)methoxy)phenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>26A</b>)</h4><div class="NLM_p last">The title compound was obtained as a light yellow solid using a method similar to that described for compound <b>9</b> in 14.2% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.40 (d, <i>J</i> = 9.6 Hz, 1H), 8.05 (d, <i>J</i> = 6.8 Hz, 1H), 7.65 (d, <i>J</i> = 9.2 Hz, 1H), 7.51 (d, <i>J</i> = 8.0 Hz, 1H), 7.22 (t, <i>J</i> = 8.0 Hz, 1H), 7.12 (d, <i>J</i> = 7.6 Hz, 1H), 6.89 (s, 1H), 6.73 (dd, <i>J</i> = 1.6, 7.6 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.47 (dd, <i>J</i> = 3.6, 7.6 Hz, 1H), 5.33 (dd, <i>J</i> = 3.6, 11.2 Hz, 1H), 5.21 (d, <i>J</i> = 5.2 Hz, 1H), 5.18 (d, <i>J</i> = 7.2 Hz, 1H), 5.06–5.13 (m, 2H), 4.96–5.01 (m, 1H), 4.89–4.93 (m, 1H), 4.78–4.89 (m, 2H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.37–4.45 (m, 1H), 4.30 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 4.01 (dd, <i>J</i> = 3.2, 11.2 Hz, 3H), 3.78 (d, <i>J</i> = 6.8 Hz, 3H), 3.44 (s, 3H), 3.37 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.38–2.46 (m, 1H), 2.26–2.33 (m, 1H), 2.02–2.16 (m, 6H), 1.93–2.00 (m, 2H), 1.74–1.77 (m, 3H), 1.58–1.69 (m, 5H), 1.40–1.49 (m, 3H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.17 (d, <i>J</i> = 6.8Hz, 3H), 0.98–1.01 (m, 8H), 0.90–0.95 (m, 10H), 0.84–0.88 (m, 14H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.77 (d, <i>J</i> = 6.4 Hz, 3H), 0.61 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.68, 173.20, 173.12, 173.00, 171.51, 171.14, 170.82, 170.74, 170.32, 169.80, 168.67, 158.79, 137.30, 129.88, 122.67, 116.21, 113.28, 86.72, 81.94, 72.49, 70.93, 67.62, 59.93, 57.85, 57.06, 54.91, 54.56, 54.20, 50.02, 48.59, 48.29, 47.96, 44.59, 41.25, 40.84, 39.26, 39.22, 39.12, 37.26, 36.31, 35.16, 35.08, 32.61, 31.65, 31.30, 31.21, 29.91, 29.90, 29.72, 29.69, 29.63, 25.91, 24.83, 24.69, 24.60, 24.38, 23.87, 23.73, 23.67, 23.47, 23.42, 21.92, 21.40, 21.09, 20.31, 20.22, 18.90, 18.63, 18.59, 17.70, 14.90, 9.83. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>72</sub>H<sub>122</sub>N<sub>11</sub>O<sub>14</sub>S 1396.8893, found 1396.8875.</div></div><div id="sec4_8_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-(Benzyloxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>27A</b>) (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>R</i>)-5-((3-(Benzyloxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>27B</b>)</h4><div class="NLM_p">The title compounds <b>27A</b> and <b>27B</b> were obtained as a white solid using a method similar to that described for compound <b>9</b> in 17.1% and 2.05% yields in one step, respectively.</div><div id="sec4_8_24_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> Compound <b>27A</b></h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.40 (d, <i>J</i> = 9.6 Hz, 1H), 8.06 (d, <i>J</i> = 7.2 Hz, 1H), 7.63 (d, <i>J</i> = 9.2 Hz, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 1H), 7.43–7.44 (m, 2H), 7.35–7.39 (m, 2H), 7.29–7.33 (m, 1H), 7.23 (d, <i>J</i> = 8.0 Hz, 1H), 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.01–7.04 (m, 1H), 6.82 (dd, <i>J</i> = 2.4, 8.0 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.49 (dd, <i>J</i> = 3.6, 7.6 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.21 (d, <i>J</i> = 6.0 Hz, 1H), 5.19 (d, <i>J</i> = 8.0 Hz, 1H), 5.07–5.14 (m, 2H), 5.05 (s, 2H), 4.98–5.02 (m, 1H), 4.83–4.97 (m, 3H), 4.65 (d, <i>J</i> = 14.0 Hz, 1H), 4.37–4.44 (m, 1H), 4.32 (dd, <i>J</i> = 6.0, 8.8 Hz, 1H), 3.46 (s, 3H), 3.37 (s, 3H), 3.25 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.39–2.47 (m, 1H), 2.26–2.33 (m, 1H), 2.07–2.15 (m, 3H), 1.93–2.05 (m, 3H), 1.55–1.70 (m, 5H), 1.42–1.49 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 7.2 Hz, 3H), 1.17 (d, <i>J</i> = 6.8 Hz, 3H), 0.97–1.04 (m, 8H), 0.93–0.95 (m, 8H), 0.84–0.90 (m, 16H), 0.81 (d, <i>J</i> = 6.8 Hz, 4H), 0.79 (d, <i>J</i> = 6.4 Hz, 3H), 0.62 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl3) δ 173.83, 173.29, 173.24, 173.20, 171.58, 171.31, 171.00, 170.88, 170.49, 169.98, 168.81, 158.75, 137.47, 137.03, 130.02, 128.64(2C), 128.04, 127.64(2C), 127.58, 123.10, 116.75, 113.78, 86.85, 82.15, 70.07, 59.88, 58.04, 57.19, 55.07, 54.73, 54.35, 50.18, 48.85, 48.49, 48.14, 44.80, 41.37, 40.90, 39.38, 39.17, 37.35, 36.41, 35.30, 32.83, 31.74, 31.42, 31.32, 30.05, 29.86, 29.80, 26.02, 24.97, 24.84, 24.77, 24.55, 23.98, 23.87, 23.67, 23.62, 23.51, 22.04, 21.54, 21.35, 20.35, 20.26, 19.03, 18.80, 18.74, 17.87, 15.23, 9.99. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup>calcd for C<sub>73</sub>H<sub>118</sub>N<sub>11</sub>O<sub>13</sub>S 1388.8631, found 1388.8595.</div></div><div id="sec4_8_24_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Compound <b>27B</b></h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.32 (d, <i>J</i> = 10.0 Hz, 1H), 7.97 (d, <i>J</i> = 6.8 Hz, 1H), 7.31–7.45 (m, 7H), 7.15 (t, <i>J</i> = 8.0 Hz, 1H), 7.13 (t, <i>J</i> = 2.4 Hz, 1H), 7.00 (d, <i>J</i> = 7.6 Hz, 1H), 6.79 (dd, <i>J</i> = 2.4, 8.4 Hz, 1H), 5.67 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.40 (dd, <i>J</i> = 6.0, 9.2 Hz, 1H), 5.31 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.27–5.29 (m, 2H), 5.20 (d, <i>J</i> = 11.2 Hz, 1H), 5.04–5.09 (m, 2H), 5.03 (s, 2H), 4.89–4.95 (m, 1H), 4.79–4.86 (m, 2H), 4.55 (d, <i>J</i> = 13.6 Hz, 1H), 4.40–4.47 (m, 1H), 4.08 (dd, <i>J</i> = 6.0, 6.8 Hz, 1H), 3.56 (s, 3H), 3.24 (s, 6H), 3.15 (s, 3H), 3.02 (s, 3H), 2.67 (s, 6H), 2.28–2.36 (m, 1H), 2.18–2.24 (m, 1H), 2.05–2.14 (m, 3H), 1.90–1.99 (m, 3H), 1.76–1.87 (m, 2H), 1.54–1.68 (m, 3H), 1.35–1.46 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.23–1.25 (m, 6H), 1.02 (d, <i>J</i> = 6.4 Hz, 3H), 0.97 (d, <i>J</i> = 6.8 Hz, 3H), 0.91–0.95 (m, 14H), 0.82–0.87 (m, 15H), 0.80 (d, <i>J</i> = 6.4 Hz, 4H), 0.67 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.94, 173.94, 173.86, 173.67, 173.36, 171.75, 171.37, 171.05, 170.89, 170.81, 170.34, 169.62, 159.08, 137.52, 137.08, 129.66, 128.75, 128.22, 127.99, 127.73, 122.99, 116.32, 112.88, 85.70, 84.43, 70.18, 59.89, 58.01, 57.45, 55.09, 54.98, 54.53, 49.87, 49.06, 48.52, 48.16, 44.82, 40.87, 40.59, 39.41, 39.23, 37.25, 36.34, 34.20, 33.70, 31.73, 31.54, 31.27, 30.19, 30.02, 29.90, 29.80, 25.61, 25.08, 24.88, 24.77, 24.35, 24.05, 23.97, 23.93, 23.66, 22.06, 21.43, 20.77, 20.66, 20.11, 19.43, 18.69, 18.08, 15.40, 10.15. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup>calcd for C<sub>73</sub>H<sub>118</sub>N<sub>11</sub>O<sub>13</sub>S 1388.8631, found 1388.8613.</div></div></div><div id="sec4_8_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-(1-phenylethoxy)phenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>28A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 18.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.36 (d, <i>J</i> = 9.6 Hz, 1H), 8.05 (d, <i>J</i> = 6.4 Hz, 1H), 7.62 (d, <i>J</i> = 8.8 Hz, 1H), 7.49 (d, <i>J</i> = 7.6 Hz, 1H), 7.28–7.35 (m, 5H), 7.20–7.24 (m, 1H), 7.03–7.05 (m, 1H), 6.85–6.90 (m, 1H), 6.66–6.68 (m, 1H), 5.65 (d, <i>J</i> = 9.2 Hz, 1H), 5.41–5.44 (m, 1H), 5.29–5.32 (m, 1H), 5.25–5.26 (m, 1H), 5.19 (s, 1H), 5.16 (s, 1H), 5.02–5.12 (m, 2H), 4.93–4.99 (m, 2H), 4.89 (t, <i>J</i> = 8.4 Hz, 1H), 4.83 (t, <i>J</i> = 6.8 Hz, 1H), 4.63 (d, <i>J</i> = 14.0 Hz, 1H), 4.34–4.39 (m, 1H), 4.24–4.28 (m, 1H), 3.42 (s, 3H), 3.34 (s, 3H), 3.20 (s, 3H), 3.16 (s, 3H), 3.04 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.35–2.43 (m, 1H), 2.24–2.30 (m, 1H), 2.03–2.13 (m, 4H), 1.92–2.00 (m, 2H), 1.60–1.67 (m, 5H), 1.59 (d, <i>J</i> = 6.0 Hz, 3H), 1.39–1.52 (m, 3H), 1.31 (d, <i>J</i> = 7.2 Hz, 3H), 1.24 (d, <i>J</i> = 6.0 Hz, 3H), 1.12 (d, <i>J</i> = 6.4 Hz, 3H), 0.95–1.00 (m, 8H), 0.92–0.94 (m, 11H), 0.84–0.88 (m, 13H), 0.75–0.80 (m, 7H), 0.62 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>74</sub>H<sub>120</sub>N<sub>11</sub>O<sub>13</sub>S 1402.8788, found 1402.8754.</div></div><div id="sec4_8_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-Tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-phenethoxyphenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>29A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 2.0% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.38 (d, <i>J</i> = 9.6 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 1H), 7.29–7.33 (m, 5H), 7.20–7.24 (m, 1H), 7.12 (d, <i>J</i> = 7.6 Hz, 1H), 6.92 (s, 1H), 6.73–6.75 (m, 1H), 5.67 (dd, <i>J</i> = 3.2, 10.8 Hz, 1H), 5.47 (dd, <i>J</i> = 3.6, 7.6 Hz, 1H), 5.31–5.37 (m, 2H), 5.20–5.22 (m, 1H), 5.18 (d, <i>J</i> = 3.6 Hz, 1H), 5.11–5.13 (m, 1H), 5.08 (t, <i>J</i> = 6.8 Hz, 2H), 4.96–5.01 (m, 2H), 4.91 (t, <i>J</i> = 8.4 Hz, 1H), 4.85 (t, <i>J</i> = 6.8 Hz, 1H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.39 (t, <i>J</i> = 6.8 Hz, 1H), 4.31 (dd, <i>J</i> = 6.4, 8.8 Hz, 1H), 4.16 (dt, <i>J</i> = 2.4, 7.2 Hz, 2H), 3.43 (s, 3H), 3.37 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.06 (s, 3H), 2.70 (s, 3H), 2.66 (s, 3H), 2.39–2.44 (m, 1H), 2.28–2.31 (m, 1H), 2.09–2.15 (m, 3H), 1.93–2.00 (m, 3H), 1.57–1.63 (m, 5H), 1.44–1.51 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.26 (d, <i>J</i> = 6.8 Hz, 3H), 1.17 (d, <i>J</i> = 6.8 Hz, 3H), 0.98–1.02 (m, 8H), 0.93–0.95 (m, 8H), 0.89–0.91 (m, 5H), 0.85–0.88 (m, 11H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.78 (d, <i>J</i> = 6.8 Hz, 3H), 0.61 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>74</sub>H<sub>120</sub>N<sub>11</sub>O<sub>13</sub>S 1402.8788, found 1402.8752.</div></div><div id="sec4_8_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-(pyridin-2-ylmethoxy)phenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>30A</b>)</h4><div class="NLM_p last">The title compound <b>30A</b> (30 mg) and the mixture <b>30m</b> (10 mg, major: minor = 1:1) were obtained as white solid using a method similar to that described for compound <b>9</b> in total 17.8% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (brs, 1H), 8.39 (d, <i>J</i> = 9.6 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 8.03 (s, 1H), 7.81 (s, 1H), 7.64 (d, <i>J</i> = 9.2 Hz, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.27 (t, <i>J</i> = 8.0 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 7.03 (s, 1H), 6.83 (d, <i>J</i> = 7.2 Hz, 1H), 5.64 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.49 (dd, <i>J</i> = 3.2, 7.6 Hz, 1H), 5.29–5.36 (m, 4H), 5.20 (d, <i>J</i> = 9.2 Hz, 1H), 5.17 (d, <i>J</i> = 11.2 Hz, 1H), 5.11 (dd, <i>J</i> = 5.6, 10.0 Hz, 1H), 5.06 (t, <i>J</i> = 6.8 Hz, 1H), 4.98 (dd, <i>J</i> = 8.4, 14.8 Hz, 1H), 4.90 (t, <i>J</i> = 8.4 Hz, 1H), 4.80–4.85 (m, 1H), 4.65 (d, <i>J</i> = 14.0 Hz, 1H), 4.36–4.43 (m, 1H), 4.32 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.45 (s, 3H), 3.37 (s, 3H), 3.21 (s, 3H), 3.16 (s, 3H), 3.05 (s, 3H), 2.65 (s, 3H), 2.64 (s, 3H), 2.40–2.48 (m, 1H), 2.25–2.34 (m, 1H), 2.07–2.14 (m, 3H), 1.93–2.03 (m, 3H), 1.54–1.70 (m, 6H), 1.41–1.48 (m, 2H), 1.31 (d, <i>J</i> = 7.2 Hz, 3H), 1.24 (d, <i>J</i> = 6.4 Hz, 3H), 1.16 (d, <i>J</i> = 6.8 Hz, 3H), 1.00 (d, <i>J</i> = 6.8 Hz, 3H), 0.96–0.98 (m, 4H), 0.92–0.95 (m, 9H), 0.88–0.89 (m, 4H), 0.83–0.86 (m, 12H), 0.80 (d, <i>J</i> = 6.4 Hz, 4H), 0.77 (d, <i>J</i> = 6.4 Hz, 3H), 0.62 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.66, 173.11, 173.05, 173.01, 171.41, 171.14, 170.82, 170.72, 170.31, 169.82, 168.62, 157.81,156.21,138.62, 137.75, 130.03, 123.15, 116.68, 112.99, 86.51, 81.90, 59.66, 57.86, 57.00, 54.89, 54.56, 54.15, 50.01, 48.67, 48.30, 47.96, 44.62, 41.20, 40.73, 39.19, 39.02, 37.18, 36.24, 35.16, 32.65, 31.56, 31.25, 31.17, 29.89, 29.87, 29.72, 29.70, 29.64, 29.63, 29.29, 25.86, 24.79, 24.66, 24.59, 24.36, 23.80, 23.70, 23.52, 23.45, 23.32, 21.86, 21.35, 21.20, 20.19, 20.06, 18.85, 18.62, 18.54, 17.68, 16.76, 15.03, 9.82. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>72</sub>H<sub>117</sub>N<sub>12</sub>O<sub>13</sub>S 1389.8584, found 1389.8567.</div></div><div id="sec4_8_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-(pyridin-3-ylmethoxy)phenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>31A</b>)</h4><div class="NLM_p last">The title compound <b>31A</b> (major, 40 mg) and the mixture <b>31m</b> (10 mg, major: minor = 1:1.5) were obtained as white solid using a method similar to that described for compound <b>9</b> in total 23.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.90 (brs, 2H), 8.40 (d, <i>J</i> = 9.6 Hz, 1H), 8.21 (d, <i>J</i> = 4.0 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.80 (brs, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.51 (d, <i>J</i> = 8.0 Hz, 1H), 7.27 (t, <i>J</i> = 8.0 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 7.07 (s, 1H), 6.83 (d, <i>J</i> = 8.0 Hz, 1H), 5.63 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.48 (dd, <i>J</i> = 3.6, 7.6 Hz, 1H), 5.33 (dd, <i>J</i> = 3.6, 11.2 Hz, 1H), 5.21 (d, <i>J</i> = 9.2 Hz, 2H), 5.17 (d, <i>J</i> = 11.2 Hz, 2H), 5.11 (dd, <i>J</i> = 5.6, 10.4 Hz, 1H), 5.06 (t, <i>J</i> = 6.8 Hz, 1H), 4.95–5.01 (m, 1H), 4.89 (t, <i>J</i> = 8.4 Hz, 1H), 4.80–4.86 (m, 1H), 4.66 (d, <i>J</i> = 13.6Hz, 1H), 4.41–4.49 (m, 1H), 4.33–4.40 (m, 2H), 3.48 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.65 (s, 3H), 2.64 (s, 3H), 2.39–2.47 (m, 1H), 2.27–2.35 (m, 1H), 2.09–2.15 (m, 3H), 1.90–2.04 (m, 3H), 1.55–1.71 (m, 5H), 1.38–1.49 (m, 3H), 1.32 (d, <i>J</i> = 7.2 Hz, 3H), 1.24 (d, <i>J</i> = 7.2 Hz, 3H), 1.18 (d, <i>J</i> = 6.4 Hz, 3H), 1.01 (d, <i>J</i> = 6.8 Hz, 3H), 0.93–0.95 (m, 10H), 0.90–0.92 (m, 5H), 0.88–0.89 (m, 4H), 0.83–0.87 (m, 9H), 0.79–0.82 (m, 5H), 0.76 (d, <i>J</i> = 6.4 Hz, 3H), 0.58 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.73, 173.20, 173.12, 173.08, 171.36, 171.15, 170.86, 170.74, 170.38, 169.99, 168.68, 157.89, 137.83, 130.02, 123.68, 116.18, 113.86, 86.75, 82.23, 66.81, 59.55, 57.96, 57.01, 54.93, 54.63, 54.18, 50.04, 48.73, 48.31, 48.00, 44.65, 41.10, 40.69, 39.21, 39.03, 37.19, 36.26, 35.12, 32.67, 31.57, 31.27, 31.18, 29.93, 29.87, 29.75, 29.66(2C), 25.83, 24.82(2C), 24.68, 24.56, 24.32, 23.81(2C), 23.72(2C), 23.56, 23.47, 23.38, 21.86, 21.37, 21.15, 20.24, 20.14, 18.91, 18.62, 18.55, 17.71, 15.08, 14.35, 9.86. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>72</sub>H<sub>117</sub>N<sub>12</sub>O<sub>13</sub>S 1389.8584, found 1389.8593.</div></div><div id="sec4_8_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-(pyridin-4-ylmethoxy)phenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>32A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 13.3% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.90 (brs, 2H), 8.40 (d, <i>J</i> = 9.6 Hz, 1H), 8.04 (d, <i>J</i> = 7.2 Hz, 1H), 7.83 (brs, 2H), 7.62 (d, <i>J</i> = 9.2 Hz, 1H), 7.51 (d, <i>J</i> = 8.0 Hz, 1H), 7.27 (t, <i>J</i> = 8.0 Hz, 1H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 7.02–7.04 (m, 1H), 6.82 (dd, <i>J</i> = 2.0, 8.0 Hz, 1H), 5.63 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.47 (dd, <i>J</i> = 3.6, 7.6 Hz, 1H), 5.31 (dd, <i>J</i> = 4.0, 11.6 Hz, 1H), 5.29 (s, 2H), 5.19–5.24 (m, 2H), 5.16 (d, <i>J</i> = 10.8 Hz, 1H), 5.10 (dd, <i>J</i> = 5.6, 10.4 Hz, 1H), 5.06 (t, <i>J</i> = 6.8 Hz, 1H), 4.94–5.00 (m, 1H), 4.88 (t, <i>J</i> = 8.4 Hz, 1H), 4.83 (t, <i>J</i> = 7.2 Hz, 1H), 4.65 (d, <i>J</i> = 13.6 Hz, 1H), 4.31–4.39 (m, 2H), 3.46 (s, 3H), 3.37 (s, 3H), 3.22 (s, 3H), 3.16 (s, 3H), 3.06 (s, 3H), 2.65 (s, 3H), 2.64 (s, 3H), 2.39–2.46 (m, 1H), 2.26–2.35 (m, 1H), 2.09–2.16 (m, 3H), 1.92–2.04 (m, 3H), 1.54–1.72 (m, 6H), 1.39–1.46 (m, 2H), 1.31 (d, <i>J</i> = 7.2 Hz, 3H), 1.24 (d, <i>J</i> = 6.8 Hz, 3H), 1.16 (d, <i>J</i> = 6.8 Hz, 3H), 1.01 (d, <i>J</i> = 6.4 Hz, 3H), 0.92–0.96 (m, 13H), 0.87–0.89 (m, 7H), 0.83–0.86 (m, 9H), 0.80–0.82 (m, 4H), 0.76 (d, <i>J</i> = 6.4 Hz, 3H), 0.58 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.72, 173.18, 173.09, 173.04, 171.30, 171.11, 170.83, 170.72, 170.37, 170.00, 168.69, 157.49, 145.50, 145.47, 145.44, 138.02, 130.07, 123.77, 116.05, 113.68, 86.60, 82.28, 67.53, 59.44, 57.92, 56.97, 54.89, 54.61, 54.12, 50.00, 48.70, 48.26, 47.95, 44.62, 41.07, 40.70, 40.68, 39.19, 39.02, 37.16, 36.23, 35.09, 32.64, 31.54, 31.25, 31.16, 29.90, 29.85, 29.74, 29.63, 25.78, 24.79, 24.66, 24.52, 24.32, 24.28, 23.81, 23.70, 23.58, 23.45, 23.38, 21.83, 21.33, 21.11, 20.26, 20.04, 18.92, 18.57, 17.67, 16.39, 15.03, 9.84. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>72</sub>H<sub>117</sub>N<sub>12</sub>O<sub>13</sub>S 1389.8584, found 1389.8556.</div></div><div id="sec4_8_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-((1-methyl-6-oxo-1,6-dihydropyridin-3-yl)methoxy)phenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>33A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 12.7% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.41 (d, <i>J</i> = 9.2 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.67 (d, <i>J</i> = 8.8 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.38–7.44 (m, 1H), 7.23–7.25 (m, 1H), 7.16–7.17 (m, 1H), 6.95–6.97 (m, 1H), 6.83–6.87 (m, 1H), 6.76–6.80 (m, 1H), 6.44–6.49 (m, 1H), 5.65 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.49 (dd, <i>J</i> = 3.2, 7.6 Hz, 1H), 5.34 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.22 (d, <i>J</i> = 9.2 Hz, 1H), 5.18 (d, <i>J</i> = 10.8 Hz, 1H), 5.05–5.14 (m, 2H), 4.92–5.02 (m, 4H), 4.81–4.91 (m, 2H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.37–4.44 (m, 1H), 4.32 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.64 (s, 3H), 3.46 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.07 (s, 3H), 2.68 (s, 3H), 2.66 (s, 3H), 2.40–2.48 (m, 1H), 2.28–2.34 (m, 1H), 2.09–2.17 (m, 3H), 1.95–2.05 (m, 3H), 1.60–1.72 (m, 5H), 1.40–1.51 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.17 (d, <i>J</i> = 6.8Hz, 3H), 0.97–1.02 (m, 9H), 0.92–0.95 (m, 10H), 0.85–0.89 (m, 13H), 0.81 (d, <i>J</i> = 6.8 Hz, 4H), 0.78 (d, <i>J</i> = 6.4 Hz, 3H), 0.62 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>119</sub>N<sub>12</sub>O<sub>14</sub>S 1419.8689, found 1419.8671.</div></div><div id="sec4_8_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-3-methyl-5-((3-(methylamino)phenyl)thio)tetrahydrofuran-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>34A</b>)</h4><div class="NLM_p last">The title compound was obtained as a light yellow solid using a method similar to that described for compound <b>9</b> in 13.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 9.6 Hz, 1H), 8.09 (d, <i>J</i> = 6.4 Hz, 1H), 7.67 (d, <i>J</i> = 8.8 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 1H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 7.09 (s, 1H), 6.83 (d, <i>J</i> = 7.6 Hz, 1H), 6.66 (d, <i>J</i> = 7.6 Hz, 1H), 5.64 (dd, <i>J</i> = 3.2, 10.8 Hz, 1H), 5.53 (dd, <i>J</i> = 2.8, 8.0 Hz, 1H), 5.34 (dd, <i>J</i> = 3.2, 10.8 Hz, 1H), 5.25 (d, <i>J</i> = 9.6 Hz, 1H), 5.15 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 5.08–5.11 (m, 2H), 4.97–5.03 (m, 1H), 4.84–4.93 (m, 2H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.40 (t, <i>J</i> = 7.2 Hz, 1H), 4.29–4.33 (m, 2H), 3.45 (s, 3H), 3.40 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.07 (s, 3H), 2.89 (s, 3H), 2.70 (s, 3H), 2.69 (s, 3H), 2.47–2.54 (m, 1H), 2.29–2.37 (m, 1H), 2.11–2.17 (m, 2H), 2.03–2.07 (m, 1H), 1.93–2.01 (m, 2H), 1.83–1.88 (m, 1H), 1.55–1.70 (m, 5H), 1.40–1.50 (m, 3H), 1.31 (d, <i>J</i> = 7.2 Hz, 3H), 1.26 (d, <i>J</i> = 6.8 Hz, 3H), 1.16 (d, <i>J</i> = 6.8 z, 3H), 1.01 (d, <i>J</i> = 6.8 Hz, 3H), 0.93–0.98 (m, 14H), 0.87–0.91 (m, 11H), 0.77–0.85 (m, 11H), 0.68 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>67</sub>H<sub>115</sub>N<sub>12</sub>O<sub>12</sub>S 1311.8478, found 1311.8447.</div></div><div id="sec4_8_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-(ethyl(methyl)amino)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>35A</b>)</h4><div class="NLM_p last">The title compound was obtained as a light yellow solid using a method similar to that described for compound <b>9</b> in 6.8% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 9.6 Hz, 1H), 8.07 (d, <i>J</i> = 7.2 Hz, 1H), 7.63 (d, <i>J</i> = 9.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.40–7.44 (m, 2H), 7.29–7.35 (m, 1H), 7.19–7.23 (m, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.6 Hz, 1H), 5.55 (dd, <i>J</i> = 3.2, 7.6 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.6 Hz, 1H), 5.23 (d, <i>J</i> = 9.2 Hz, 1H), 5.09–5.16 (m, 3H), 4.97–5.01 (m, 1H), 4.89–4.95 (m, 2H), 4.82–4.87 (m, 1H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.37–4.43 (m, 1H), 4.34 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.48 (q, <i>J</i> = 6.8 Hz, 2H), 3.43 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.09 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.67 (s, 3H), 2.43–2.50 (m, 1H), 2.26–2.35 (m, 1H), 2.11–2.17 (m, 3H), 1.93–2.03 (m, 3H), 1.59–1.71 (m, 5H), 1.41–1.51 (m, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.26 (d, <i>J</i> = 7.2 Hz, 3H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H), 1.15 (t, <i>J</i> = 6.8 Hz, 3H), 0.97–1.02 (m, 9H), 0.93–0.95 (m, 8H), 0.84–0.90 (m, 15H), 0.79–0.83 (m, 7H), 0.67 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>69</sub>H<sub>119</sub>N<sub>12</sub>O<sub>12</sub>S 1339.8791, found 1339.8862.</div></div><div id="sec4_8_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-(Benzylamino)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>36A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 49.3% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.40 (d, <i>J</i> = 9.6 Hz, 1H), 8.09 (d, <i>J</i> = 6.8 Hz, 1H), 7.65 (d, <i>J</i> = 9.2 Hz, 1H), 7.54 (d, <i>J</i> = 8.0 Hz, 1H), 7.35 (d, <i>J</i> = 7.2 Hz, 2H), 7.29 (t, <i>J</i> = 7.6 Hz, 2H), 7.22 (t, <i>J</i> = 7.6 Hz, 1H), 7.03 (t, <i>J</i> = 8.0 Hz, 1H), 6.92 (s, 1H), 6.70 (d, <i>J</i> = 7.6 Hz, 1H), 6.39 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 5.64 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.55 (dd, <i>J</i> = 3.2, 7.6 Hz, 1H), 5.34 (dd, <i>J</i> = 3.6, 11.2 Hz, 1H), 5.24 (d, <i>J</i> = 9.2 Hz, 1H), 5.16 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 5.09 (d, <i>J</i> = 11.2 Hz, 1H), 5.05 (d, <i>J</i> = 7.2 Hz, 1H), 4.97–5.01 (m, 1H), 4.92 (t, <i>J</i> = 8.0 Hz, 1H), 4.86 (t, <i>J</i> = 7.2 Hz, 1H), 4.65 (d, <i>J</i> = 13.6 Hz, 1H), 4.40 (d, <i>J</i> = 6.4 Hz, 1H), 4.36 (d, <i>J</i> = 12.4 Hz, 2H), 4.28–4.32 (m, 2H), 3.45 (s, 3H), 3.40 (s, 3H), 3.22 (s, 3H), 3.16 (s, 3H), 3.07 (s, 3H), 2.66 (s, 3H), 2.53 (s, 3H), 2.28–2.37 (m, 1H), 2.08–2.17 (m, 2H), 1.92–2.05 (m, 5H), 1.57–1.69 (m, 5H), 1.40–1.49 (m, 3H), 1.32 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.16 (d, <i>J</i> = 6.8 Hz, 3H), 1.01 (d, <i>J</i> = 6.4 Hz, 3H), 0.92–0.97 (m, 13H), 0.87–0.91 (m, 10H), 0.81–0.86 (m, 13H), 0.70 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.77, 173.12, 173.08, 172.77, 171.36, 171.20, 170.82, 170.29, 170.25, 168.67, 137.41, 129.45, 128.47, 127.32, 127.03, 118.15, 114.25, 85.55, 80.82, 80.80, 59.64, 58.18, 57.16, 54.96, 54.58, 54.15, 50.02, 48.67, 48.24, 48.21, 48.00, 44.54, 41.69, 40.42, 39.20, 39.12, 37.26, 36.34, 35.61, 32.71, 31.91, 31.59, 31.30, 31.24, 30.06, 29.76, 29.68, 29.63, 29.60, 29.35, 29.31, 25.93, 24.84, 24.68, 24.61, 24.25, 23.74, 23.65, 23.50, 23.30, 22.68, 21.91, 21.47, 21.41, 20.40, 19.95, 18.90, 18.64, 18.59, 17.92, 14.96, 14.11, 9.86. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>119</sub>N<sub>12</sub>O<sub>12</sub>S 1387.8791, found 1387.8770.</div></div><div id="sec4_8_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3,4-Dimethoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>37A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white foam using a method similar to that described for compound <b>9</b> in 19.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.36 (d, <i>J</i> = 9.6 Hz, 1H), 8.01 (d, <i>J</i> = 6.4 Hz, 1H), 7.61 (d, <i>J</i> = 8.8 Hz, 1H), 7.50 (d, <i>J</i> = 7.6 Hz, 1H), 7.04 (d, <i>J</i> = 7.6 Hz, 1H), 6.99 (s, 1H), 6.81 (d, <i>J</i> = 8.0 Hz, 1H), 5.62–5.65 (m, 1H), 5.30–5.32 (m, 2H), 5.12–5.20 (m, 2H), 5.04–5.10 (m, 2H), 4.90–5.00 (m, 3H), 4.81–4.84 (m, 1H), 4.64 (d, <i>J</i> = 13.2 Hz, 1H), 4.33–4.38 (m, 1H), 4.28–4.30 (m, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.47 (s, 3H), 3.37 (s, 3H), 3.20 (s, 3H), 3.15 (s, 3H), 3.04 (s, 3H), 2.67 (s, 3H), 2.64 (s, 3H), 2.27–2.35 (m, 2H), 2.06–2.12 (m, 3H), 1.89–2.03 (m, 3H), 1.54–1.66 (m, 5H), 1.37–1.49 (m, 3H), 1.31 (d, <i>J</i> = 6.4 Hz, 3H), 1.23 (d, <i>J</i> = 6.0 Hz, 3H), 1.16 (d, <i>J</i> = 6.0 Hz, 3H), 0.95–0.99 (m, 9H), 0.89–0.93 (m, 10H), 0.82–0.87 (m, 13H), 0.79–0.80 (m, 4H), 0.73 (d, <i>J</i> = 6.0 Hz, 3H), 0.57 (d, <i>J</i> = 6.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.67, 173.09(2C), 173.05, 171.37, 171.12, 170.87, 170.70, 170.29, 169.88, 168.66, 148.77, 148.58, 126.57, 124.67, 115.21, 111.47, 87.99, 82.12, 60.04, 57.87, 56.97, 55.91, 55.82, 54.89, 54.53, 54.19, 50.01, 48.68, 48.28, 48.00, 44.62, 41.01, 40.57, 39.19, 38.99, 37.09, 36.26, 35.06, 32.62, 31.51, 31.20, 31.15, 29.88, 29.86, 29.73, 29.62, 25.91, 24.79, 24.65, 24.52, 24.36, 23.67, 23.60, 23.49, 23.43, 23.28, 21.84, 21.35, 21.15, 20.32, 20.15, 18.71, 18.68, 18.54, 17.66, 15.04, 9.84. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup>calcd for C<sub>68</sub>H<sub>115</sub>N<sub>11</sub>O<sub>14</sub>S 1342.8424, found 1342.8405.</div></div><div id="sec4_8_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3,5-Dimethoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>38A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 28.4% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 10.0 Hz, 1H), 8.03 (d, <i>J</i> = 7.2 Hz, 1H), 7.57 (d, <i>J</i> = 9.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 6.62–6.65 (m, 2H), 6.31–6.32 (m, 1H), 5.65 (dd, <i>J</i> = 3.2, 10.8 Hz, 1H), 5.46 (dd, <i>J</i> = 2.4, 7.6 Hz, 1H), 5.33 (dd, <i>J</i> = 3.6, 10.8 Hz, 1H), 5.20 (d, <i>J</i> = 11.2 Hz, 1H), 5.05–5.12 (m, 3H), 4.93–5.01 (m, 2H), 4.81–4.88 (m, 2H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.34–4.43 (m, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.49 (s, 3H), 3.37 (s, 3H), 3.21 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.25–2.35 (m, 2H), 2.10–2.20 (m, 3H), 1.92–2.00 (m, 3H), 1.54–1.67 (m, 5H), 1.39–1.47 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.22–1.26 (m, 6H), 0.97–1.01 (m, 8H), 0.91–0.95 (m, 10H), 0.83–0.89 (m, 14H), 0.80 (d, <i>J</i> = 6.4 Hz, 4H), 0.76 (d, <i>J</i> = 6.4 Hz, 3H), 0.58 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.72, 173.32, 173.26, 173.10, 171.47, 171.11, 170.87, 170.68, 170.38, 169.93, 168.74, 160.62(2C), 137.81, 108.33, 100.13, 87.75, 82.87, 60.52, 57.87, 56.99, 55.44, 55.39, 55.32, 54.82, 54.47, 54.23, 50.01, 48.62, 48.18, 47.96, 44.54, 40.85, 40.58, 39.21, 39.07, 37.20, 36.29, 34.68, 32.61, 31.59, 31.21, 31.13, 30.03, 29.91, 29.87, 29.59, 25.90, 24.81, 24.66, 24.44, 24.21, 23.73, 23.69, 23.65, 23.43, 23.30, 21.87, 21.38, 21.10, 21.01, 20.28, 18.71, 18.63, 18.52, 17.64, 14.85, 9.90. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>68</sub>H<sub>116</sub>N<sub>11</sub>O<sub>14</sub>S 1342.8424, found 1342.8416.</div></div><div id="sec4_8_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-Chloro-5-methoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>39A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 16.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 9.6 Hz, 1H), 8.05 (d, <i>J</i> = 6.8 Hz, 1H), 7.59 (d, <i>J</i> = 9.2 Hz, 1H), 7.54 (d, <i>J</i> = 8.4 Hz, 1H), 7.03 (dd, <i>J</i> = 1.6, 3.2 Hz, 1H), 6.89 (dd, <i>J</i> = 1.2, 2.0 Hz, 1H), 6.74 (t, <i>J</i> = 2.0 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.49 (dd, <i>J</i> = 2.4, 7.6 Hz, 1H), 5.32 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.21 (d, <i>J</i> = 11.2 Hz, 1H), 5.13 (d, <i>J</i> = 9.2 Hz, 1H), 5.06–5.11 (m, 2H), 4.92–5.01 (m, 2H), 4.81–4.88 (m, 2H), 4.67 (d, <i>J</i> = 14.0 Hz, 1H), 4.35–4.4 (m, 2H), 3.79 (s, 3H), 3.47 (s, 3H), 3.36 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 2.31–2.39 (m, 1H), 2.23–2.29 (m, 1H), 2.11–2.18 (m, 2H), 1.93–2.04 (m, 4H), 1.55–1.66 (m, 5H), 1.41–1.49 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.4 Hz, 3H), 1.22 (d, <i>J</i> = 6.8 Hz, 3H), 0.99–1.01 (m, 8H), 0.94–0.95 (m, 8H), 0.89–0.91 (m, 5H), 0.84–0.87 (m, 12H), 0.80 (d, <i>J</i> = 6.4 Hz, 6H), 0.62 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>67</sub>H<sub>113</sub>ClN<sub>11</sub>O<sub>13</sub>S 1346.7929, found 1346.7944.</div></div><div id="sec4_8_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((4-Chloro-3-methoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>40A</b>)</h4><div class="NLM_p last">The title compound was obtained as a light yellow foam using a method similar to that described for compound <b>9</b> in 19.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.40 (d, <i>J</i> = 10.0 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.63 (d, <i>J</i> = 9.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 1H), 7.33 (d, <i>J</i> = 8.4 Hz, 1H), 7.06 (dd, <i>J</i> = 2.0, 8.4 Hz, 1H), 7.02 (d, <i>J</i> = 2.0 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.44 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.6 Hz, 1H), 5.19 (d, <i>J</i> = 8.0 Hz, 1H), 5.17 (d, <i>J</i> = 9.6 Hz, 1H), 5.07–5.13 (m, 3H), 4.96–5.02 (m, 1H), 4.91–4.95 (m, 1H), 4.83–4.89 (m, 1H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.33–4.42 (m, 2H), 3.90 (s, 3H), 3.48 (s, 3H), 3.39 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.07 (s, 3H), 2.70 (s, 3H), 2.66 (s, 3H), 2.38–2.46 (m, 1H), 2.26–2.35 (m, 1H), 2.11–2.17 (m, 3H), 1.96–2.04 (m, 3H), 1.59–1.69 (m, 5H), 1.44–1.48 (m, 3H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.20 (d, <i>J</i> = 6.8 Hz, 3H), 1.00–1.04 (m, 9H), 0.94–0.95 (m, 8H), 0.89–0.91 (m, 5H), 0.85–0.88 (m, 10H), 0.82 (d, <i>J</i> = 6.8 Hz, 4H), 0.75 (d, <i>J</i> = 6.8 Hz, 3H), 0.59 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.76, 173.22, 173.17(2C), 171.45, 171.13, 170.88, 170.73, 170.34, 170.12, 168.59, 154.70, 136.13, 130.35, 123.06, 121.02, 114.14, 87.25, 82.17, 59.98, 58.03, 57.11, 56.25, 54.89, 54.55, 54.19, 50.04, 48.59, 48.22, 47.97, 44.55, 41.08, 40.78, 39.22, 39.12, 37.26, 36.33, 35.05, 32.54, 31.61, 31.28, 31.21, 29.93(3C), 29.62, 25.91, 24.83, 24.70, 24.48, 24.27, 23.77, 23.75, 23.66, 23.47, 23.37, 21.88, 21.39, 21.12, 20.54, 20.37, 18.82, 18.65, 18.56, 17.67, 14.88, 9.87. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>67</sub>H<sub>113</sub>ClN<sub>11</sub>O<sub>13</sub>S 1346.7929, found 1346.7924.</div></div><div id="sec4_8_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-(Benzyloxy)-4-chlorophenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>41A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 24.2% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 9.6 Hz, 1H), 8.08 (d, <i>J</i> = 6.8 Hz, 1H), 7.66 (d, <i>J</i> = 9.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.49 (d, <i>J</i> = 7.2 Hz, 2H), 7.36–7.40 (m, 3H), 7.29–7.33 (m, 1H), 7.13 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 1.6 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.42 (dd, <i>J</i> = 4.0, 8.0 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.23 (d, <i>J</i> = 9.2 Hz, 1H), 5.15–5.18 (m, 2H), 5.14 (s, 2H), 5.06–5.11 (m, 2H), 4.96–5.02 (m, 1H), 4.83–4.93 (m, 2H), 4.65 (d, <i>J</i> = 14.0 Hz, 1H), 4.36–4.43 (m, 1H), 4.31 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.48 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.68 (s, 3H), 2.66 (s, 3H), 2.41–2.48 (m, 1H), 2.27–2.35 (m, 1H), 2.07–2.17 (m, 3H), 1.97–2.03 (m, 3H), 1.56–1.69 (m, 5H), 1.41–1.49 (m, 3H), 1.31 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.15 (d, <i>J</i> = 6.8 Hz, 3H), 0.98–1.02 (m, 9H), 0.93–0.95 (m, 8H), 0.89–0.90 (m, 4H), 0.82–0.86 (m, 14H), 0.77 (d, <i>J</i> = 6.4 Hz, 4H), 0.62 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.66, 173.09, 173.05, 172.99, 171.29, 171.08, 170.82, 170.69, 170.28, 170.00, 168.52, 153.70, 136.31, 135.82, 130.50, 128.41(2C), 127.83, 127.06(2C), 123.35, 121.68, 115.85, 86.69, 81.86, 70.60, 59.33, 57.97, 57.01, 54.85, 54.55, 54.09, 49.95, 48.63, 48.24, 47.92, 44.56, 41.10, 40.58, 39.12, 38.95, 37.14, 36.19, 35.13, 32.58, 31.47, 31.20, 31.13, 29.83, 29.62, 29.58, 25.78, 24.74, 24.62, 24.49, 24.25, 23.67(3C), 23.47, 23.41, 23.30, 21.79, 21.29, 21.18, 20.25, 19.81, 18.83, 18.55, 18.50, 17.64, 15.02, 9.78. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>117</sub>ClN<sub>11</sub>O<sub>13</sub>S 1422.8242, found 1422.8207.</div></div><div id="sec4_8_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((2,6-Dimethoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>42A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 3.7% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.10 (d, <i>J</i> = 9.6 Hz, 1H), 7.97 (d, <i>J</i> = 6.4 Hz, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 1H), 7.28–7.33 (m, 2H), 7.18–7.22 (m, 1H), 5.67–5.71 (m, 1H), 5.43–5.50 (m, 1H), 5.31–5.34 (m, 1H), 5.28–5.30 (m, 1H), 5.21–5.25 (m, 1H), 5.08–5.13 (m, 2H), 5.04–5.07 (m, 1H), 4.85–4.88 (m, 1H), 4.81–4.84 (m, 1H), 4.74 (t, <i>J</i> = 8.8 Hz, 1H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.48–4.52 (m, 1H), 4.42–4.46 (m, 1H), 3.82 (s, 6H), 3.50 (s, 3H), 3.24 (s, 3H), 3.15 (s, 3H), 3.07 (s, 3H), 3.02 (s, 3H), 2.71 (s, 6H), 2.42–2.48 (m, 1H), 2.26–2.34 (m, 2H), 2.08–2.15 (m, 5H), 1.97–2.01 (m, 3H), 1.84–1.89 (m, 5H), 1.55–1.60 (m, 3H), 1.44–1.48 (m, 3H), 1.30–1.33 (m, 3H), 1.24–1.27 (m, 5H), 1.14–1.17 (m, 2H), 1.03–1.06(m, 4H), 0.94–1.00 (m, 14H), 0.84–0.88 (m, 13H), 0.73–0.76 (m, 4H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>68</sub>H<sub>116</sub>N<sub>11</sub>O<sub>14</sub>S 1342.8424, found 1342.8396.</div></div><div id="sec4_8_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-(3-(Benzyloxy)phenoxy)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>43A</b>) (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>R</i>)-5-(3-(Benzyloxy)phenoxy)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>43B</b>)</h4><div class="NLM_p">Compound <b>9</b> (150 mg, 0.122 mmol) and 3-(benzyloxy)phenol (24.4 mg, 0.122 mmol) were dissolved in 4 mL of CH<sub>2</sub>Cl<sub>2</sub>. FeCl<sub>3</sub> (10 mg, 0.061 mmol) and 4 Å molecular sieves (10 mg) were added to the solution, stirred at room temperature for 16 h, and filtered. The filtrate was evaporated to dryness, and the residue was purified by prep. HPLC to give compound <b>43A</b> (2 mg) and <b>43B</b> (2 mg) as a white solid. Total yield: 2.4%.</div><div id="sec4_8_40_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Compound <b>43A</b></h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 9.6 Hz, 1H), 8.06 (d, <i>J</i> = 7.2 Hz, 1H), 7.62 (d, <i>J</i> = 8.8 Hz, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 1H), 7.43 (d, <i>J</i> = 7.6 Hz, 2H), 7.37 (t, <i>J</i> = 8.0 Hz, 3H), 7.32 (d, <i>J</i> = 7.2 Hz, 1H), 7.14 (t, <i>J</i> = 8.0 Hz, 1H), 6.59 (s, 2H), 5.69 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.62 (d, <i>J</i> = 5.2 Hz, 1H), 5.33 (dd, <i>J</i> = 3.6, 11.6 Hz, 1H), 5.22 (d, <i>J</i> = 9.2 Hz, 1H), 5.14 (d, <i>J</i> = 9.2 Hz, 1H), 5.09–5.10 (m, 1H), 5.03 (s, 2H), 4.95–5.00 (m, 2H), 4.83–4.89 (m, 3H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.39–4.44 (m, 1H), 4.33 (dd, <i>J</i> = 4.0, 9.6 Hz, 1H), 3.44 (s, 3H), 3.35 (s, 3H), 3.24 (s, 3H), 3.18 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.68 (s, 3H), 2.32–2.38 (m, 1H), 2.22–2.29 (m, 1H), 2.06–2.16 (m, 6H), 1.56–1.67 (m, 5H), 1.44–1.52 (m, 3H), 1.34 (d, <i>J</i> = 7.2 Hz, 3H), 1.28 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 1.2 Hz, 3H), 0.98–1.03 (m, 12H), 0.93–0.95 (m, 9H), 0.86–0.91 (m, 14H), 0.82 (d, <i>J</i> = 6.4 Hz, 4H), 0.76 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>118</sub>N<sub>11</sub>O<sub>14</sub> 1372.8860, found 1372.8803.</div></div><div id="sec4_8_40_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Compound <b>43B</b></h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.33 (d, <i>J</i> = 10.0 Hz, 1H), 7.93 (d, <i>J</i> = 6.8 Hz, 1H), 7.51 (d, <i>J</i> = 9.2 Hz, 1H), 7.44 (d, <i>J</i> = 7.6 Hz, 1H), 7.34–7.39 (m, 3H), 7.27–7.33 (m, 2H), 7.09–7.14 (m, 1H), 6.62–6.63 (m, 1H), 6.55–6.59 (m, 2H), 5.66–5.69 (m, 1H), 5.60–5.62 (m, 1H), 5.31–5.35 (m, 1H), 5.28–5.29 (m, 1H), 5.18–5.22 (m, 1H), 5.03–5.07 (m, 2H), 5.02 (s, 2H), 4.93–4.98 (m, 1H), 4.82–4.87 (m, 2H), 4.69 (d, <i>J</i> = 7.6 Hz, 1H), 4.42–4.46 (m, 1H), 4.12–4.16 (m, 1H), 4.07–4.09 (m, 1H), 3.49 (s, 3H), 3.38 (s, 3H), 3.20 (s, 3H), 3.16 (s, 3H), 3.08 (s, 3H), 2.69 (s, 3H), 2.68 (s, 3H), 2.27–2.37 (m, 2H), 2.09–2.17 (m, 3H), 1.95–2.04 (m, 3H), 1.57–1.65 (m, 5H), 1.39–1.47 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 5H), 1.23–1.24 (m, 2H), 1.16–1.20 (m, 2H), 1.02–1.04 (m, 4H), 0.98–0.99 (m, 7H), 0.92–0.95 (m, 9H), 0.87–0.90 (m, 8H), 0.84 (d, <i>J</i> = 7.2 Hz, 4H), 0.79 (d, <i>J</i> = 6.8 Hz, 4H), 0.76 (d, <i>J</i> = 6.0 Hz, 3H), 0.59 (d, <i>J</i> = 6.0 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>118</sub>N<sub>11</sub>O<sub>14</sub> 1372.8860, found 1372.8825.</div></div></div><div id="sec4_8_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-(3,5-Dimethoxyphenoxy)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>44A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>43A</b> in 10.1% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.34 (d, <i>J</i> = 9.2 Hz, 1H), 8.04 (d, <i>J</i> = 6.0 Hz, 1H), 7.63 (d, <i>J</i> = 9.2 Hz, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 1H), 6.08–6.17 (m, 1H), 6.01 (s, 1H), 5.95 (s, 1H), 5.64–5.69 (m, 1H), 5.33–5.39 (m, 2H), 5.20–5.29 (m, 2H), 4.98–5.14 (m, 5H), 4.83–4.88 (m, 1H), 4.67–4.74 (m, 1H), 4.36–4.42 (m, 2H), 3.74 (s, 3H), 3.71 (s, 3H), 3.51 (s, 3H), 3.37 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.67 (s, 3H), 2.28–2.41 (m, 3H), 2.06–2.20 (m, 5H), 1.91–2.00 (m, 3H), 1.56–1.72 (m, 4H), 1.41–1.49 (m, 2H), 1.34 (d, <i>J</i> = 6.8 Hz, 3H), 1.24–1.27 (m, 3H), 1.12 (d, <i>J</i> = 6.0 Hz, 2H), 0.97–1.03 (m, 5H), 0.90–0.95 (m, 13H), 0.80–0.86 (m, 15H), 0.65–0.69 (m, 2H), 0.63 (d, <i>J</i> = 6.4 Hz, 4H), 0.52 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>68</sub>H<sub>116</sub>N<sub>11</sub>O<sub>15</sub> 1326.8652, found 1326.8628.</div></div><div id="sec4_8_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-((2-fluorobenzyl)oxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>45A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 22.8% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.40 (d, <i>J</i> = 9.6 Hz, 1H), 8.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.64 (d, <i>J</i> = 8.8 Hz, 1H), 7.49–7.53 (m, 2H), 7.29–7.32 (m, 1H), 7.14–7.18 (m, 3H), 7.05–7.10 (m, 1H), 7.02 (t, <i>J</i> = 2.0 Hz, 1H), 6.83 (dd, <i>J</i> = 2.4, 8.0 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.50 (dd, <i>J</i> = 3.6, 7.6 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.18–5.23 (m, 2H), 5.12 (s, 2H), 5.02–5.11 (m, 3H), 4.96–5.00 (m, 1H), 4.90–4.95 (m, 1H), 4.83–4.87 (m, 1H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.37–4.41 (m, 1H), 4.32 (dd, <i>J</i> = 6.4, 9.6 Hz, 1H), 3.47 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.68 (s, 3H), 2.66 (s, 3H), 2.40–2.48 (m, 1H), 2.28–2.34 (m, 1H), 2.09–2.17 (m, 3H), 1.96–2.05 (m, 3H), 1.57–1.69 (m, 5H), 1.42–1.51 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H), 0.97–1.02 (m, 9H), 0.93–0.95 (m, 8H), 0.89–0.91 (m, 4H), 0.85–0.88 (m, 11H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.79 (d, <i>J</i> = 6.4 Hz, 3H), 0.63 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>117</sub>FN<sub>11</sub>O<sub>13</sub>S 1406.8537, found 1406.8514.</div></div><div id="sec4_8_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-((3-fluorobenzyl)oxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>46A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 53.0% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.40 (d, <i>J</i> = 10.0 Hz, 1H), 8.05 (d, <i>J</i> = 6.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 1H), 7.51 (d, <i>J</i> = 7.6 Hz, 1H), 7.31–7.35 (m, 1H), 7.19–7.21 (m, 2H), 7.14–7.17 (m, 2H), 6.98–7.02 (m, 2H), 6.80–6.82 (m, 1H), 5.66 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.49 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.18–5.23 (m, 2H), 5.07–5.14 (m, 3H), 5.05 (s, 2H), 4.98–5.02 (m, 1H), 4.92 (t, <i>J</i> = 8.4 Hz, 1H), 4.85 (t, <i>J</i> = 6.4 Hz, 1H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.37–4.42 (m, 1H), 4.32 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.47 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.18 (s, 3H), 3.06 (s, 3H), 2.68 (s, 3H), 2.66 (s, 3H), 2.40–2.48 (m, 1H), 2.28–2.34 (m, 1H), 2.08–2.17 (m, 3H), 1.96–2.03 (m, 3H), 1.58–1.70 (m, 5H), 1.40–1.50 (m, 3H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.25 (d, <i>J</i> = 7.2 Hz, 3H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H), 1.01 (d, <i>J</i> = 6.4 Hz, 3H), 0.96–0.99 (m, 7H), 0.93–0.95 (m, 8H), 0.89–0.91 (m, 4H), 0.85–0.88 (m, 10H), 0.82 (d, <i>J</i> = 6.4 Hz, 4H), 0.78 (d, <i>J</i> = 6.8 Hz, 3H), 0.62 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.65, 173.10, 173.04, 173.03, 171.37, 171.11, 170.81, 170.69, 170.30, 169.82, 168.62, 158.28, 137.42, 130.00, 129.85, 123.12, 122.70, 122.68, 116.45, 114.76, 114.55, 114.33, 114.11, 113.62, 86.66, 81.99, 69.03, 69.01, 59.62, 57.86, 56.99, 54.88, 54.54, 54.14, 49.98, 48.66, 48.28, 47.94, 44.60, 41.15, 40.67, 38.97, 37.15, 36.21, 35.10, 32.63, 31.53, 31.22, 31.13, 29.85, 29.83, 29.60, 25.82, 24.77, 24.64, 24.55, 24.32, 23.76, 23.67, 23.47, 23.42, 23.30, 21.83, 21.33, 21.14, 20.17, 20.05, 18.83, 18.59, 18.53, 17.67, 15.03, 9.80. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>117</sub>FN<sub>11</sub>O<sub>13</sub>S 1406.8537, found 1406.8513.</div></div><div id="sec4_8_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-((4-fluorobenzyl)oxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>47A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 47.0% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 10.0 Hz, 1H), 8.05 (d, <i>J</i> = 7.2 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 1H), 7.41 (dd, <i>J</i> = 5.6, 8.8 Hz, 2H), 7.23 (d, <i>J</i> = 8.0 Hz, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.06 (t, <i>J</i> = 8.8 Hz, 2H), 7.00 (t, <i>J</i> = 2.0 Hz, 1H), 6.80 (ddd, <i>J</i> = 0.8, 2.4, 8.4 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.49 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.21 (d, <i>J</i> = 7.2 Hz, 1H), 5.19 (d, <i>J</i> = 8.4 Hz, 1H), 5.06–0.14 (m, 3H), 5.01 (s, 2H), 4.96–4.98 (m, 1H), 4.92 (t, <i>J</i> = 8.0 Hz, 1H), 4.85 (t, <i>J</i> = 8.0 Hz, 1H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.37–4.42 (m, 1H), 4.32 (dd, <i>J</i> = 6.4, 9.6 Hz, 1H), 3.46 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 2.39–2.47 (m, 1H), 2.28–2.33 (m, 1H), 2.08–2.16 (m, 3H), 1.93–2.04 (m, 3H), 1.58–1.70 (m, 5H), 1.39–1.50 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.17 (d, <i>J</i> = 6.8 Hz, 3H), 1.01 (d, <i>J</i> = 6.4 Hz, 3H), 0.96–0.99 (m, 6H), 0.93–0.95 (m, 7H), 0.89–0.91 (m, 4H), 0.85–0.88 (m, 12H), 0.81 (d, <i>J</i> = 6.8 Hz, 4H), 0.78 (d, <i>J</i> = 6.4 Hz, 3H), 0.62 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.65, 173.10, 173.07, 173.00, 171.39, 171.11, 170.81, 170.70, 170.30, 169.81, 168.62, 163.63, 163.17, 158.38, 137.38, 132.59, 129.87, 129.35, 129.27, 123.00, 116.46, 115.46, 115.24, 113.60, 86.65, 81.96, 69.19, 59.70, 57.85, 56.99, 54.88, 54.54, 54.15, 49.99, 48.64, 48.29, 47.94, 44.60, 41.16, 40.72, 39.18, 39.00, 37.16, 36.23, 35.11, 32.62, 31.55, 31.24, 31.15, 29.86, 29.70, 29.61, 25.84, 24.78, 24.65, 24.56, 24.34, 23.79, 23.69, 23.50, 23.44, 23.33, 21.85, 21.34, 21.13, 20.18, 20.10, 18.84, 18.60, 18.54, 17.67, 15.01, 9.81. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>117</sub>FN<sub>11</sub>O<sub>13</sub>S 1406.8537, found 1406.8511.</div></div><div id="sec4_8_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-((2-Chloro-4-fluorobenzyl)oxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>48A</b>)</h4><div class="NLM_p last">The title compound was obtained as a light yellow solid using a method similar to that described for compound <b>9</b> in 14.3% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (d, <i>J</i> = 9.6 Hz, 1H), 8.05 (d, <i>J</i> = 6.8 Hz, 1H), 7.63 (d, <i>J</i> = 9.2 Hz, 1H), 7.55 (d, <i>J</i> = 6.4 Hz, 1H), 7.49–7.54 (m, 2H), 7.13–7.18 (m, 2H), 7.01–7.03 (m, 2H), 6.81 (dd, <i>J</i> = 2.0, 8.0 Hz, 1H), 5.66 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.50 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.17–5.22 (m, 2H), 5.12–5.14 (m, 1H), 5.10 (s, 2H), 5.05–5.08 (m, 2H), 4.96–5.02 (m, 1H), 4.92 (t, <i>J</i> = 8.4 Hz, 1H), 4.84 (t, <i>J</i> = 7.6 Hz, 1H), 4.65 (d, <i>J</i> = 13.6 Hz, 1H), 4.37–4.42 (m, 1H), 4.32 (dd, <i>J</i> = 6.4, 9.2 Hz, 1H), 3.46 (s, 3H), 3.37 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.42–2.48 (m, 1H), 2.28–2.33 (m, 1H), 2.08–2.14 (m, 3H), 1.93–2.03 (m, 3H), 1.54–1.69 (m, 6H), 1.43–1.49 (m, 2H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 7.2 Hz, 3H), 1.17 (d, <i>J</i> = 6.4 Hz, 3H), 0.97–1.02 (m, 8H), 0.93–0.96 (m, 8H), 0.89–0.90 (m, 4H), 0.84–0.87 (m, 12H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.78 (d, <i>J</i> = 6.8 Hz, 3H), 0.63 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.67, 173.10, 173.00, 171.46, 171.14, 170.82, 170.73, 170.31, 169.81, 168.63, 158.14, 137.56, 130.17, 130.08, 129.98, 123.18, 116.88, 116.63, 116.60, 114.21, 114.01, 113.36, 86.62, 81.88, 66.58, 59.80, 57.87, 57.04, 54.91, 54.55, 54.17, 50.02, 48.63, 48.29, 47.96, 44.60, 41.23, 40.75, 39.21, 39.07, 37.21, 36.27, 35.17, 32.64, 31.60, 31.28, 31.19, 29.89, 29.75, 29.63, 25.89, 24.80, 24.67(2C), 24.59, 24.36, 23.83, 23.72(2C), 23.59, 23.47, 23.36, 21.89, 21.37, 21.17, 20.22(2C), 18.86, 18.63, 18.57, 17.69, 14.97, 9.83. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup>calcd for C<sub>73</sub>H<sub>116</sub>ClFN<sub>11</sub>O<sub>13</sub>S 1440.8147, found 1440.8098.</div></div><div id="sec4_8_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-((3-Chloro-4-fluorobenzyl)oxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>49A</b>)</h4><div class="NLM_p last">The title compound was obtained as a light yellow solid using a method similar to that described for compound <b>9</b> in 38.6% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 9.6 Hz, 1H), 8.05 (d, <i>J</i> = 6.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.55 (dd, <i>J</i> = 2.0, 6.8 Hz, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 1H), 7.30–7.33 (m, 1H), 7.24 (d, <i>J</i> = 8.0 Hz, 1H), 7.14–7.16 (d, <i>J</i> = 8.8 Hz, 2H), 7.10 (dd, <i>J</i> = 1.6, 2.4 Hz, 1H), 6.80 (ddd, <i>J</i> = 0.8, 2.8, 7.6 Hz, 1H), 5.65 (dd, <i>J</i> = 4.0, 10.8 Hz, 1H), 5.48 (dd, <i>J</i> = 3.6, 8.0 Hz, 1H), 5.33 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.21 (d, <i>J</i> = 9.6 Hz, 1H), 5.19 (d, <i>J</i> = 11.2 Hz, 1H), 5.02–5.14 (m, 3H), 5.00 (d, <i>J</i> = 2.8 Hz, 2H), 4.96–4.98 (m, 1H), 4.91 (t, <i>J</i> = 8.0 Hz, 1H), 4.85 (t, <i>J</i> = 8.0 Hz, 1H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.37–4.42 (m, 1H), 4.33 (dd, <i>J</i> = 6.0, 9.2 Hz, 1H), 3.47 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 2.39–2.47 (m, 1H), 2.27–2.35 (m, 1H), 2.11–2.17 (m, 3H), 1.96–2.04 (m, 3H), 1.59–1.69 (m, 5H), 1.42–1.49 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H), 1.01 (d, <i>J</i> = 6.4 Hz, 3H), 0.97 (d, <i>J</i> = 2.8 Hz, 3H), 0.96 (d, <i>J</i> = 3.2 Hz, 3H), 0.93–0.95 (m, 7H), 0.89–0.91 (m, 4H), 0.85–0.88 (m, 12H), 0.81 (d, <i>J</i> = 6.4 Hz, 4H), 0.77 (d, <i>J</i> = 6.4 Hz, 3H), 0.60 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.85, 173.31, 173.22(2C), 171.53, 171.31, 171.01, 170.88, 170.51, 170.03, 168.81, 159.01, 158.35, 156.54, 137.65, 134.18, 130.05, 129.92, 127.39, 127.32, 123.52, 116.80, 116.59, 113.92, 86.89, 82.23, 68.66, 59.77, 58.07, 57.17, 55.07, 54.76, 54.33, 50.18, 48.86, 48.47, 48.14, 44.80, 41.30, 40.86, 39.35, 39.16, 37.32, 36.40, 35.27, 32.81, 31.71, 31.41, 31.33, 30.04, 29.86, 29.80, 26.00, 24.95, 24.82, 24.73, 24.50, 23.95, 23.86, 23.65, 23.62, 23.49, 22.01, 21.52, 21.31, 20.37, 20.26, 19.03, 18.78, 18.71, 17.85, 15.23, 9.99. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>116</sub>ClFN<sub>11</sub>O<sub>13</sub>S 1440.8147, found 1440.8121.</div></div><div id="sec4_8_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-((4-fluoro-2-methylbenzyl)oxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>50A</b>)</h4><div class="NLM_p last">The title compound was obtained as a white solid using a method similar to that described for compound <b>9</b> in 49.3% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (d, <i>J</i> = 10.0 Hz, 1H), 8.04 (d, <i>J</i> = 6.0 Hz, 1H), 7.63 (d, <i>J</i> = 9.2 Hz, 1H), 7.50 (d, <i>J</i> = 7.2 Hz, 1H), 7.35–7.38 (m, 1H), 7.23–7.26 (m, 1H), 7.14–7.20 (m, 1H), 7.00–7.02 (m, 1H), 6.79–6.97 (m, 3H), 5.63–5.68 (m, 1H), 5.48–5.53 (m, 1H), 5.30–5.34 (m, 1H), 5.18–5.23 (m, 2H), 5.05–5.14 (m, 2H), 4.99–5.01 (m, 1H), 4.96 (s, 2H), 4.82–4.93 (m, 3H), 4.65 (d, <i>J</i> = 13.6 Hz, 1H), 4.36–4.42 (m, 1H), 4.30–4.34 (m, 1H), 3.46 (s, 3H), 3.38 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 2.39–2.49 (m, 1H), 2.35 (s, 3H), 2.23–2.33 (m, 1H), 2.07–2.18 (m, 3H), 1.90–2.05 (m, 3H), 1.54–1.73 (m, 5H), 1.38–1.52 (m, 3H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.17 (d, <i>J</i> = 6.8Hz, 3H), 0.96–1.02 (m, 9H), 0.90–0.94 (m, 10H), 0.84–0.88 (m, 13H), 0.77–0.82 (m, 7H), 0.63 (d, <i>J</i> = 6.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.67, 173.13, 173.11, 173.00, 171.46, 171.14, 170.82, 170.74, 170.31, 169.83, 168.64, 158.52, 137.45, 130.61, 130.52, 130.42, 129.96, 122.90, 117.23, 117.02, 116.31, 113.49, 112.60, 112.39, 86.62, 81.90, 67.93, 59.80, 57.87, 57.04, 54.91, 54.56, 54.17, 50.01, 48.62, 48.29, 47.95, 44.60, 41.23, 40.78, 39.22, 39.07, 37.22, 36.28, 35.17, 32.63, 31.61, 31.28, 31.19, 30.94, 29.90, 29.77, 29.63, 25.89, 24.81, 24.68, 24.60, 24.36, 23.84, 23.72, 23.59, 23.47, 23.38, 21.89, 21.37, 21.15, 20.22, 19.00, 18.88, 18.62, 18.57, 17.69, 14.97, 9.83. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>74</sub>H<sub>119</sub>FN<sub>11</sub>O<sub>13</sub>S 1420.8694, found 1420.8663.</div></div><div id="sec4_8_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-Chloro-5-((4-fluorobenzyl)oxy)phenyl)thio)-3-methyltetrahydrofuran-2-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>51A</b>)</h4><div class="NLM_p last">The title compound <b>51A</b> (major, 12 mg) and the mixture <b>50m</b> (15 mg, major:minor = 3:1) were obtained as a white solid using a method similar to that described for compound <b>9</b> in total 11.6% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 9.6 Hz, 1H), 8.04 (d, <i>J</i> = 6.8 Hz, 1H), 7.60 (d, <i>J</i> = 8.8 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.42 (dd, <i>J</i> = 5.6 Hz, 1H), 7.40 (d, <i>J</i> = 5.6 Hz, 1H), 7.04–7.09 (m, 3H), 6.88–6.92 (m, 1H), 6.78–6.81 (m, 1H), 5.65 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.48 (dd, <i>J</i> = 2.8, 7.6 Hz, 1H), 5.32 (dd, <i>J</i> = 3.6, 11.2 Hz, 1H), 5.20 (d, <i>J</i> = 10.8 Hz, 1H), 5.16 (d, <i>J</i> = 8.8 Hz, 1H), 5.04–5.11 (m, 2H), 5.00 (s, 2H), 4.94–4.98 (m, 2H), 4.90–4.92 (m, 1H), 4.81–4.88 (m, 1H), 4.66 (d, <i>J</i> = 13.6 Hz, 1H), 4.34–4.44 (m, 2H), 3.47 (s, 3H), 3.35 (s, 3H), 3.22 (s, 3H), 3.17 (s, 3H), 3.06 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.33–2.41 (m, 1H), 2.24–2.31(m, 1H), 2.10–2.18 (m, 3H), 1.94–2.04 (m, 3H), 1.55–1.68 (m, 5H), 1.39–1.46 (m, 3H), 1.33 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.19 (d, <i>J</i> = 6.8 Hz, 3H), 1.00 (d, <i>J</i> = 6.4 Hz, 3H), 0.93–0.97 (m, 12H), 0.89–0.91 (m, 6H), 0.85–0.86 (m, 11H), 0.83 (d, <i>J</i> = 3.2 Hz, 3H), 0.79–0.81 (m, 4H), 0.64 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>73</sub>H<sub>116</sub>ClFN<sub>11</sub>O<sub>13</sub>S 1440.8147, found 1440.8153.</div></div><div id="sec4_8_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (3<i>S</i>,6<i>S</i>,9<i>S</i>,12<i>R</i>,15<i>S</i>,18<i>S</i>,21<i>S</i>,24<i>S</i>,30<i>S</i>,33<i>S</i>)-30-Ethyl-33-((2<i>R</i>,3<i>R</i>,5<i>S</i>)-5-((3-((4-fluorobenzyl)oxy)-5-methoxyphenyl)thio)-3-methyltetrahydrofuran-2-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone (<b>52A</b>)</h4><div class="NLM_p last">The title compound <b>52A</b> (major, 50 mg) and the mixture <b>52m</b> (50 mg, major: minor = 1:1.4) were obtained as a white solid using a method similar to that described for compound <b>9</b> in total 42.9% yield in one step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.37 (d, <i>J</i> = 10.0 Hz, 1H), 8.05 (d, <i>J</i> = 6.8 Hz, 1H), 7.57 (d, <i>J</i> = 9.2 Hz, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 1H), 7.41 (dd, <i>J</i> = 5.2, 8.4 Hz, 2H), 7.05 (t, <i>J</i> = 8.8 Hz, 2H), 6.71 (dd, <i>J</i> = 1.2, 2.0 Hz, 1H), 6.66 (dd, <i>J</i> = 1.2, 2.0 Hz, 1H), 6.37 (t, <i>J</i> = 2.4 Hz, 1H), 5.63 (dd, <i>J</i> = 4.0, 11.2 Hz, 1H), 5.44 (dd, <i>J</i> = 3.2, 8.0 Hz, 1H), 5.32 (dd, <i>J</i> = 4.0, 11.6 Hz, 1H), 5.18 (d, <i>J</i> = 10.8 Hz, 1H), 5.12 (d, <i>J</i> = 9.2 Hz, 1H), 5.06–5.10 (m, 1H), 5.00–5.06 (m, 2H), 4.99 (s, 2H), 4.90–4.96 (m, 2H), 4.80–4.87 (m, 1H), 4.66 (d, <i>J</i> = 14.0 Hz, 1H), 4.36–4.40 (m, 2H), 3.77 (s, 3H), 3.50 (s, 3H), 3.36 (s, 3H), 3.21 (s, 3H), 3.17 (s, 3H), 3.05 (s, 3H), 2.67 (s, 3H), 2.64 (s, 3H), 2.27–2.38 (m, 2H), 2.08–2.17 (m, 3H), 1.92–1.99 (m, 3H), 1.58–1.68 (m, 5H), 1.39–1.49 (m, 3H), 1.32 (d, <i>J</i> = 7.2 Hz, 3H), 1.25 (d, <i>J</i> = 6.8 Hz, 3H), 1.20 (d, <i>J</i> = 7.2 Hz, 3H), 1.00 (d, <i>J</i> = 6.8 Hz, 3H), 0.94–0.97 (m, 8H), 0.92–0.94 (m, 4H), 0.88–0.91 (m, 5H), 0.85–0.87 (m, 8H), 0.83–0.84 (m, 4H), 0.80 (d, <i>J</i> = 6.8 Hz, 4H), 0.76 (d, <i>J</i> = 6.4 Hz, 3H), 0.57 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 173.69, 173.31, 173.13, 173.11, 171.32, 171.09, 170.86, 170.66, 170.38, 169.91, 168.72, 166.68, 163.62, 161.17, 160.69, 159.43, 137.65, 132.58, 132.55, 129.40, 129.32, 115.44, 115.23, 109.72, 108.79, 100.91, 87.48, 82.92, 69.28, 59.97, 57.87, 56.94, 55.48, 54.84, 54.53, 54.17, 49.98, 48.74, 48.24, 47.98, 44.60, 40.84, 40.46, 39.18, 38.95, 37.12, 36.21, 34.74, 32.71, 31.50, 31.18, 31.10, 29.83, 29.61, 25.80, 24.79, 24.64, 24.47, 24.24, 23.69, 23.62, 23.49, 23.42, 23.29, 21.82, 21.35, 21.11, 20.60, 20.23, 18.68, 18.51, 17.68, 15.06, 9.89. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>74</sub>H<sub>119</sub>FN<sub>11</sub>O<sub>14</sub>S 1436.8643, found 1436.8613.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01484" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01484?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01484</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Concentration in plasma of preliminary pharmacokinetics experiment (PO) data of the selected compounds; plasma protein binding study of the compound <b>27A</b>; 2D-NMR analysis of <b>27A</b> and <b>27B</b>; inhibition of HBV infection by <b>27A</b> and <b>27B</b> on primary human hepatocytes (PHH); fluorescence intensity analysis of <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B,C; treatment of C57B/L mice by <b>27A</b> of indicated dosage (<i>n</i> = 5 for each group) for 14 days; inhibition of HBV virus infection of HepG2-NTCP cells by 27A and Alisporivir; synthesis of mercapto heterocyclic and aromatic intermediates (1–28); and <sup>1</sup>H and <sup>13</sup>C NMR spectra of compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf">jm0c01484_si_001.pdf (3.67 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_002.csv">jm0c01484_si_002.csv (14.43 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01484" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77516" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77516" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenhui Li</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c9a5a0beaca7a1bca089a7a0abbae7a8aae7aaa7"><span class="__cf_email__" data-cfemail="fb97928c9e95938e92bb95929988d59a98d59895">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiyuan Zhang</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2910-1986" title="Orcid link">http://orcid.org/0000-0002-2910-1986</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dca6b4bdb2bba6b4b5a5a9bdb29cb2b5beaff2bdbff2bfb2"><span class="__cf_email__" data-cfemail="176d7f7679706d7f7e6e62767957797e7564397674397479">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Liu</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate
Program, Tsinghua University, Beijing 100084, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanying Ruan</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying Li</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guoliang Sun</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate
Program, Peking University, Beijing 100080, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao Liu</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenhui He</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengfeng Mao</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miaomiao He</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate
Program, Chinese Academy of Medical Sciences
and Peking Union Medical College, Beijing 100005, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liwei Yan</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guocai Zhong</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huan Yan</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Biological Sciences, Beijing 102206, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.L. and H.R. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. Z.Z. and W.L. conceived the project; Z.Z. and H.R. designed the project; H.R. and Y.L. synthesized all of the compounds; W.L. and Y.L. designed the project; Y.L. conducted the biological experiments in vitro and in vivo; X.L. tested liver microsomes stability, prepared compounds formulation, and tested pharmacokinetic parameters; G.S. helped with biological experiments in vitro; W.H. and F.M. helped with mice experiments; M.H. conducted mice spleen T cells assays; L.Y. produced HBV and HDV inoculum for antiviral assays; G.Z. and H.Y. conducted IC50 determine assays of several compounds; and Y.L. and H.R. drafted the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This project was funded by the National Natural Science Foundation of China to W.L. (81525018); the Science and Technology Major Project of Beijing to W.L. (D171100003117003); the Beijing Scholar Project to W.L.; and the Science and Technology Bureau of Beijing Municipal Government to W.L.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e10393-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Metabolomic Center of National Institute of Biological Sciences for assistance with LC–MS analysis, Chemistry Center of National Institute of Biological Sciences for assistance with 2D-NMR analysis, and Tsinghua University for Ph.D. program support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">Hepatitis B virus</p></td></tr><tr><td class="NLM_term">HDV</td><td class="NLM_def"><p class="first last">Hepatitis D virus</p></td></tr><tr><td class="NLM_term">NTCP</td><td class="NLM_def"><p class="first last">Sodium taurocholate co-transporting peptide</p></td></tr><tr><td class="NLM_term">CsA</td><td class="NLM_def"><p class="first last">Cyclosporine A</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TMSOTf</td><td class="NLM_def"><p class="first last">trimethylsilyl trifluoromethanesulfonate</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">TCA</td><td class="NLM_def"><p class="first last">taurocholic acid</p></td></tr><tr><td class="NLM_term">TLCA</td><td class="NLM_def"><p class="first last">taurolithocholic acid</p></td></tr><tr><td class="NLM_term">OATP</td><td class="NLM_def"><p class="first last">organic anion-transporting polypeptide</p></td></tr><tr><td class="NLM_term">CFSE</td><td class="NLM_def"><p class="first last">carboxyfluorescein succinimidyl ester</p></td></tr><tr><td class="NLM_term">PMA</td><td class="NLM_def"><p class="first last">phorbol myristate acetate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87271" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87271" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Polaris
Observatory, C.</span> <span> </span><span class="NLM_article-title">Global prevalence,
treatment, and prevention of hepatitis B virus infection in 2016:
a modelling study</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/S2468-1253(18)30056-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2FS2468-1253%2818%2930056-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=29599078" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=383-403&author=Polaris%0AObservatory%2C+C.&title=Global+prevalence%2C%0Atreatment%2C+and+prevention+of+hepatitis+B+virus+infection+in+2016%3A%0Aa+modelling+study&doi=10.1016%2FS2468-1253%2818%2930056-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS2468-1253%2818%2930056-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2468-1253%252818%252930056-6%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%2520prevalence%252C%250Atreatment%252C%2520and%2520prevention%2520of%2520hepatitis%2520B%2520virus%2520infection%2520in%25202016%253A%250Aa%2520modelling%2520study%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2018%26volume%3D3%26spage%3D383%26epage%3D403%26doi%3D10.1016%2FS2468-1253%2818%2930056-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanford, R. E.</span></span> <span> </span><span class="NLM_article-title">Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1128/JVI.67.1.366-372.1993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.67.1.366-372.1993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=8416375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaK3sXlsleitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=366-372&author=C.+Sureauauthor=B.+Guerraauthor=R.+E.+Lanford&title=Role+of+the+large+hepatitis+B+virus+envelope+protein+in+infectivity+of+the+hepatitis+delta+virion&doi=10.1128%2FJVI.67.1.366-372.1993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion</span></div><div class="casAuthors">Sureau, Camille; Guerra, Bernadette; Lanford, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">366-72</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">The hepatitis delta virus (HDV) is coated with large (L), middle (M), and small (S) envelope proteins encoded by coinfecting hepatitis B virus (HBV).  To study the role of the HBV envelope proteins in the assembly and infectivity of HDV, we produced three types of recombinant particles in Huh7 cells by transfection with HBV DNA and HDV cDNA: (i) particles with an envelope contg. the S HBV envelope protein only, (ii) particles with an envelope contg. S and M proteins, and (iii) particles with an envelope contg. S, M, and L proteins.  Although the resulting S-, SM-, and SML-HDV particles contained both hepatitis delta antigen and HDV RNA, only particles coated with all three envelope proteins (SML) showed evidence of infectivity in an in vitro culture system susceptible to HDV infection.  We concluded that the L HBV envelope protein, and more specifically the pre- S1 domain, is important for infectivity of HDV particles and that the M protein, which has been reported to bear a site for binding to polymd. albumin in the pre-S2 domain, is not sufficient for infectivity.  Our data also show that the helper HBV is not required for initiation of HDV infection.  The mechanism by which the L protein may affect HDV infectivity is discussed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiHc4X4_5QV7Vg90H21EOLACvtfcHk0lj_pmsC4x2SiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsleitA%253D%253D&md5=3e436e69840f20e918c08cfbc7c8418f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1128%2FJVI.67.1.366-372.1993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.67.1.366-372.1993%26sid%3Dliteratum%253Aachs%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DLanford%26aufirst%3DR.%2BE.%26atitle%3DRole%2520of%2520the%2520large%2520hepatitis%2520B%2520virus%2520envelope%2520protein%2520in%2520infectivity%2520of%2520the%2520hepatitis%2520delta%2520virion%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D366%26epage%3D372%26doi%3D10.1128%2FJVI.67.1.366-372.1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanford, R. E.</span></span> <span> </span><span class="NLM_article-title">Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5233</span>– <span class="NLM_lpage">5243</span>, <span class="refDoi"> DOI: 10.1128/JVI.78.10.5233-5243.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.78.10.5233-5243.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15113905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFeqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=5233-5243&author=A.+Barreraauthor=B.+Guerraauthor=H.+Leeauthor=R.+E.+Lanford&title=Analysis+of+host+range+phenotypes+of+primate+hepadnaviruses+by+in+vitro+infections+of+hepatitis+D+virus+pseudotypes&doi=10.1128%2FJVI.78.10.5233-5243.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes</span></div><div class="casAuthors">Barrera, Azeneth; Guerra, Bernadette; Lee, Helen; Lanford, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5233-5243</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) and woolly monkey hepatitis B virus (WMHBV) have natural host ranges that are limited to closely related species.  The barrier for infection of primates seems to be at the adsorption and/or entry steps of the viral replication cycle, since a human hepatoma cell line is permissive for HBV and WMHBV replication following transfection of cloned DNA.  We hypothesized that the HBV and WMHBV envelope proteins contain the principal viral determinants of host range.  As previously shown by using the hepatitis D virus (HDV) system, recombinant HBV-HDV particles were infectious in chimpanzee as well as human hepatocytes.  We extended the HDV system to include HDV particles pseudotyped with the WMHBV envelope.  In agreement with the natural host ranges of HBV and WMHBV, in vitro infections demonstrated that HBV-HDV and WM-HDV particles preferentially infected human and spider monkey cells, resp.  Previous studies have implicated the pre-S1 region of the large (L) envelope protein in receptor binding and host range; therefore, recombinant HDV particles were pseudotyped with the hepadnaviral envelopes contg. chimeric L proteins with the 1st 40 amino acids from the pre-S1 domain exchanged between HBV and WMHBV.  Surprisingly, addn. of the human amino terminus to the WMHBV L protein increased infectivity on spider monkey hepatocytes but did not increase infectivity for human hepatocytes.  Based upon these data, we discuss the possibility that the L protein may be comprised of 2 domains that affect infectivity and that sequences downstream of residue 40 may influence host range and receptor binding or entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN6vnsWRzMALVg90H21EOLACvtfcHk0lhIgU_IOR-L7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFeqsLY%253D&md5=ace31fcc43643b1889448255c972a2c9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.10.5233-5243.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.10.5233-5243.2004%26sid%3Dliteratum%253Aachs%26aulast%3DBarrera%26aufirst%3DA.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLanford%26aufirst%3DR.%2BE.%26atitle%3DAnalysis%2520of%2520host%2520range%2520phenotypes%2520of%2520primate%2520hepadnaviruses%2520by%2520in%2520vitro%2520infections%2520of%2520hepatitis%2520D%2520virus%2520pseudotypes%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D5233%26epage%3D5243%26doi%3D10.1128%2FJVI.78.10.5233-5243.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedemeyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, P. M.</span></span> <span> </span><span class="NLM_article-title">Hepatitis delta virus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)61931-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2FS0140-6736%2810%2961931-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=21511329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A280%3ADC%252BC3MnkvF2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=73-85&author=S.+A.+Hughesauthor=H.+Wedemeyerauthor=P.+M.+Harrison&title=Hepatitis+delta+virus&doi=10.1016%2FS0140-6736%2810%2961931-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis delta virus</span></div><div class="casAuthors">Hughes Sarah A; Wedemeyer Heiner; Harrison Phillip M</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9785</span>),
    <span class="NLM_cas:pages">73-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatitis delta virus (HDV) is a small, defective RNA virus that can infect only individuals who have hepatitis B virus (HBV); worldwide more than 15 million people are co-infected.  There are eight reported genotypes of HDV with unexplained variations in their geographical distribution and pathogenicity.  The hepatitis D virion is composed of a coat of HBV envelope proteins surrounding the nucleocapsid, which consists of a single-stranded, circular RNA genome complexed with delta antigen, the viral protein.  HDV is clinically important because although it suppresses HBV replication, it causes severe liver disease with rapid progression to cirrhosis and hepatic decompensation.  The range of clinical presentation is wide, varying from mild disease to fulminant liver failure.  The prevalence of HDV is declining in some endemic areas but increasing in northern and central Europe because of immigration.  Treatment of HDV is with pegylated interferon alfa; however, response rates are poor.  Increased understanding of the molecular virology of HDV will identify novel therapeutic targets for this most severe form of chronic viral hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3jL0e3Tx5HEbxh97K6Vt6fW6udTcc2eYe2R_LVEgborntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnkvF2ksw%253D%253D&md5=0b085e954f1340d10f3965cf975af56e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2961931-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252961931-9%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DS.%2BA.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DHarrison%26aufirst%3DP.%2BM.%26atitle%3DHepatitis%2520delta%2520virus%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D73%26epage%3D85%26doi%3D10.1016%2FS0140-6736%2810%2961931-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span>. <i>Elife</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e00049</span> <span class="refDoi"> DOI: 10.7554/eLife.00049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.7554%2FeLife.00049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=23150796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&author=H.+Yanauthor=G.+Zhongauthor=G.+Xuauthor=W.+Heauthor=Z.+Jingauthor=Z.+Gaoauthor=Y.+Huangauthor=Y.+Qiauthor=B.+Pengauthor=H.+Wangauthor=L.+Fuauthor=M.+Songauthor=P.+Chenauthor=W.+Gaoauthor=B.+Renauthor=Y.+Sunauthor=T.+Caiauthor=X.+Fengauthor=J.+Suiauthor=W.+Li&title=Sodium+taurocholate+cotransporting+polypeptide+is+a+functional+receptor+for+human+hepatitis+B+and+D+virus&doi=10.7554%2FeLife.00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span></div><div class="casAuthors">Yan, Huan; Zhong, Guocai; Xu, Guangwei; He, Wenhui; Jing, Zhiyi; Gao, Zhenchao; Huang, Yi; Qi, Yonghe; Peng, Bo; Wang, Haimin; Fu, Liran; Song, Mei; Chen, Pan; Gao, Wenqing; Ren, Bijie; Sun, Yinyan; Cai, Tao; Feng, Xiaofeng; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e00049, 28 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Human hepatitis B virus (HBV) infection and HBV-related diseases remain a major public health problem.  Individuals coinfected with its satellite hepatitis D virus (HDV) have more severe disease.  Cellular entry of both viruses is mediated by HBV envelope proteins.  The pre-S1 domain of the large envelope protein is a key determinant for receptor(s) binding.  However, the identity of the receptor(s) is unknown.  Here, by using near zero distance photo-crosslinking and tandem affinity purifn., the authors revealed that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the liver.  Silencing NTCP inhibited HBV and HDV infection, while exogenous NTCP expression rendered nonsusceptible hepatocarcinoma cells susceptible to these viral infections.  Moreover, replacing amino acids 157-165 of nonfunctional monkey NTCP with the human counterpart conferred its ability in supporting both viral infections.  The authors' results demonstrate that NTCP is a functional receptor for HBV and HDV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0tqZhmqs37Vg90H21EOLACvtfcHk0lhIgU_IOR-L7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK&md5=7380905d92bd82b9cf3407b7c113bdfb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.7554%2FeLife.00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.00049%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DSodium%2520taurocholate%2520cotransporting%2520polypeptide%2520is%2520a%2520functional%2520receptor%2520for%2520human%2520hepatitis%2520B%2520and%2520D%2520virus%26jtitle%3DElife%26date%3D2012%26volume%3D1%26doi%3D10.7554%2FeLife.00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortune, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qadri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, E.</span></span> <span> </span><span class="NLM_article-title">Multihormonal regulation of hepatic sinusoidal Ntcp gene expression</span>. <i>Am. J. Physiol.: Gastrointest. Liver Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">G782</span>– <span class="NLM_lpage">G794</span>, <span class="refDoi"> DOI: 10.1152/ajpgi.00379.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1152%2Fajpgi.00379.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15361361" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2004&pages=G782-G794&author=F.+R.+Simonauthor=J.+Fortuneauthor=M.+Iwahashiauthor=I.+Qadriauthor=E.+Sutherland&title=Multihormonal+regulation+of+hepatic+sinusoidal+Ntcp+gene+expression&doi=10.1152%2Fajpgi.00379.2003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00379.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00379.2003%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DF.%2BR.%26aulast%3DFortune%26aufirst%3DJ.%26aulast%3DIwahashi%26aufirst%3DM.%26aulast%3DQadri%26aufirst%3DI.%26aulast%3DSutherland%26aufirst%3DE.%26atitle%3DMultihormonal%2520regulation%2520of%2520hepatic%2520sinusoidal%2520Ntcp%2520gene%2520expression%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Gastrointest.%2520Liver%2520Physiol.%26date%3D2004%26volume%3D287%26spage%3DG782%26epage%3DG794%26doi%3D10.1152%2Fajpgi.00379.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span> <span> </span><span class="NLM_article-title">The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation</span>.  <i>Handbook of Experimental Pharmacology</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2011</span>;  <span class="NLM_volume">201</span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">259</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=205-259&author=B.+Stieger&title=Handbook+of+Experimental+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStieger%26aufirst%3DB.%26atitle%3DThe%2520role%2520of%2520the%2520sodium-taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%2520and%2520of%2520the%2520bile%2520salt%2520export%2520pump%2520%2528BSEP%2529%2520in%2520physiology%2520and%2520pathophysiology%2520of%2520bile%2520formation%26btitle%3DHandbook%2520of%2520Experimental%2520Pharmacology%26pub%3DSpringer%26date%3D2011%26volume%3D201%26spage%3D205%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notvall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanford, R. E.</span></span> <span> </span><span class="NLM_article-title">Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">9786</span>– <span class="NLM_lpage">9798</span>, <span class="refDoi"> DOI: 10.1128/JVI.79.15.9786-9798.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.79.15.9786-9798.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=16014940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVels7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=9786-9798&author=A.+Barreraauthor=B.+Guerraauthor=L.+Notvallauthor=R.+E.+Lanford&title=Mapping+of+the+hepatitis+B+virus+pre-S1+domain+involved+in+receptor+recognition&doi=10.1128%2FJVI.79.15.9786-9798.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping of the Hepatitis B virus pre-S1 domain involved in receptor recognition</span></div><div class="casAuthors">Barrera, Azeneth; Guerra, Bernadette; Notvall, Lena; Lanford, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">9786-9798</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) and Woolly monkey hepatitis B virus (WMHBV) are primate hapadnaviruses that display restricted tissue and host tropisms.  Hepatitis D virus (HDV) particles pseudotyped with HBV and WMHBV envelopes (HBV-HDV and WM-HDV) preferentially infect human and spider monkey hepatocytes, resp., thereby confirming host range bias in vitro.  The anal. of chimeric HBV and WMHBV large (L) envelope proteins suggests that the pre-S1 domain may comprise two regions that affect infectivity: one within the amino-terminal 40 amino acids of pre-S1 and one downstream of this region.  In the present study, we further characterized the role of the amino terminus of pre-S1 in infectivity by examg. the ability of synthetic peptides to competitively block HDV infection of primary human and spider monkey hepatocytes.  A synthetic peptide representing the first 45 residues of the pre-S1 domain of the HBV L protein blocked infectivity of HBV-HDV and WM-HDV, with a requirement for myristylation of the amino terminal residue.  Competition studies with truncated peptides suggested that pre-S1 residues 5 to 20 represent the minimal domain for inhibition of HDV infection and, thus, presumably represent the residues involved in virus-host receptor interaction.  Recombinant pre-S1 proteins expressed in insect cells blocked infection with HBV-HDV and WM-HDV at a concn. of 1 nanomolar.  The ability of short pre-S1 peptides to efficiently inhibit HDV infection suggests that they represent suitable ligands for identification of the HBV receptor and that a pre-S1 mimetic may represent a rational therapy for the treatment of HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK-SwGGMbHVLVg90H21EOLACvtfcHk0liYX3EnyH_Q3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVels7c%253D&md5=dd9b37b314fb7c03a21fb27f0427cc09</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.15.9786-9798.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.15.9786-9798.2005%26sid%3Dliteratum%253Aachs%26aulast%3DBarrera%26aufirst%3DA.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DNotvall%26aufirst%3DL.%26aulast%3DLanford%26aufirst%3DR.%2BE.%26atitle%3DMapping%2520of%2520the%2520hepatitis%2520B%2520virus%2520pre-S1%2520domain%2520involved%2520in%2520receptor%2520recognition%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D9786%26epage%3D9798%26doi%3D10.1128%2FJVI.79.15.9786-9798.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glebe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoop, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cag, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krass, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulavaite, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasnauskas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlich, W. H.</span></span> <span> </span><span class="NLM_article-title">Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2005.03.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1053%2Fj.gastro.2005.03.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=16012950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVGrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2005&pages=234-245&author=D.+Glebeauthor=S.+Urbanauthor=E.+V.+Knoopauthor=N.+Cagauthor=P.+Krassauthor=S.+Grunauthor=A.+Bulavaiteauthor=K.+Sasnauskasauthor=W.+H.+Gerlich&title=Mapping+of+the+hepatitis+B+virus+attachment+site+by+use+of+infection-inhibiting+preS1+lipopeptides+and+tupaia+hepatocytes&doi=10.1053%2Fj.gastro.2005.03.090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes</span></div><div class="casAuthors">Glebe, Dieter; Urban, Stephan; Knoop, Eva V.; Cag, Nilguen; Krass, Peter; Grun, Stefanie; Bulavaite, Aiste; Sasnauskas, Kestutis; Gerlich, Wolfram H.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-245</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background & Aims: Studies on the early steps in the life cycle of hepatitis B virus have been hampered by the lack of readily available target cells.  In this study, we mapped a defined virus attachment site to primary hepatocytes that is essential for infection.  Methods: We used purified virus particles from human carrier plasma as an inoculum and primary cultures of tupaia hepatocytes as susceptible target cells and studied the inhibitory effect of amino-terminally acylated preS1-derived lipopeptides on infection interference.  Results: Infectivity of virus could be blocked efficiently in this system by amino-terminally acylated peptides contg. amino acids 2-18 from the preS1 domain.  The addn. of amino acids 28-48 enhanced the inhibitory capacity, whereas amino acids 49-78 did not contribute to inhibition.  Myristoylated preS1 peptides 2-48 bound strongly to tupaia hepatocytes but not to nonhepatic cells or rodent hepatocytes and thereby inhibited infection even at concns. of 1 nmol/L completely.  Particles consisting only of the small hepatitis B surface protein - the active component of current hepatitis B vaccines - did not bind at all to tupaia hepatocytes, but the addn. of the preS1 domain to the particles allowed binding.  Conclusions: The preS1 sequence 2-48 mediates attachment of the virus to its target cells, whereas the small surface protein seems to be involved in other steps.  These findings indicate that the current subunit hepatitis B vaccines may be improved by the addn. of distinct preS1 epitopes.  Moreover, preS1 lipopeptides are promising candidates for specific antiviral therapy against hepatitis B infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocg0MMTWvTnrVg90H21EOLACvtfcHk0libzaUb9wEsnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVGrsbs%253D&md5=50e06abf7c21964d3ba336db2e48bfd3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2005.03.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2005.03.090%26sid%3Dliteratum%253Aachs%26aulast%3DGlebe%26aufirst%3DD.%26aulast%3DUrban%26aufirst%3DS.%26aulast%3DKnoop%26aufirst%3DE.%2BV.%26aulast%3DCag%26aufirst%3DN.%26aulast%3DKrass%26aufirst%3DP.%26aulast%3DGrun%26aufirst%3DS.%26aulast%3DBulavaite%26aufirst%3DA.%26aulast%3DSasnauskas%26aufirst%3DK.%26aulast%3DGerlich%26aufirst%3DW.%2BH.%26atitle%3DMapping%2520of%2520the%2520hepatitis%2520B%2520virus%2520attachment%2520site%2520by%2520use%2520of%2520infection-inhibiting%2520preS1%2520lipopeptides%2520and%2520tupaia%2520hepatocytes%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D129%26spage%3D234%26epage%3D245%26doi%3D10.1053%2Fj.gastro.2005.03.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lempp, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkongolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stindt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koniger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span> <span> </span><span class="NLM_article-title">Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1083</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2013.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1053%2Fj.gastro.2013.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24361467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslWitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=1070-1083&author=Y.+Niauthor=F.+A.+Lemppauthor=S.+Mehrleauthor=S.+Nkongoloauthor=C.+Kaufmanauthor=M.+Falthauthor=J.+Stindtauthor=C.+Konigerauthor=M.+Nassalauthor=R.+Kubitzauthor=H.+Sultmannauthor=S.+Urban&title=Hepatitis+B+and+D+viruses+exploit+sodium+taurocholate+co-transporting+polypeptide+for+species-specific+entry+into+hepatocytes&doi=10.1053%2Fj.gastro.2013.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes</span></div><div class="casAuthors">Ni, Yi; Lempp, Florian A.; Mehrle, Stefan; Nkongolo, Shirin; Kaufman, Christina; Falth, Maria; Stindt, Jan; Koniger, Christian; Nassal, Michael; Kubitz, Ralf; Sultmann, Holger; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1070-1083.e6</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Hepatitis B and D viruses (HBV and HDV) are human pathogens with restricted host ranges and high selectivity for hepatocytes; the HBV L-envelope protein interacts specifically with a receptor on these cells.  We aimed to identify this receptor and analyze whether it is the recently described sodium-taurocholate co-transporter polypeptide (NTCP), encoded by the SLC10A1 gene.  To identify receptor candidates, we compared gene expression patterns between differentiated HepaRG cells, which express the receptor, and naive cells, which do not.  Receptor candidates were evaluated by small hairpin RNA silencing in HepaRG cells; the ability of receptor expression to confer binding and infection were tested in transduced hepatoma cell lines.  We used interspecies domain swapping to identify motifs for receptor-mediated host discrimination of HBV and HDV binding and infection.  Bioinformatic analyses of comparative expression arrays confirmed that NTCP, which was previously identified through a biochem. approach is a bona fide receptor for HBV and HDV.  NTCPs from rat, mouse, and human bound Myrcludex B, a peptide ligand derived from the HBV L-protein.  Myrcludex B blocked NTCP transport of bile salts; small hairpin RNA-mediated knockdown of NTCP in HepaRG cells prevented their infection by HBV or HDV.  Expression of human but not mouse NTCP in HepG2 and HuH7 cells conferred a limited cell-type-related and virus-dependent susceptibility to infection; these limitations were overcome when cells were cultured with DMSO.  We identified 2 short-sequence motifs in human NTCP that were required for species-specific binding and infection by HBV and HDV.  Human NTCP is a specific receptor for HBV and HDV.  NTCP-expressing cell lines can be efficiently infected with these viruses, and might be used in basic research and high-throughput screening studies.  Mapping of motifs in NTCPs have increased our understanding of the species specificities of HBV and HDV, and could lead to small animal models for studies of viral infection and replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnxfIdRSMiSbVg90H21EOLACvtfcHk0libzaUb9wEsnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslWitLs%253D&md5=9a6474af0ba645b685289066a35e972c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DY.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DMehrle%26aufirst%3DS.%26aulast%3DNkongolo%26aufirst%3DS.%26aulast%3DKaufman%26aufirst%3DC.%26aulast%3DFalth%26aufirst%3DM.%26aulast%3DStindt%26aufirst%3DJ.%26aulast%3DKoniger%26aufirst%3DC.%26aulast%3DNassal%26aufirst%3DM.%26aulast%3DKubitz%26aufirst%3DR.%26aulast%3DSultmann%26aufirst%3DH.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DHepatitis%2520B%2520and%2520D%2520viruses%2520exploit%2520sodium%2520taurocholate%2520co-transporting%2520polypeptide%2520for%2520species-specific%2520entry%2520into%2520hepatocytes%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D1070%26epage%3D1083%26doi%3D10.1053%2Fj.gastro.2013.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">7977</span>– <span class="NLM_lpage">7991</span>, <span class="refDoi"> DOI: 10.1128/JVI.03540-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.03540-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=23678176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFWjt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=7977-7991&author=H.+Yanauthor=B.+Pengauthor=W.+Heauthor=G.+Zhongauthor=Y.+Qiauthor=B.+Renauthor=Z.+Gaoauthor=Z.+Jingauthor=M.+Songauthor=G.+Xuauthor=J.+Suiauthor=W.+Li&title=Molecular+determinants+of+hepatitis+B+and+D+virus+entry+restriction+in+mouse+sodium+taurocholate+cotransporting+polypeptide&doi=10.1128%2FJVI.03540-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide</span></div><div class="casAuthors">Yan, Huan; Peng, Bo; He, Wenhui; Zhong, Guocai; Qi, Yonghe; Ren, Bijie; Gao, Zhenchao; Jing, Zhiyi; Song, Mei; Xu, Guangwei; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7977-7991</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human hepatitis B virus (HBV) and its satellite virus, hepatitis D virus (HDV), primarily infect humans, chimpanzees, or tree shrews (Tupaia belangeri).  Viral infections in other species are known to be mainly restricted at the entry level since viral replication can be achieved in the cells by transfection of the viral genome.  Sodium taurocholate cotransporting polypeptide (NTCP) is a functional receptor for HBV and HDV, and amino acids 157 to 165 of NTCP are crit. for viral entry and likely limit viral infection of macaques.  However, the mol. determinants for viral entry restriction in mouse NTCP (mNTCP) remain unclear.  In this study, mNTCP was found to be unable to support either HBV or HDV infection, although it can bind to pre-S1 of HBV L protein and is functional in transporting substrate taurocholate; comprehensive swapping and point mutations of human NTCP (hNTCP) and mNTCP revealed mol. determinants restricting mNTCP for viral entry of HBV and HDV.  Remarkably, when mNTCP residues 84 to 87 were substituted by human counterparts, mNTCP can effectively support viral infections.  In addn., a no. of cell lines, regardless of their species or tissue origin, supported HDV infection when transfected with hNTCP or mNTCP with residues 84 to 87 replaced by human counterparts, highlighting the central role of NTCP for viral infections mediated by HBV envelope proteins.  These studies advance our understanding of NTCP-mediated viral entry of HBV and HDV and have important implications for developing the mouse model for their infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo181QjmyElmLVg90H21EOLACvtfcHk0libzaUb9wEsnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFWjt7zK&md5=59f5669452aad2a667b6dfd1ba54d525</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FJVI.03540-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.03540-12%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DG.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DMolecular%2520determinants%2520of%2520hepatitis%2520B%2520and%2520D%2520virus%2520entry%2520restriction%2520in%2520mouse%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D7977%26epage%3D7991%26doi%3D10.1128%2FJVI.03540-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">3273</span>– <span class="NLM_lpage">3284</span>, <span class="refDoi"> DOI: 10.1128/JVI.03478-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.03478-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24390325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVOqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=3273-3284&author=H.+Yanauthor=B.+Pengauthor=Y.+Liuauthor=G.+Xuauthor=W.+Heauthor=B.+Renauthor=Z.+Jingauthor=J.+Suiauthor=W.+Li&title=Viral+entry+of+hepatitis+B+and+D+viruses+and+bile+salts+transportation+share+common+molecular+determinants+on+sodium+taurocholate+cotransporting+polypeptide&doi=10.1128%2FJVI.03478-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide</span></div><div class="casAuthors">Yan, Huan; Peng, Bo; Liu, Yang; Xu, Guangwei; He, Wenhui; Ren, Bijie; Jing, Zhiyi; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3273-3284, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The liver bile acids transporter sodium taurocholate cotransporting polypeptide (NTCP) is responsible for the majority of sodium-dependent bile salts uptake by hepatocytes.  NTCP also functions as a cellular receptor for viral entry of hepatitis B virus (HBV) and hepatitis D virus (HDV) through a specific interaction between NTCP and the pre-S1 domain of HBV large envelope protein.  However, it remains unknown if these two functions of NTCP are independent or if they interfere with each other.  Here we show that binding of the pre-S1 domain to human NTCP blocks taurocholate uptake by the receptor; conversely, some bile acid substrates of NTCP inhibit HBV and HDV entry.  Mutations of NTCP residues crit. for bile salts binding severely impair viral infection by HDV and HBV; to a lesser extent, the residues important for sodium binding also inhibit viral infection.  The mutation S267F, corresponding to a single nucleotide polymorphism (SNP) found in about 9% of the East Asian population, renders NTCP without either taurocholate transporting activity or the ability to support HBV or HDV infection in cell culture.  These results demonstrate that mol. determinants crit. for HBV and HDV entry overlap with that for bile salts uptake by NTCP, indicating that viral infection may interfere with the normal function of NTCP and bile acids and their derivs. hold the potential for further development into antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsAWAqX4p6L7Vg90H21EOLACvtfcHk0liYgxh_l6EADQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVOqtr4%253D&md5=22fe09e746ad3f6ee76002a316de82b1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FJVI.03478-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.03478-13%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DViral%2520entry%2520of%2520hepatitis%2520B%2520and%2520D%2520viruses%2520and%2520bile%2520salts%2520transportation%2520share%2520common%2520molecular%2520determinants%2520on%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D3273%26epage%3D3284%26doi%3D10.1128%2FJVI.03478-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">König, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geipel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glebe, D.</span></span> <span> </span><span class="NLM_article-title">Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2014.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.jhep.2014.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24845614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A280%3ADC%252BC2cjkslSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=867-875&author=A.+K%C3%B6nigauthor=B.+Doringauthor=C.+Mohrauthor=A.+Geipelauthor=J.+Geyerauthor=D.+Glebe&title=Kinetics+of+the+bile+acid+transporter+and+hepatitis+B+virus+receptor+Na%2B%2Ftaurocholate+cotransporting+polypeptide+%28NTCP%29+in+hepatocytes&doi=10.1016%2Fj.jhep.2014.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes</span></div><div class="casAuthors">Konig Alexander; Mohr Christina; Geipel Andreas; Doring Barbara; Geyer Joachim; Glebe Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">867-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  The human liver bile acid transporter Na(+)/taurocholate cotransporting polypeptide (NTCP) has recently been identified as liver-specific receptor for infection of hepatitis B virus (HBV), which attaches via the myristoylated preS1 (myr-preS1) peptide domain of its large surface protein to NTCP.  Since binding of the myr-preS1 peptide to NTCP is an initiating step of HBV infection, we investigated if this process interferes with the physiological bile acid transport function of NTCP.  METHODS:  HBV infection, myr-preS1 peptide binding, and bile acid transport assays were performed with primary Tupaia belangeri (PTH) and human (PHH) hepatocytes as well as NTCP-transfected human hepatoma HepG2 cells allowing regulated NTCP expression, in the presence of various bile acids, ezetimibe, and myr-preS1 peptides.  RESULTS:  The myr-preS1 peptide of HBV inhibited bile acid transport in PTH and PHH as well as in NTCP-expressing HEK293 and HepG2 cells.  Inversely, HBV infection of PTH, PHH, and NTCP-transfected HepG2 cells was inhibited in a concentration-dependent manner by taurine and glycine conjugates of cholic acid and ursodeoxycholic acid as well as by ezetimibe.  In NTCP-HepG2 cells and PTH, NTCP expression, NTCP transport function, myr-preS1 peptide binding, and HBV infection followed comparable kinetics.  CONCLUSIONS:  Myr-preS1 virus binding to NTCP, necessary for productive HBV infection, interferes with the physiological bile acid transport function of NTCP.  Therefore, HBV infection via NTCP may be lockable by NTCP substrates and NTCP-inhibiting drugs.  This opens a completely new way for an efficient management of HBV infection by the use of NTCP-directed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL8uPrQ26gtXtlzo9xastyfW6udTcc2eYlPVDKF_JJcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjkslSgug%253D%253D&md5=46106af8958ba2cd35a321f29fe58970</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6nig%26aufirst%3DA.%26aulast%3DDoring%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DGeipel%26aufirst%3DA.%26aulast%3DGeyer%26aufirst%3DJ.%26aulast%3DGlebe%26aufirst%3DD.%26atitle%3DKinetics%2520of%2520the%2520bile%2520acid%2520transporter%2520and%2520hepatitis%2520B%2520virus%2520receptor%2520Na%252B%252Ftaurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%2520in%2520hepatocytes%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3D867%26epage%3D875%26doi%3D10.1016%2Fj.jhep.2014.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jen, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-J.</span></span> <span> </span><span class="NLM_article-title">The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1514</span>– <span class="NLM_lpage">1521</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2015-310686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1136%2Fgutjnl-2015-310686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=26642861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSkt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=1514-1521&author=H.-H.+Huauthor=J.+Liuauthor=Y.-L.+Linauthor=W.-S.+Luoauthor=Y.-J.+Chuauthor=C.-L.+Changauthor=C.-L.+Jenauthor=M.-H.+Leeauthor=S.-N.+Luauthor=L.-Y.+Wangauthor=S.-L.+Youauthor=H.-I.+Yangauthor=C.-J.+Chen&title=The+rs2296651+%28S267F%29+variant+on+NTCP+%28SLC10A1%29+is+inversely+associated+with+chronic+hepatitis+B+and+progression+to+cirrhosis+and+hepatocellular+carcinoma+in+patients+with+chronic+hepatitis+B&doi=10.1136%2Fgutjnl-2015-310686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B</span></div><div class="casAuthors">Hu, Hui-Han; Liu, Jessica; Lin, Yu-Ling; Luo, Wun-Sheng; Chu, Yu-Ju; Chang, Chia-Lin; Jen, Chin-Lan; Lee, Mei-Hsuan; Lu, Sheng-Nan; Wang, Li-Yu; You, San-Lin; Yang, Hwai-I.; Chen, Chien-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1514-1521</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective: The sodium taurocholate co-transporting polypeptide (NTCP), encoded by SLC10A1, was recently identified as a receptor for HBV.  We assessed the assocn. of the p.Ser267Phe variant (rs2296651) with chronic hepatitis B (CHB) serostatus, cirrhosis and hepatocellular carcinoma (HCC) in patients with CHB.  Design: The variant was genotyped in 3801 patients with CHB and 3801 matched hepatitis B surface antigen (HBsAg) seroneg. individuals.  ORs with 95% CIs for the variant's assocn. with CHB, cirrhosis and HCC were estd. using logistic regression.  Results: In patients with CHB, the S267F variant was obsd. in 515 (18.5%) controls, 40 (17.2%) cirrhosis only cases, 49 (13.2%) non-cirrhotic HCC cases, and 52 (12.7%) cirrhotic-HCC cases.  After adjustment for known risk factors, S267F was significantly assocd. with decreased risk for cirrhosis (OR 0.65 (95% CI 0.49 to 0.86), p=0.002) and HCC (OR 0.55 (95% CI 0.42 to 0.72), p<0.001).  This assocn. persisted for noncirrhotic and cirrhotic-HCC.  Compared with patients with HBV DNA levels greater than 105 copies/mL who carried the GG genotype, patients who had undetectable HBV DNA and the GA or AA genotypes had a 25-fold decreased risk of developing HCC (OR 0.04 (95% CI 0.02 to 0.11), p<0.001).  The AA genotype was also assocd. with HBsAg seronegativity (OR 0.13 (95% CI 0.05 to 0.34), p<0.001).  Conclusions: The SLC10A1 (NTCP) S267F variant is independently assocd. with decreased risk of cirrhosis and HCC, and resistance to CHB infection.  Together with serum HBV DNA levels, S267F may help to identify patients with CHB with very low risk of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAZUGcfX19kbVg90H21EOLACvtfcHk0liYgxh_l6EADQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSkt7s%253D&md5=d3fe750d172588c40910031e38de878e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2015-310686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2015-310686%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.-H.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.-L.%26aulast%3DLuo%26aufirst%3DW.-S.%26aulast%3DChu%26aufirst%3DY.-J.%26aulast%3DChang%26aufirst%3DC.-L.%26aulast%3DJen%26aufirst%3DC.-L.%26aulast%3DLee%26aufirst%3DM.-H.%26aulast%3DLu%26aufirst%3DS.-N.%26aulast%3DWang%26aufirst%3DL.-Y.%26aulast%3DYou%26aufirst%3DS.-L.%26aulast%3DYang%26aufirst%3DH.-I.%26aulast%3DChen%26aufirst%3DC.-J.%26atitle%3DThe%2520rs2296651%2520%2528S267F%2529%2520variant%2520on%2520NTCP%2520%2528SLC10A1%2529%2520is%2520inversely%2520associated%2520with%2520chronic%2520hepatitis%2520B%2520and%2520progression%2520to%2520cirrhosis%2520and%2520hepatocellular%2520carcinoma%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520B%26jtitle%3DGut%26date%3D2016%26volume%3D65%26spage%3D1514%26epage%3D1521%26doi%3D10.1136%2Fgutjnl-2015-310686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1008</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1021/mp300453k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300453k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1008-1019&author=Z.+Dongauthor=S.+Ekinsauthor=J.+E.+Polli&title=Structure-activity+relationship+for+FDA+approved+drugs+as+inhibitors+of+the+human+sodium+taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1021%2Fmp300453k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship for FDA Approved Drugs As Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP)</span></div><div class="casAuthors">Dong, Zhongqi; Ekins, Sean; Polli, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1008-1019</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hepatic bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP) is less well characterized than its ileal paralog, the apical sodium dependent bile acid transporter (ASBT), in terms of drug inhibition requirements.  The objectives of this study were (a) to identify FDA approved drugs that inhibit human NTCP, (b) to develop pharmacophore and Bayesian computational models for NTCP inhibition, and (c) to compare NTCP and ASBT transport inhibition requirements.  A series of NTCP inhibition studies were performed using FDA approved drugs, in concert with iterative computational model development.  Screening studies identified 27 drugs as novel NTCP inhibitors, including irbesartan (Ki = 11.9 μM) and ezetimibe (Ki = 25.0 μM).  The common feature pharmacophore indicated that two hydrophobes and one hydrogen bond acceptor were important for inhibition of NTCP.  From 72 drugs screened in vitro, a total of 31 drugs inhibited NTCP, while 51 drugs (i.e., more than half) inhibited ASBT.  Hence, while there was inhibitor overlap, ASBT unexpectedly was more permissive to drug inhibition than was NTCP, and this may be related to NTCP possessing fewer pharmacophore features.  Findings reflected that a combination of computational and in vitro approaches enriched the understanding of these poorly characterized transporters and yielded addnl. chem. probes for possible drug-transporter interaction detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbGhpWyONrzbVg90H21EOLACvtfcHk0ljjlRCadOYwUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsL8%253D&md5=0a0e0af7c8d1acb875ef8208c84f13c6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fmp300453k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300453k%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPolli%26aufirst%3DJ.%2BE.%26atitle%3DStructure-activity%2520relationship%2520for%2520FDA%2520approved%2520drugs%2520as%2520inhibitors%2520of%2520the%2520human%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D1008%26epage%3D1019%26doi%3D10.1021%2Fmp300453k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nkongolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lempp, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esser-Nobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span> <span> </span><span class="NLM_article-title">Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2013.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.jhep.2013.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24295872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=723-731&author=S.+Nkongoloauthor=Y.+Niauthor=F.+A.+Lemppauthor=C.+Kaufmanauthor=T.+Lindnerauthor=K.+Esser-Nobisauthor=V.+Lohmannauthor=W.+Mierauthor=S.+Mehrleauthor=S.+Urban&title=Cyclosporin+A+inhibits+hepatitis+B+and+hepatitis+D+virus+entry+by+cyclophilin-independent+interference+with+the+NTCP+receptor&doi=10.1016%2Fj.jhep.2013.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor</span></div><div class="casAuthors">Nkongolo, Shirin; Ni, Yi; Lempp, Florian A.; Kaufman, Christina; Lindner, Thomas; Esser-Nobis, Katharina; Lohmann, Volker; Mier, Walter; Mehrle, Stefan; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">723-731</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic hepatitis B and hepatitis D are global health problems caused by the human hepatitis B and hepatitis D virus.  The myristoylated preS1 domain of the large envelope protein mediates specific binding to hepatocytes by sodium taurocholate co-transporting polypeptide (NTCP).  NTCP is a bile salt transporter known to be inhibited by cyclosporin A.  This study aimed to characterize the effect of cyclosporin A on HBV/HDV infection.  HepaRG cells, primary human hepatocytes, and susceptible NTCP-expressing hepatoma cell lines were applied for infection expts.  The mode of action of cyclosporin A was studied by comparing the effect of different inhibitors, cyclophilin A/B/C-silenced cell lines as well as NTCP variants and mutants.  Bile salt transporter and HBV receptor functions were investigated by taurocholate uptake and quantification of HBVpreS binding.Cyclosporin A inhibited hepatitis B and D virus infections during and - less pronounced - prior to virus inoculation.  Binding of HBVpreS to NTCP was blocked by cyclosporin A concns. at 8 μM.  An NTCP variant deficient in HBVpreS binding but competent for bile salt transport showed resistance to cyclosporin A.  Silencing of cyclophilins A/B/C did not abrogate transporter and receptor inhibition.  In contrast, tacrolimus, a cyclophilin-independent calcineurin inhibitor, was inactive.HBV and HDV entry via sodium taurocholate co-transporting polypeptide is inhibited by cyclosporin A.  The interaction between the drug and the viral receptor is direct and overlaps with a functional binding site of the preS1 domain, which mediates viral entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTAVAhQe6_ErVg90H21EOLACvtfcHk0ljjlRCadOYwUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlagtw%253D%253D&md5=d8c7e3698ac926cd5c06a9e7e2c4717b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DNkongolo%26aufirst%3DS.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DKaufman%26aufirst%3DC.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DEsser-Nobis%26aufirst%3DK.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DMehrle%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DCyclosporin%2520A%2520inhibits%2520hepatitis%2520B%2520and%2520hepatitis%2520D%2520virus%2520entry%2520by%2520cyclophilin-independent%2520interference%2520with%2520the%2520NTCP%2520receptor%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D723%26epage%3D731%26doi%3D10.1016%2Fj.jhep.2013.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borroto-Esoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span> <span> </span><span class="NLM_article-title">Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1726</span>– <span class="NLM_lpage">1737</span>, <span class="refDoi"> DOI: 10.1002/hep.26982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1002%2Fhep.26982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24375637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1726-1737&author=K.+Watashiauthor=A.+Sluderauthor=T.+Daitoauthor=S.+Matsunagaauthor=A.+Ryoauthor=S.+Nagamoriauthor=M.+Iwamotoauthor=S.+Nakajimaauthor=S.+Tsukudaauthor=K.+Borroto-Esodaauthor=M.+Sugiyamaauthor=Y.+Tanakaauthor=Y.+Kanaiauthor=H.+Kusuharaauthor=M.+Mizokamiauthor=T.+Wakita&title=Cyclosporin+A+and+its+analogs+inhibit+hepatitis+B+virus+entry+into+cultured+hepatocytes+through+targeting+a+membrane+transporter%2C+sodium+taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1002%2Fhep.26982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)</span></div><div class="casAuthors">Watashi, Koichi; Sluder, Ann; Daito, Takuji; Matsunaga, Satoko; Ryo, Akihide; Nagamori, Shushi; Iwamoto, Masashi; Nakajima, Syo; Tsukuda, Senko; Borroto-Esoda, Katyna; Sugiyama, Masaya; Tanaka, Yasuhito; Kanai, Yoshikatsu; Kusuhara, Hiroyuki; Mizokami, Masashi; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1726-1737</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide.  Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clin. available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other targets.  Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes.  The anti-HBV effect of CsA was independent of binding to cyclophilin and calcineurin.  Rather, blockade of HBV infection correlated with the ability to inhibit the transporter activity of sodium taurocholate cotransporting polypeptide (NTCP).  We also found that HBV infection-susceptible cells, differentiated HepaRG cells and primary human hepatocytes expressed NTCP, while nonsusceptible cell lines did not.  A series of compds. targeting NTCP could inhibit HBV infection.  CsA inhibited the binding between NTCP and large envelope protein in vitro.  Evaluation of CsA analogs identified a compd. with higher anti-HBV potency, having a median inhibitory concn. <0.2 μM.  Conclusion: This study provides a proof of concept for the novel strategy to identify anti-HBV agents by targeting the candidate HBV receptor, NTCP, using CsA as a structural platform. (Hepatol. 2014;59:1726-1737).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRV21kvExmObVg90H21EOLACvtfcHk0ljBGOAPObLdOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFCltro%253D&md5=d83ae63fbe3e8b827f9fbf5f6601b316</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fhep.26982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26982%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DSluder%26aufirst%3DA.%26aulast%3DDaito%26aufirst%3DT.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DNagamori%26aufirst%3DS.%26aulast%3DIwamoto%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DTsukuda%26aufirst%3DS.%26aulast%3DBorroto-Esoda%26aufirst%3DK.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DCyclosporin%2520A%2520and%2520its%2520analogs%2520inhibit%2520hepatitis%2520B%2520virus%2520entry%2520into%2520cultured%2520hepatocytes%2520through%2520targeting%2520a%2520membrane%2520transporter%252C%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D1726%26epage%3D1737%26doi%3D10.1002%2Fhep.26982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanchet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, P.</span></span> <span> </span><span class="NLM_article-title">Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2014.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.antiviral.2014.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24717262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=111-115&author=M.+Blanchetauthor=C.+Sureauauthor=P.+Labonte&title=Use+of+FDA+approved+therapeutics+with+hNTCP+metabolic+inhibitory+properties+to+impair+the+HDV+lifecycle&doi=10.1016%2Fj.antiviral.2014.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle</span></div><div class="casAuthors">Blanchet, Matthieu; Sureau, Camille; Labonte, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-115</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Worldwide there are approx. 240 million individuals chronically infected with the hepatitis B virus (HBV), including 15-20 million coinfected with the hepatitis delta virus (HDV).  Treatments available today are not fully efficient and often assocd. to important side effects and development of drug resistance.  Targeting the HBV/HDV entry step using preS1-specific lipopeptides appears as a promising strategy to block viral entry for both HBV and HDV (Gripon et al., 2005; Petersen et al., 2008).  Recently, the human Sodium Taurocholate Cotransporting Polypeptide (hNTCP) has been identified as a functional, preS1-specific receptor for HBV and HDV.  This groundbreaking discovery has opened a very promising avenue for the treatment of chronic HBV and HDV infections.  Here we investigated the ability of FDA approved therapeutics with documented inhibitory effect on hNTCP cellular function to impair viral entry using a HDV in vitro infection model based on a hNTCP-expressing Huh7 cell line.  We demonstrate the potential of three FDA approved mols., irbesartan, ezetimibe, and ritonavir, to alter HDV infection in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5uuuK9vPHVbVg90H21EOLACvtfcHk0ljBGOAPObLdOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSrsLc%253D&md5=abe5262a9fa3fc4daaff030ae1a080c1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchet%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DLabonte%26aufirst%3DP.%26atitle%3DUse%2520of%2520FDA%2520approved%2520therapeutics%2520with%2520hNTCP%2520metabolic%2520inhibitory%2520properties%2520to%2520impair%2520the%2520HDV%2520lifecycle%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D106%26spage%3D111%26epage%3D115%26doi%3D10.1016%2Fj.antiviral.2014.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucifora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protzer, U.</span></span> <span> </span><span class="NLM_article-title">Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2012.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.antiviral.2012.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=23266293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=195-197&author=J.+Luciforaauthor=K.+Esserauthor=U.+Protzer&title=Ezetimibe+blocks+hepatitis+B+virus+infection+after+virus+uptake+into+hepatocytes&doi=10.1016%2Fj.antiviral.2012.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes</span></div><div class="casAuthors">Lucifora, Julie; Esser, Knud; Protzer, Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-197</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Current treatment of chronic hepatitis B virus (HBV) infection mainly targets viral replication in hepatocytes and leads to curing only in exceptional cases.  Despite their potential to improve therapeutic success, no drugs interfering with early infection steps of the hepatotropic pathogen HBV are available to date.  Recently, entry of the hepatitis C virus (HCV) was shown to occur along hepatic cholesterol uptake pathways and ezetimibe, a drug which blocks this lipid transport, was shown to inhibit HCV infection.  We here investigated the effect of ezetimibe on HBV infection using differentiated HepaRG cells as a cell-culture infection model.  Treatment with ezetimibe inhibited establishment of intrahepatic cccDNA and expression of viral replication markers when cells were infected with HBV virions, while we obsd. no effect when the HBV viral genome was transduced via an adenoviral vector.  Our data suggest that modulating hepatic cholesterol uptake by ezetimibe inhibits early HBV infection and that ezetimibe sensitive lipid transport pathways represent new targets for antiviral therapy in HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNJ1wQJ_RUkbVg90H21EOLACvtfcHk0ljBGOAPObLdOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSrsrw%253D&md5=dcfca7855b8cacdad584203e23690f85</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2012.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2012.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DEsser%26aufirst%3DK.%26aulast%3DProtzer%26aufirst%3DU.%26atitle%3DEzetimibe%2520blocks%2520hepatitis%2520B%2520virus%2520infection%2520after%2520virus%2520uptake%2520into%2520hepatocytes%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D97%26spage%3D195%26epage%3D197%26doi%3D10.1016%2Fj.antiviral.2012.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veloso
Alves Pereira, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprinzl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaphoff, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vondran, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarrazin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manns, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto Marques Souza de Oliveira, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodeik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Hahn, T.</span></span> <span> </span><span class="NLM_article-title">Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0117152</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0117152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1371%2Fjournal.pone.0117152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=25646622" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=I.+Veloso%0AAlves+Pereiraauthor=B.+Buchmannauthor=L.+Sandmannauthor=K.+Sprinzlauthor=V.+Schlaphoffauthor=K.+Dohnerauthor=F.+Vondranauthor=C.+Sarrazinauthor=M.+P.+Mannsauthor=C.+Pinto+Marques+Souza+de+Oliveiraauthor=B.+Sodeikauthor=S.+Ciesekauthor=T.+von+Hahn&title=Primary+biliary+acids+inhibit+hepatitis+D+virus+%28HDV%29+entry+into+human+hepatoma+cells+expressing+the+sodium-taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1371%2Fjournal.pone.0117152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0117152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0117152%26sid%3Dliteratum%253Aachs%26aulast%3DVeloso%2BAlves%2BPereira%26aufirst%3DI.%26aulast%3DBuchmann%26aufirst%3DB.%26aulast%3DSandmann%26aufirst%3DL.%26aulast%3DSprinzl%26aufirst%3DK.%26aulast%3DSchlaphoff%26aufirst%3DV.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DVondran%26aufirst%3DF.%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3DPinto%2BMarques%2BSouza%2Bde%2BOliveira%26aufirst%3DC.%26aulast%3DSodeik%26aufirst%3DB.%26aulast%3DCiesek%26aufirst%3DS.%26aulast%3Dvon%2BHahn%26aufirst%3DT.%26atitle%3DPrimary%2520biliary%2520acids%2520inhibit%2520hepatitis%2520D%2520virus%2520%2528HDV%2529%2520entry%2520into%2520human%2520hepatoma%2520cells%2520expressing%2520the%2520sodium-taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0117152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucifora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knolle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkirane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durantel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosset, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick-Marchand, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barre-Sinoussi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delfraissy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoulim, F.</span></span> <span> </span><span class="NLM_article-title">Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1314</span>– <span class="NLM_lpage">1326</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2014-308943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1136%2Fgutjnl-2014-308943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=25670809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVCrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1314-1326&author=M.+B.+Zeiselauthor=J.+Luciforaauthor=W.+S.+Masonauthor=C.+Sureauauthor=J.+Beckauthor=M.+Levreroauthor=M.+Kannauthor=P.+A.+Knolleauthor=M.+Benkiraneauthor=D.+Durantelauthor=M.+L.+Michelauthor=B.+Autranauthor=F.+L.+Cossetauthor=H.+Strick-Marchandauthor=C.+Trepoauthor=J.+H.+Kaoauthor=F.+Carratauthor=K.+Lacombeauthor=R.+F.+Schinaziauthor=F.+Barre-Sinoussiauthor=J.+F.+Delfraissyauthor=F.+Zoulim&title=Towards+an+HBV+cure%3A+state-of-the-art+and+unresolved+questions%2D%2Dreport+of+the+ANRS+workshop+on+HBV+cure&doi=10.1136%2Fgutjnl-2014-308943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure</span></div><div class="casAuthors">Zeisel, Mirjam B.; Lucifora, Julie; Mason, William S.; Sureau, Camille; Beck, Jurgen; Levrero, Massimo; Kann, Michael; Knolle, Percy A.; Benkirane, Monsef; Durantel, David; Michel, Marie-Louise; Autran, Brigitte; Cosset, Francois-Loic; Strick-Marchand, Helene; Trepo, Christian; Kao, Jia-Horng; Carrat, Fabrice; Lacombe, Karine; Schinazi, Raymond F.; Barre-Sinoussi, Francoise; Delfraissy, Jean-Francois; Zoulim, Fabien</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1314-1326</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma.  Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide.  Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons.  In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' program, a scientific workshop was held in Paris in June 2014 to define the state-ofthe- art and unanswered questions regarding HBV pathobiol., and to develop a concerted strategy towards an HBV cure.  This review summarizes our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq3d3BmB6kC7Vg90H21EOLACvtfcHk0lhSxPfmhL0RQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVCrt7g%253D&md5=3fb4876ea829381ac9fbf8f9f3deeda7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2014-308943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2014-308943%26sid%3Dliteratum%253Aachs%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DW.%2BS.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DLevrero%26aufirst%3DM.%26aulast%3DKann%26aufirst%3DM.%26aulast%3DKnolle%26aufirst%3DP.%2BA.%26aulast%3DBenkirane%26aufirst%3DM.%26aulast%3DDurantel%26aufirst%3DD.%26aulast%3DMichel%26aufirst%3DM.%2BL.%26aulast%3DAutran%26aufirst%3DB.%26aulast%3DCosset%26aufirst%3DF.%2BL.%26aulast%3DStrick-Marchand%26aufirst%3DH.%26aulast%3DTrepo%26aufirst%3DC.%26aulast%3DKao%26aufirst%3DJ.%2BH.%26aulast%3DCarrat%26aufirst%3DF.%26aulast%3DLacombe%26aufirst%3DK.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DBarre-Sinoussi%26aufirst%3DF.%26aulast%3DDelfraissy%26aufirst%3DJ.%2BF.%26aulast%3DZoulim%26aufirst%3DF.%26atitle%3DTowards%2520an%2520HBV%2520cure%253A%2520state-of-the-art%2520and%2520unresolved%2520questions--report%2520of%2520the%2520ANRS%2520workshop%2520on%2520HBV%2520cure%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D1314%26epage%3D1326%26doi%3D10.1136%2Fgutjnl-2014-308943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gripon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span> <span> </span><span class="NLM_article-title">Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1613</span>– <span class="NLM_lpage">1622</span>, <span class="refDoi"> DOI: 10.1128/JVI.79.3.1613-1622.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.79.3.1613-1622.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15650187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=1613-1622&author=P.+Griponauthor=I.+Cannieauthor=S.+Urban&title=Efficient+inhibition+of+hepatitis+B+virus+infection+by+acylated+peptides+derived+from+the+large+viral+surface+protein&doi=10.1128%2FJVI.79.3.1613-1622.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein</span></div><div class="casAuthors">Gripon, Philippe; Cannie, Isabelle; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1613-1622</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The lack of an appropriate in vitro infection system for the major human pathogen hepatitis B virus (HBV) has prevented a mol. understanding of the early infection events of HBV.  We used the novel HBV-infectible cell line HepaRG and primary human hepatocytes to investigate the interference of infection by HBV envelope protein-derived peptides.  We found that a peptide consisting of the authentically myristoylated N-terminal 47 amino acids of the pre-S1 domain of the large viral envelope protein (L protein) specifically prevented HBV infection, with a 50% inhibitory concn. (IC50) of 8 nM.  The replacement of myristic acid with other hydrophobic moieties resulted in changes in the inhibitory activity, most notably by a decrease in the IC50 to picomolar concns. for longer unbranched fatty acids.  The obstruction of HepaRG cell susceptibility to HBV infection after short preincubation times with the peptides suggested that the peptides efficiently target and inactivate a receptor at the hepatocyte surface.  Our data both shed light on the mol. mechanism of HBV entry into hepatocytes and provide a basis for the development of potent hepadnaviral entry inhibitors as a novel therapeutic concept for the treatment of hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ35R_8zOmS7Vg90H21EOLACvtfcHk0lhSxPfmhL0RQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtb8%253D&md5=519a08a82ce4de9e5db5692cf2a5ae80</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.3.1613-1622.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.3.1613-1622.2005%26sid%3Dliteratum%253Aachs%26aulast%3DGripon%26aufirst%3DP.%26aulast%3DCannie%26aufirst%3DI.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DEfficient%2520inhibition%2520of%2520hepatitis%2520B%2520virus%2520infection%2520by%2520acylated%2520peptides%2520derived%2520from%2520the%2520large%2520viral%2520surface%2520protein%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D1613%26epage%3D1622%26doi%3D10.1128%2FJVI.79.3.1613-1622.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allweiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warlich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutgehetmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandri, M.</span></span> <span> </span><span class="NLM_article-title">The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.jhep.2012.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=23246506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFyqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=861-867&author=T.+Volzauthor=L.+Allweissauthor=M.+M.+Benauthor=M.+Warlichauthor=A.+W.+Lohseauthor=J.+M.+Pollokauthor=A.+Alexandrovauthor=S.+Urbanauthor=J.+Petersenauthor=M.+Lutgehetmannauthor=M.+Dandri&title=The+entry+inhibitor+Myrcludex-B+efficiently+blocks+intrahepatic+virus+spreading+in+humanized+mice+previously+infected+with+hepatitis+B+virus&doi=10.1016%2Fj.jhep.2012.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus</span></div><div class="casAuthors">Volz, Tassilo; Allweiss, Lena; Ben Mbarek, Mounira; Warlich, Michael; Lohse, Ansgar W.; Pollok, Joerg M.; Alexandrov, Alexander; Urban, Stephan; Petersen, Joerg; Luetgehetmann, Marc; Dandri, Maura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">861-867</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Currently approved antivirals rarely cure hepatitis B virus (HBV) infection.  Therefore addnl. therapeutic strategies interfering with other viral replication steps are needed.  Using synthetic lipopeptides derived from the HBV envelope protein, we previously demonstrated prevention of de novo HBV infection in vivo.  We aimed at investigating the ability of the lipopeptide Myrcludex-B to block HBV spreading post-infection.uPA/SCID mice reconstituted with human hepatocytes were infected with HBV.  Daily s.c. Myrcludex-B administration was initiated either 3 days, 3 wk or 8 wk post HBV inoculation.  Viral loads were quantitated in serum and liver, and visualized by immunohistochem.Myrcludex-B efficiently prevented viral spreading from the initially infected human hepatocytes, as demonstrated by the lack of increase in viremia, antigen levels and amt. of HBcAg-pos. human hepatocytes detd. 6 wk after treatment.  Myrcludex-B efficiently blocked HBV dissemination also when treatment was started in the ramp-up phase of infection, in mice displaying moderate levels of circulating virions (median 3 × 106 HBV DNA copies/mL).  Notably, after 6 wk of treatment, not only the amt. of HBcAg-pos. hepatocytes, but also intrahepatic cccDNA loads, remained comparable to values found in mice sacrificed 3 wk post-infection.  In none of the exptl. settings, drug administration affected human hepatocyte half-life or altered virion productivity.Myrcludex-B efficiently not only prevented HBV spreading from infected human hepatocytes in vivo, but also hindered amplification of the cccDNA pool in initially infected hepatocytes.  Administration of an entry inhibitor, possibly used in combination with current HBV drugs, may improve patients' treatment outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa56-oby3iE7Vg90H21EOLACvtfcHk0lhSxPfmhL0RQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFyqsb8%253D&md5=308396c033ffd1f57f2ded28890c173a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DVolz%26aufirst%3DT.%26aulast%3DAllweiss%26aufirst%3DL.%26aulast%3DBen%26aufirst%3DM.%2BM.%26aulast%3DWarlich%26aufirst%3DM.%26aulast%3DLohse%26aufirst%3DA.%2BW.%26aulast%3DPollok%26aufirst%3DJ.%2BM.%26aulast%3DAlexandrov%26aufirst%3DA.%26aulast%3DUrban%26aufirst%3DS.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DLutgehetmann%26aufirst%3DM.%26aulast%3DDandri%26aufirst%3DM.%26atitle%3DThe%2520entry%2520inhibitor%2520Myrcludex-B%2520efficiently%2520blocks%2520intrahepatic%2520virus%2520spreading%2520in%2520humanized%2520mice%2520previously%2520infected%2520with%2520hepatitis%2520B%2520virus%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D861%26epage%3D867%26doi%3D10.1016%2Fj.jhep.2012.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogomolov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voronkova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macievich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrachenkova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lempp, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedemeyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haefeli, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">490</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2016.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.jhep.2016.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=27132170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVynsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=490-498&author=P.+Bogomolovauthor=A.+Alexandrovauthor=N.+Voronkovaauthor=M.+Macievichauthor=K.+Kokinaauthor=M.+Petrachenkovaauthor=T.+Lehrauthor=F.+A.+Lemppauthor=H.+Wedemeyerauthor=M.+Haagauthor=M.+Schwabauthor=W.+E.+Haefeliauthor=A.+Blankauthor=S.+Urban&title=Treatment+of+chronic+hepatitis+D+with+the+entry+inhibitor+myrcludex+B%3A+First+results+of+a+phase+Ib%2FIIa+study&doi=10.1016%2Fj.jhep.2016.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study</span></div><div class="casAuthors">Bogomolov, Pavel; Alexandrov, Alexander; Voronkova, Natalia; Macievich, Maria; Kokina, Ksenia; Petrachenkova, Maria; Lehr, Thorsten; Lempp, Florian A.; Wedemeyer, Heiner; Haag, Mathias; Schwab, Matthias; Haefeli, Walter E.; Blank, Antje; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">490-498</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The therapeutic option for patients with chronic hepatitis delta virus infection (CHD) is limited to interferon alpha with rare curative outcome.  Myrcludex B is a first-in-class entry inhibitor inactivating the hepatitis B virus (HBV) and hepatitis D virus (HDV) receptor sodium taurocholate co-transporting polypeptide.  We report the interim results of a pilot trial on chronically infected HDV patients treated with myrcludex B, or pegylated interferon alpha (PegIFNα-2a) or their combination.  Twenty-four patients with CHD infection were equally randomized (1:1:1) to receive myrcludex B, or PegIFNα-2a or their combination.  Patients were evaluated for virol. and biochem. response and tolerability of the study drugs at weeks 12 and 24.  Myrcludex B was well tolerated and no serious adverse event occurred.  Although hepatitis B surface antigen levels remained unchanged, HDV RNA significantly declined at week 24 in all cohorts.  HDV RNA became neg. in two patients each in the Myrcludex B and PegIFNα-2a cohorts, and in five patients of the Myrcludex B + PegIFNα-2a cohort.  ALT decreased significantly in the Myrcludex B cohort (six of eight patients), and HBV DNA was significantly reduced at week 24 in the Myrcludex B + PegIFNα-2a cohort.  Virus kinetic modeling suggested a strong synergistic effect of myrcludex B and PegIFNα-2a on both HDV and HBV.  Myrcludex B showed a strong effect on HDV RNA serum levels and induced ALT normalization under monotherapy.  Synergistic antiviral effects on HDV RNA and HBV DNA in the Myr-IFN cohort indicated a benefit of the combination of entry inhibition with PegIFNα-2a to treat CHD patients.  Myrcludex B is a new drug to treat hepatitis B and D infection.  After 24 wk of treatment with myrcludex B and/or pegylated interferon α-2a, HDV RNA, a relevant marker for hepatitis D infection, decreased in all patients with chronic hepatitis B and D.  Two of eight patients which received either myrcludex B or pegylated interferon α-2a, became neg. for HDV RNA, and five of seven patients who received both drugs at the same time became neg.  The drug was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo29Ewz7ZuCMrVg90H21EOLACvtfcHk0lgtg5dQp0bC-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVynsbrE&md5=9b31bd4df1423aa2da1e49d41a89192a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DBogomolov%26aufirst%3DP.%26aulast%3DAlexandrov%26aufirst%3DA.%26aulast%3DVoronkova%26aufirst%3DN.%26aulast%3DMacievich%26aufirst%3DM.%26aulast%3DKokina%26aufirst%3DK.%26aulast%3DPetrachenkova%26aufirst%3DM.%26aulast%3DLehr%26aufirst%3DT.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DHaag%26aufirst%3DM.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26aulast%3DBlank%26aufirst%3DA.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DTreatment%2520of%2520chronic%2520hepatitis%2520D%2520with%2520the%2520entry%2520inhibitor%2520myrcludex%2520B%253A%2520First%2520results%2520of%2520a%2520phase%2520Ib%252FIIa%2520study%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D65%26spage%3D490%26epage%3D498%26doi%3D10.1016%2Fj.jhep.2016.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rüegger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loosli, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguenin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiquerez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Wartburg, A.</span></span> <span> </span><span class="NLM_article-title">[Cyclosporin A, a Peptide Metabolite from <i>Trichoderma polysporum</i> (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity]</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1092</span>, <span class="refDoi"> DOI: 10.1002/hlca.19760590412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1002%2Fhlca.19760590412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=950308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaE28Xkt12ksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1976&pages=1075-1092&author=A.+R%C3%BCeggerauthor=M.+Kuhnauthor=H.+Lichtiauthor=H.+R.+Loosliauthor=R.+Hugueninauthor=C.+Quiquerezauthor=A.+von+Wartburg&title=%5BCyclosporin+A%2C+a+Peptide+Metabolite+from+Trichoderma+polysporum+%28Link+ex+Pers.%29+Rifai%2C+with+a+remarkable+immunosuppressive+activity%5D&doi=10.1002%2Fhlca.19760590412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A, a peptide metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with immunosuppressive activity</span></div><div class="casAuthors">Ruegger, Arthur; Kuhn, Max; Lichti, Heinz; Loosli, Hans R.; Huguenin, Rene; Quiquerez, Charles; Von Wartburg, Albert</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1075-92</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    </div><div class="casAbstract">Cyclosporin A (I), the main component of T. polysporum Rifai known to possess immunosuppressive and antiinflammatory activity, was isolated from this organism and the amino acid structure of the cyclic peptide I was detd.  Some properties of the minor component cyclosporin C were also detd.  I contained 11 amino acids, as detd. by hydrolysis, including a new C9 amino acid.  The amino acid sequence of the iso-cyclosporin A, a basic rearrangement product formed from I by N,O-acyl migration, was detd., and some evidence for the configuration about the double bond of the new C9 amino acid [(2S,3R,4R)-2-methylamino-3-hydroxy-4-methyl-6-octenoic acid] is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ZhJk4jT_abVg90H21EOLACvtfcHk0lgtg5dQp0bC-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28Xkt12ksro%253D&md5=a83026035f18d748aa3ca23b99aab69d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19760590412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19760590412%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25BCegger%26aufirst%3DA.%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DLichti%26aufirst%3DH.%26aulast%3DLoosli%26aufirst%3DH.%2BR.%26aulast%3DHuguenin%26aufirst%3DR.%26aulast%3DQuiquerez%26aufirst%3DC.%26aulast%3Dvon%2BWartburg%26aufirst%3DA.%26atitle%3D%255BCyclosporin%2520A%252C%2520a%2520Peptide%2520Metabolite%2520from%2520Trichoderma%2520polysporum%2520%2528Link%2520ex%2520Pers.%2529%2520Rifai%252C%2520with%2520a%2520remarkable%2520immunosuppressive%2520activity%255D%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1976%26volume%3D59%26spage%3D1075%26epage%3D1092%26doi%3D10.1002%2Fhlca.19760590412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagenbuch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, P. J.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1326</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1172/JCI117091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1172%2FJCI117091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=8132774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFKqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1994&pages=1326-1331&author=B.+Hagenbuchauthor=P.+J.+Meier&title=Molecular+cloning%2C+chromosomal+localization%2C+and+functional+characterization+of+a+human+liver+Na%2B%2Fbile+acid+cotransporter&doi=10.1172%2FJCI117091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter</span></div><div class="casAuthors">Hagenbuch, Bruno; Meier, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1326-31</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">A cDNA probe from a cloned rat liver Na+/taurocholate-cotransporting polypeptide (Ntcp) was used to screen a human liver cDNA library.  A 1599-bp cDNA clone that encodes a human Na+/taurocholate cotransporting polypeptide (NTCP) was isolated.  The human NTCP consists of 349 amino acids (calcd. mol. mass of 38 kDa) and exhibits 77% amino acid homol. with the rat Ntcp.  In vitro translation expts. indicate that the protein is glycosylated and has a mol. wt. similar to the rat Ntcp.  Injection of in vitro transcribed cRNA into Xenopus laevis oocytes resulted in the expression of Na+-dependent taurocholate uptake.  Satn. kinetics indicated that the human NTCP has a higher affinity for taurocholate (apparent Km = 6 μM) than the previously cloned rat protein (apparent Km = 25 μM).  NTCP-mediated taurocholate uptake into oocytes was inhibited by all major bile acid derivs. (100 μM), bumetanide (500 μM), and bromosulfophthalein (100 μM).  Southern blot anal. of genomic DNA from a panel of human/hamster somatic cell hybrids mapped the human NTCP gene to chromosome 14.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqmQsr-mlVh7Vg90H21EOLACvtfcHk0lgtg5dQp0bC-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFKqtLk%253D&md5=1e49aa2044dce90f56b3671d4cca53c4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1172%2FJCI117091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI117091%26sid%3Dliteratum%253Aachs%26aulast%3DHagenbuch%26aufirst%3DB.%26aulast%3DMeier%26aufirst%3DP.%2BJ.%26atitle%3DMolecular%2520cloning%252C%2520chromosomal%2520localization%252C%2520and%2520functional%2520characterization%2520of%2520a%2520human%2520liver%2520Na%252B%252Fbile%2520acid%2520cotransporter%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1994%26volume%3D93%26spage%3D1326%26epage%3D1331%26doi%3D10.1172%2FJCI117091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leake, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvetkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roden, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walubo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G. R.</span></span> <span> </span><span class="NLM_article-title">Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">1204</span>– <span class="NLM_lpage">1209</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10565843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaK1MXnslyns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1999&pages=1204-1209&author=R.+B.+Kimauthor=B.+Leakeauthor=M.+Cvetkovicauthor=M.+M.+Rodenauthor=J.+Nadeauauthor=A.+Waluboauthor=G.+R.+Wilkinson&title=Modulation+by+drugs+of+human+hepatic+sodium-dependent+bile+acid+transporter+%28sodium+taurocholate+cotransporting+polypeptide%29+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity</span></div><div class="casAuthors">Kim, Richard B.; Leake, Brenda; Cvetkovic, Mirjana; Roden, Mark M.; Nadeau, Jessica; Walubo, Andrew; Wilkinson, Grant R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1204-1209</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Adequate bile flow, maintained in part by the efficient enterohepatic recirculation of bile acids, is crit. for normal liver function.  One important component of this process is the uptake of bile acids from the portal circulation into hepatocytes by the bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP).  Thus, the expression and functional activity of this transporter may affect the rate of bile acid removal from the portal circulation.  Accordingly, we assessed NTCP mRNA expression from human livers using a sensitive RNase protection assay.  In addn., the ability of various bile acids and drugs to inhibit NTCP activity was detd. using a recombinant vaccinia expression system.  A 40-fold interindividual variability was found in NTCP mRNA levels detd. in eight liver samples of disease-free donors.  Expressed NTCP exhibited high-affinity, sodium-dependent uptake of taurocholate, and as expected, this was markedly inhibited by bile acids and org. anions.  A no. of drugs, including peptidomimetic renin inhibitors, propranolol, cyclosporin, and progesterone, were found to be potent inhibitors, whereas antiarrhythmic agents, including bupivacaine, lidocaine, and quinidine, were found to enhance NTCP activity.  Accordingly, these results indicate that large interindividual variability exists in NTCP mRNA level and that a no. of drugs currently in clin. use have the potential to interact with and alter NTCP activity, thereby affecting hepatic bile acid uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNsDZlZNuqb7Vg90H21EOLACvtfcHk0ljP6B60bsnSSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnslyns7g%253D&md5=7e3f384ab1fe72b2bd2162c47fd7be42</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DLeake%26aufirst%3DB.%26aulast%3DCvetkovic%26aufirst%3DM.%26aulast%3DRoden%26aufirst%3DM.%2BM.%26aulast%3DNadeau%26aufirst%3DJ.%26aulast%3DWalubo%26aufirst%3DA.%26aulast%3DWilkinson%26aufirst%3DG.%2BR.%26atitle%3DModulation%2520by%2520drugs%2520of%2520human%2520hepatic%2520sodium-dependent%2520bile%2520acid%2520transporter%2520%2528sodium%2520taurocholate%2520cotransporting%2520polypeptide%2529%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D291%26spage%3D1204%26epage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span> <span> </span><span class="NLM_article-title">The role of the HBV envelope proteins in the HDV replication cycle</span>. In  <i>Current Topics in Microbiology and Immunology</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2006</span>; Vol.  <span class="NLM_volume">307</span>, pp  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">131</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=113-131&author=C.+Sureau&title=Current+Topics+in+Microbiology+and+Immunology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSureau%26aufirst%3DC.%26atitle%3DThe%2520role%2520of%2520the%2520HBV%2520envelope%2520proteins%2520in%2520the%2520HDV%2520replication%2520cycle%26btitle%3DCurrent%2520Topics%2520in%2520Microbiology%2520and%2520Immunology%26pub%3DSpringer%26date%3D2006%26volume%3D307%26spage%3D113%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e1004840</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1004840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1371%2Fjournal.ppat.1004840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=25902143" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&author=W.+Heauthor=B.+Renauthor=F.+Maoauthor=Z.+Jingauthor=Y.+Liauthor=Y.+Liuauthor=B.+Pengauthor=H.+Yanauthor=Y.+Qiauthor=Y.+Sunauthor=J.+T.+Guoauthor=J.+Suiauthor=F.+Wangauthor=W.+Li&title=Hepatitis+D+Virus+Infection+of+Mice+Expressing+Human+Sodium+Taurocholate+Co-transporting+Polypeptide&doi=10.1371%2Fjournal.ppat.1004840"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004840%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DHepatitis%2520D%2520Virus%2520Infection%2520of%2520Mice%2520Expressing%2520Human%2520Sodium%2520Taurocholate%2520Co-transporting%2520Polypeptide%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26doi%3D10.1371%2Fjournal.ppat.1004840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">8866</span>– <span class="NLM_lpage">8874</span>, <span class="refDoi"> DOI: 10.1128/JVI.00901-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.00901-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=27466423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWkt7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=8866-8874&author=W.+Heauthor=Z.+Caoauthor=F.+Maoauthor=B.+Renauthor=Y.+Liauthor=D.+Liauthor=H.+Liauthor=B.+Pengauthor=H.+Yanauthor=Y.+Qiauthor=Y.+Sunauthor=F.+Wangauthor=J.+Suiauthor=W.+Li&title=Modification+of+Three+Amino+Acids+in+Sodium+Taurocholate+Cotransporting+Polypeptide+Renders+Mice+Susceptible+to+Infection+with+Hepatitis+D+Virus+In+Vivo&doi=10.1128%2FJVI.00901-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of three amino acids in sodium taurocholate cotransporting polypeptide renders mice susceptible to infection with hepatitis d virus in vivo</span></div><div class="casAuthors">He, Wenhui; Cao, Zhiliang; Mao, Fengfeng; Ren, Bijie; Li, Yunfei; Li, Dan; Li, Huiyu; Peng, Bo; Yan, Huan; Qi, Yonghe; Sun, Yinyan; Wang, Fengchao; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8866-8874</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Sodium taurocholate cotransporting polypeptide (NTCP) was identified as a functional receptor for hepatitis D virus (HDV) and its helper hepatitis B virus (HBV).  In cultured cell lines, HDV infection through mouse NTCP is restricted by residues 84 to 87 of the receptor.  This study shows that mice with these three amino acids altered their corresponding human residues (H84R, T86K, and S87N) in endogenous mouse NTCP support de novo HDV infection in vivo.  HDV infection was documented by the presence of replicative forms of HDV RNA and HDV proteins in liver cells at day 6 after viral inoculation.  Monoclonal antibody specifically binding to the motif centered on K86 in NTCP partially inhibited HDV infection.  These studies demonstrated specific interaction between the receptor and the viral envelopes in vivo and established a novel mouse model with minimal genetic manipulation for studying HDV infection.  The model will also be useful for evaluating entry inhibitors against HDV and its helper HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdRCyblqT1HrVg90H21EOLACvtfcHk0ljP6B60bsnSSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWkt7zE&md5=a465c633d4933e7be3979253bceb8d12</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FJVI.00901-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00901-16%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DW.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DModification%2520of%2520Three%2520Amino%2520Acids%2520in%2520Sodium%2520Taurocholate%2520Cotransporting%2520Polypeptide%2520Renders%2520Mice%2520Susceptible%2520to%2520Infection%2520with%2520Hepatitis%2520D%2520Virus%2520In%2520Vivo%26jtitle%3DJ.%2520Virol.%26date%3D2016%26volume%3D90%26spage%3D8866%26epage%3D8874%26doi%3D10.1128%2FJVI.00901-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Morais, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2004.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.cbi.2004.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15535988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2004&pages=179-187&author=S.+D.+Campbellauthor=S.+M.+de+Moraisauthor=J.+J.+Xu&title=Inhibition+of+human+organic+anion+transporting+polypeptide+OATP+1B1+as+a+mechanism+of+drug-induced+hyperbilirubinemia&doi=10.1016%2Fj.cbi.2004.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia</span></div><div class="casAuthors">Campbell, Scott D.; de Morais, Sonia M.; Xu, Jinghai J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-187</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">OATP1B1 (a.k.a. OATP-C, OATP2, LST-1, or SLC21A6) is a liver-specific org. anion uptake transporter and has been shown to be a higher affinity bilirubin uptake transporter than OATP1B3.  Using human embryonic kidney (HEK 293) cells stably transfected with OATP1B1, we have studied the effects of indinavir, saquinavir, cyclosporin A, and rifamycin SV on human OATP1B1 transport function.  These drugs are potent inhibitors of OATP1B1 transport activity in vitro.  We further provide evidence that the calcd. fraction of OATP1B1 inhibited at the clin. exposure level correlated very well with the obsd. hyperbilirubinemia outcome for these drugs in humans.  Our data support the hypothesis that inhibition of OATP1B1 is an important mechanism for drug-induced unconjugated hyperbilirubinemia.  Inhibition of OATPs may be an important mechanism in drug-drug and drug-endogenous substance interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE5V-CJDYQ9LVg90H21EOLACvtfcHk0ljiQ1W6d0vAxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKnsb4%253D&md5=de2b3edf235c967aba77a5e94d0679dc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2004.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2004.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DS.%2BD.%26aulast%3Dde%2BMorais%26aufirst%3DS.%2BM.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26atitle%3DInhibition%2520of%2520human%2520organic%2520anion%2520transporting%2520polypeptide%2520OATP%25201B1%2520as%2520a%2520mechanism%2520of%2520drug-induced%2520hyperbilirubinemia%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2004%26volume%3D150%26spage%3D179%26epage%3D187%26doi%3D10.1016%2Fj.cbi.2004.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.041921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1124%2Fjpet.102.041921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=12538813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2003&pages=610-616&author=Y.+Shitaraauthor=T.+Itohauthor=H.+Satoauthor=A.+P.+Liauthor=Y.+Sugiyama&title=Inhibition+of+transporter-mediated+hepatic+uptake+as+a+mechanism+for+drug-drug+interaction+between+cerivastatin+and+cyclosporin+A&doi=10.1124%2Fjpet.102.041921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A</span></div><div class="casAuthors">Shitara, Yoshihisa; Itoh, Tomoo; Sato, Hitoshi; Li, Albert P.; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">610-616</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The mechanism involved in the clin. relevant drug-drug interaction (DDI) between cerivastatin (CER) and cyclosporin A (CsA) has not yet been clarified.  In the present study, we examd. the possible roles of transporter-mediated hepatic uptake in this DDI.  The uptake of [14C]CER into human hepatocytes prepd. from three different donors was examd.  Kinetic analyses revealed Km values for the uptake of [14C]CER within the range of 3 to 18 μM, suggesting that more than 70% of the total uptake at therapeutic CER concns. was accounted for by a saturable process, i.e., transporter-mediated uptake.  This uptake was inhibited by CsA with Ki values of 0.3 to 0.7 μM.  The uptake of [14C]CER was also examd. in human org. anion transporting polypeptide-2 (OATP2)-expressing Madin-Darby canine kidney cells (MDCKII).  Saturable OATP2-mediated uptake of [14C]CER was obsd. and was also inhibited by CsA, with a Ki value of 0.2 μM.  These results suggest that the DDI between CER and CsA involves the inhibition of transporter-mediated uptake of CER and, at least in part, its OATP2-mediated uptake.  The effect of CsA on the in vitro metab. of [14C]CER was also examd.  The metab. of [14C]CER was inhibited by CsA with an IC50 value of more than 30 μM.  From these results, we conclude that the DDI between CER and CsA is mainly due to the inhibition of transporter (at least partly OATP2)-mediated uptake in the liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi5U1KGJaCCbVg90H21EOLACvtfcHk0ljiQ1W6d0vAxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVCguw%253D%253D&md5=36a4960df1b5b369b52fe9d00226c317</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.041921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.041921%26sid%3Dliteratum%253Aachs%26aulast%3DShitara%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DA.%2BP.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520transporter-mediated%2520hepatic%2520uptake%2520as%2520a%2520mechanism%2520for%2520drug-drug%2520interaction%2520between%2520cerivastatin%2520and%2520cyclosporin%2520A%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D304%26spage%3D610%26epage%3D616%26doi%3D10.1124%2Fjpet.102.041921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarcho, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windass, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneck, D. W.</span></span> <span> </span><span class="NLM_article-title">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2004.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.clpt.2004.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15289793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Ogu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=167-177&author=S.+G.+Simonsonauthor=A.+Razaauthor=P.+D.+Martinauthor=P.+D.+Mitchellauthor=J.+A.+Jarchoauthor=C.+D.+Brownauthor=A.+S.+Windassauthor=D.+W.+Schneck&title=Rosuvastatin+pharmacokinetics+in+heart+transplant+recipients+administered+an+antirejection+regimen+including+cyclosporine&doi=10.1016%2Fj.clpt.2004.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine</span></div><div class="casAuthors">Simonson, Steven G.; Raza, Ali; Martin, Paul D.; Mitchell, Patrick D.; Jarcho, John A.; Brown, Colin D. A.; Windass, Amy S.; Schneck, Dennis W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-177</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Cyclosporine (INN, ciclosporin) increases the systemic exposure of all statins.  Therefore rosuvastatin pharmacokinetic parameters were assessed in an open-label trial involving stable heart transplant recipients (≥6 mo after transplant) on an antirejection regimen including cyclosporine.  Rosuvastatin has been shown to be a substrate for the human liver transporter org. anion transporting polypeptide C (OATP-C).  Inhibition of this transporter could increase plasma concns. of rosuvastatin.  Therefore the effect of cyclosporine on rosuvastatin uptake by cells expressing OATP-C was also examd.  Methods: Ten subjects were assessed while taking 10 mg rosuvastatin for 10 days; 5 of these were then assessed while taking 20 mg rosuvastatin for 10 days.  Rosuvastatin steady-state area under the plasma concn.-time curve from time 0 to 24 h [AUC(0-24)] and max. obsd. plasma concn. (Cmax) were compared with values in controls (historical data from 21 healthy volunteers taking 10 mg rosuvastatin).  Rosuvastatin uptake by OATP-C-transfected Xenopus oocytes was also studied by use of radiolabeled rosuvastatin with and without cyclosporine.  Results: In transplant recipients taking 10 mg rosuvastatin, geometric mean values and percent coeff. of variation for steady-state AUC(0-24) and Cmax were 284 ng · h/mL (31.3%) and 48.7 ng/mL (47.2%), resp.  In controls, these values were 40.1 ng · h/mL (39.4%) and 4.58 ng/mL (46.9%), resp.  Compared with control values, AUC(0-24) and Cmax were increased 7.1-fold and 10.6-fold, resp., in transplant recipients.  In transplant recipients taking 20 mg rosuvastatin, these parameters increased less than dose-proportionally.  Rosuvastatin had no effect on cyclosporine blood concns.  The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (assocn. const., 8.5 ± 1.1 μmol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition const., 2.2 ± 0.4 μmol/L when the rosuvastatin concn. was 5 μmol/L).  Conclusions: Rosuvastatin exposure was significantly increased in transplant recipients on an antirejection regimen including cyclosporine.  Cyclosporine inhibition of OATP-C-mediated rosuvastatin hepatic uptake may be the mechanism of the drug-drug interaction.  Coadministration of rosuvastatin with cyclosporine needs to be undertaken with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqigXZ0UMAaibVg90H21EOLACvtfcHk0ljiQ1W6d0vAxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Ogu78%253D&md5=9da8626f6ed97a135c4e13ce9d02e9ad</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DSimonson%26aufirst%3DS.%2BG.%26aulast%3DRaza%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DP.%2BD.%26aulast%3DMitchell%26aufirst%3DP.%2BD.%26aulast%3DJarcho%26aufirst%3DJ.%2BA.%26aulast%3DBrown%26aufirst%3DC.%2BD.%26aulast%3DWindass%26aufirst%3DA.%2BS.%26aulast%3DSchneck%26aufirst%3DD.%2BW.%26atitle%3DRosuvastatin%2520pharmacokinetics%2520in%2520heart%2520transplant%2520recipients%2520administered%2520an%2520antirejection%2520regimen%2520including%2520cyclosporine%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D76%26spage%3D167%26epage%3D177%26doi%3D10.1016%2Fj.clpt.2004.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulcher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span> <span> </span><span class="NLM_article-title">Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory</span>. <i>Immunol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1046/j.1440-1711.1999.00870.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1046%2Fj.1440-1711.1999.00870.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10571678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsVCgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1999&pages=559-564&author=D.+Fulcherauthor=S.+Wong&title=Carboxyfluorescein+succinimidyl+ester-based+proliferative+assays+for+assessment+of+T+cell+function+in+the+diagnostic+laboratory&doi=10.1046%2Fj.1440-1711.1999.00870.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory</span></div><div class="casAuthors">Fulcher, D. A.; Wong, S. W. J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology and Cell Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">559-564</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Immune deficiency diseases are often accompanied by abnormalities in one or both arms of the specific immune system.  Impairment can often be detected as a decrease in the no. of T or B lymphocytes or their products in the circulation, but questions are often asked as to the functional capabilities of T lymphocytes in patients with recurrent infections.  Function of T cells has traditionally been measured by their uptake of [3H]-thymidine following stimulation with antigen or mitogen in vitro.  However, the ability of carboxyfluorescein succinimidyl ester (CFSE) to label lymphocytes intracellularly and track their mitotic activity by progressive two-fold redn. in fluorescence intensity prompted an alternative methodol. based on flow cytometry, an approach which has the advantage of allowing specific gating on particular T cell subsets and simultaneous assessment of activation markers.  This method was therefore evaluated for T cell responses to mitogen and antigen.  Phytohemagglutinin-induced blast transformation of CFSE-labeled T cells was reflected by an increase in forward and orthogonal light scatter and a progressive two-fold decrease in CFSE fluorescence intensity.  These changes allowed the derivation of various measures of mitotic activity, which correlated well with [3H]-thymidine uptake.  Patients with T cell functional deficiencies showed impairment in their responses by both assays, whereas the CFSE-based assay demonstrated that impaired blastogenesis was not simply due to depressed T cell nos.  Concomitant measurement of the activation markers CD69 and CD25 showed that CD69 was rapidly expressed on non-mitotic cells and that this expression was progressively dild. with subsequent rounds of cell division.  In contrast, CD25 expression was unaffected by cell cycle, but was expressed in proportion to the PHA dose.  Antigen-specific responsiveness to Candida was also assessed using a CFSE-based assay.  Initial gating on the relatively minor population of T cells that underwent blast transformation demonstrated progressive twofold dilns. of CFSE intensity in responsive cells.  These normal Candida responses, found in patients who had recovered from Candida infection, contrasted with those who had not been infected with Candida or who had chronic recurrent infection, in whom neither blast transformation nor significant mitosis could be detected.  Again, there was good correlation with [3H]-thymidine uptake.  The CFSE-based assays are equiv. to traditional measures of mitogen- and antigen-specific T cell responsiveness in the diagnostic lab. and have significant advantages in terms of decreased labour intensiveness, avoidance of radioactivity, the ability to gate on a specific population of lymphocytes and the concomitant measurement of activation markers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppDhcdtAHXHLVg90H21EOLACvtfcHk0lhVPanLoKjY3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsVCgtw%253D%253D&md5=731619a7c5bf8b5a5f6b9e153fa9b9eb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1046%2Fj.1440-1711.1999.00870.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1440-1711.1999.00870.x%26sid%3Dliteratum%253Aachs%26aulast%3DFulcher%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DS.%26atitle%3DCarboxyfluorescein%2520succinimidyl%2520ester-based%2520proliferative%2520assays%2520for%2520assessment%2520of%2520T%2520cell%2520function%2520in%2520the%2520diagnostic%2520laboratory%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D1999%26volume%3D77%26spage%3D559%26epage%3D564%26doi%3D10.1046%2Fj.1440-1711.1999.00870.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clipstone, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentino, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span> <span> </span><span class="NLM_article-title">Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">26431</span>– <span class="NLM_lpage">26437</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2FS0021-9258%2818%2947212-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=7523407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1Wgurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=26431-26437&author=N.+A.+Clipstoneauthor=D.+F.+Fiorentinoauthor=G.+R.+Crabtree&title=Molecular+analysis+of+the+interaction+of+calcineurin+with+drug-immunophilin+complexes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes</span></div><div class="casAuthors">Clipstone, Neil A.; Fiorentino, David F.; Crabtree, Gerald R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">26431-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The calcium/calmodulin-regulated phosphatase calcineurin (CN) is the site of action of the immunosuppressive drugs cyclosporin A (CsA) and FK506.  CN has recently been established as a key signaling enzyme in the T cell signal transduction cascade and an important regulator of transcription factors such as NF-AT and OAP/Oct-1, which are involved in the expression of a no. of important T cell early genes.  CsA and FK506 act by forming complexes with their resp. intracellular receptors cyclophilin and FKBP (immunophilins), which can then bind to CN, inhibiting its enzymic activity and thereby preventing early gene expression.  CN is comprised of two subunits: a 59-kDa catalytic subunit (CNA), which contains a calmodulin binding domain and autoinhibitory region, and a 19-kDa intrinsic calcium binding regulatory subunit (CNB).  In this study, the authors have utilized a series of deletion mutants of the CNA subunit to investigate the subunit and mol. requirements that govern the interaction of CN with drug-immunophilin complexes.  The calmodulin binding and autoinhibitory domains of the CNA subunit were dispensable for the binding to CN to drug-immunophilin complexes.  In contrast, the authors found that the regulatory CNB subunit appears to play an obligatory role in this interaction and have defined an amino acid sequence of the CNA subunit which forms the binding site for CNB.  Although necessary, the CNB subunit per se is not sufficient to mediate an interaction with drug-immunophilin complexes; amino acid residues of the the CNA subunit, specifically a region located within the putative catalytic domain, are also required for the interaction of CN with both FKBP·FK506 and cyclophilin A·CsA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0S9tu36BQBbVg90H21EOLACvtfcHk0lhVPanLoKjY3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1Wgurc%253D&md5=371ff859936ccfc9176428443b9ab7c5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2947212-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252947212-2%26sid%3Dliteratum%253Aachs%26aulast%3DClipstone%26aufirst%3DN.%2BA.%26aulast%3DFiorentino%26aufirst%3DD.%2BF.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26atitle%3DMolecular%2520analysis%2520of%2520the%2520interaction%2520of%2520calcineurin%2520with%2520drug-immunophilin%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D26431%26epage%3D26437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yong-Jin Wu, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9786-9874. <a href="https://doi.org/10.1021/acs.jmedchem.1c00790" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00790%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGeminal%252BDiheteroatomic%252BMotifs%25253A%252BSome%252BApplications%252Bof%252BAcetals%25252C%252BKetals%25252C%252Band%252BTheir%252BSulfur%252Band%252BNitrogen%252BHomologues%252Bin%252BMedicinal%252BChemistry%252Band%252BDrug%252BDesign%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30042021%26date%3D02072021%26volume%3D64%26issue%3D14%26spage%3D9786%26epage%3D9874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Kirstgen</span>, <span class="hlFld-ContribAuthor ">Simon Franz  Müller</span>, <span class="hlFld-ContribAuthor ">Kira Alessandra Alicia Theresa  Lowjaga</span>, <span class="hlFld-ContribAuthor ">Nora  Goldmann</span>, <span class="hlFld-ContribAuthor ">Felix  Lehmann</span>, <span class="hlFld-ContribAuthor ">Sami  Alakurtti</span>, <span class="hlFld-ContribAuthor ">Jari  Yli-Kauhaluoma</span>, <span class="hlFld-ContribAuthor ">Karl-Heinz  Baringhaus</span>, <span class="hlFld-ContribAuthor ">Reimar  Krieg</span>, <span class="hlFld-ContribAuthor ">Dieter  Glebe</span>, <span class="hlFld-ContribAuthor ">Joachim  Geyer</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (8)
                                     , 1489. <a href="https://doi.org/10.3390/v13081489" title="DOI URL">https://doi.org/10.3390/v13081489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13081489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13081489%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DIdentification%252Bof%252BNovel%252BHBV%25252FHDV%252BEntry%252BInhibitors%252Bby%252BPharmacophore-%252Band%252BQSAR-Guided%252BVirtual%252BScreening%26aulast%3DKirstgen%26aufirst%3DMichael%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D8%26spage%3D1489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Kirstgen</span>, <span class="hlFld-ContribAuthor ">Kira Alessandra Alicia Theresa  Lowjaga</span>, <span class="hlFld-ContribAuthor ">Simon Franz  Müller</span>, <span class="hlFld-ContribAuthor ">Nora  Goldmann</span>, <span class="hlFld-ContribAuthor ">Felix  Lehmann</span>, <span class="hlFld-ContribAuthor ">Dieter  Glebe</span>, <span class="hlFld-ContribAuthor ">Karl-Heinz  Baringhaus</span>, <span class="hlFld-ContribAuthor ">Joachim  Geyer</span>. </span><span class="cited-content_cbyCitation_article-title">Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 666. <a href="https://doi.org/10.3390/v13040666" title="DOI URL">https://doi.org/10.3390/v13040666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13040666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13040666%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DHepatitis%252BD%252BVirus%252BEntry%252BInhibitors%252BBased%252Bon%252BRepurposing%252BIntestinal%252BBile%252BAcid%252BReabsorption%252BInhibitors%26aulast%3DKirstgen%26aufirst%3DMichael%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>3</b>, <b>4</b>, <b>7</b>, and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) O<sub>3</sub>, Me<sub>2</sub>S, dichloromethane (DCM), −78 °C, 30 min; (b) MeOH, <i>p</i>-TsOH, room temperature (RT), 16 h; (c) NaBH<sub>4</sub>, MeOH, RT, 16 h; (d) MsCl, triethylamine (TEA), DCM, 0 °C then RT, overnight; (e) Jones reagent, acetone, 0 °C then RT, overnight; (f) <i>t</i>-BuOK, methyltriphenylphosphonium bromide, tetrahydrofuran (THF), −78 °C then 0 °C, 3 h; (g) 10% Pd/C, MeOH, H<sub>2</sub>, 1 atm, RT, 16 h.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>10</b>–<b>52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) acetic anhydride (Ac<sub>2</sub>O), pyridine (Py), RT, overnight; (b) appropriate mercapto heterocyclic and aromatic, trimethylsilyl trifluoromethanesulfonate (TMSOTf), <i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide (BSA), acetonitrile (ACN), 50 °C, 90 min; (c) methyl 2-hydroxyacetate or methyl 3-hydroxypropanoate, silver trifluoromethanesulfonate, activated 3 Å molecular sieves, DCM, RT, 2 h; NIS, activated 3 Å molecular sieves, ACN, RT, 2 h; (d) 1 N NaOH, MeOH, RT, 4.5 h; (e) 3-(benzyloxy)phenol or 3,5-dimethoxyphenol, FeCl<sub>3</sub>, 3 Å molecular sieves, DCM, RT, 16 h.</p></p></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Strategy for developing NTCP inhibitor from CsA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Antiviral activity of <b>27A</b>. (A) <b>27A</b> inhibits genotype B and genotype C HBV virus infection of HepG2-NTCP cells. HBeAg and HBsAg titers that secreted in the medium were determined at dpi 5 by commercial ELISA kits. The concentration of the compounds used in the assay was 2 μM for <b>27A</b> and 200 nM for Myr47. (B) Southern blot assay on HBV DNA extracted from HBV-infected HepG2-NTCP cells. HBV DNA was extracted on dpi 5 by Hirt methods. Southern blotting was conducted with DIG-labeled probe that targeting full-length HBV genome (DIG-high prime DNA-labeling and detection starter kit II, Roche, cat. No. 11585614910). (C) Northern blot assay on RNAs extracted from HBV-infected HepG2-NTCP cells. <b>27A</b> was added to the cells with the inoculum of the virus (lanes 3 and 4) or at dpi 3–5 (lanes 5 and 6). The blotting was procedure was similar to that of Southern blot except for the additional DIG-labeled glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probe. (D) <b>27A</b> inhibits HDV infection of HepG2-NTCP cells. HDV delta antigen was stained by a homemade FITC-labeled antidelta antigen antibody at dpi 5. The pictures were captured by an Opera High Content Screening System (PerkinElmer). Blue: 4′,6-diamidino-2-phenylindole (DAPI) stain, green: HDV delta antigen. (E) HDV infection ratio calculation of (D) was conducted by Columbus Image Analysis System (PerkinElmer).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>27A</b> inhibits HDV infection <i>in vivo</i>. (A) Experimental scheme of <i>in vivo</i> HDV infection of mice models. (B) Intraperitoneal injection (I.P.) of <b>27A</b> inhibits HDV infection in mice. hNTCP-Tg-C57B/L mice were challenged with HDV by intraperitoneal injection of 5 × 10<sup>9</sup> Geq of HDV on day 9 after birth and sacrificed on day 15 after birth. <b>27A</b> was administrated once (Group A, <i>n</i> = 4), twice (Group B, <i>n</i> = 4), or vehicle (Group C, <i>n</i> = 5) to mice through I.P. before HDV inoculation. HDV RNA levels were assessed by quantitative polymerase chain reaction (qPCR) of the RNA extracted from the liver of challenged mice; the levels of NTCP mRNA were also determined. The RNA copy numbers from 20 ng of liver RNA are presented. The bars indicate the median of each group. (C) Oral intake of <b>27A</b> inhibits HDV infection in the mice. <b>27A</b> (<i>n</i> = 4) or vehicle (<i>n</i> = 4) were administrated to adult NTCP-edited FVB mice for 8 days through gavage. The mice were challenged with HDV on the 2nd day by intraperitoneal injection of 5 × 10<sup>9</sup> Geq of HDV with 50 mg/kg dexamethasone. HDV RNA level and edited NTCP mRNA level were determined in the same way as in (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mechanism studies of <b>27A</b>. (A) IC<sub>50</sub> determination of <b>27A</b> on inhibiting NTCP uptake of <sup>3</sup>H-taurocholic acid (<sup>3</sup>H-TCA). (B) NTCP (green) and cell nucleus (blue) staining using anti-NTCP antibody and DAPI, respectively. HepG2-NTCP cells were stained after 2 h treatment of DMSO, <b>27A</b>, or taurolithocholic acid (TLCA). The compounds were used at 2 μM. (C) Myr59F (green) staining on HepG2-NTCP cells in the presence of DMSO, <b>27A</b> (1 μM), or Myr47 (200 nM). The fluorescence intensity analysis is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf" class="ext-link">Supplement Figure 3</a>. (D) NTCP uptake inhibition assay. <b>27A</b> (2 μM) inhibits NTCP from multiple species (hNTCP: human-NTCP; mNTCP: mouse-NTCP; mkNTCP: monkey-NTCP; tsNTCP: treeshrew-NTCP; hASBT: human-ASBT) uptake of <sup>3</sup>H-TCA on transfected HepG2 cells, compared with tauroursodeoxycholic acid (TUDCA, 20 μM) and Myr47 (200 nM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/medium/jm0c01484_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Biological evaluation of <b>27A</b>. (A) OATP1B1 uptake inhibition assay. <b>27A</b> inhibits OATP1B1 uptake of <sup>3</sup>H-estrone sulfate on transfected HepG2 cells, compared with CsA. (B, C) Immunosuppressive effect of <b>27A</b>: (B) FACS analysis of mouse primary spleen T cells stained by CSFE. The cells were stimulated by anti-CD3 antibody in the presence of indicated compounds for 48 h before analysis. Pos. control: cells stimulated by antibody and no other treatment. (C) NF-AT luciferase assay in Jurkat T cells stimulated by PMA (10 ng/mL) and ionomycin (500 nM) in the presence of indicated compounds for 48 h before analysis. The concentration of the compounds used in this assay is 2 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-1/acs.jmedchem.0c01484/20210107/images/large/jm0c01484_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01484&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64356" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64356" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Polaris
Observatory, C.</span> <span> </span><span class="NLM_article-title">Global prevalence,
treatment, and prevention of hepatitis B virus infection in 2016:
a modelling study</span>. <i>Lancet Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1016/S2468-1253(18)30056-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2FS2468-1253%2818%2930056-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=29599078" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=383-403&author=Polaris%0AObservatory%2C+C.&title=Global+prevalence%2C%0Atreatment%2C+and+prevention+of+hepatitis+B+virus+infection+in+2016%3A%0Aa+modelling+study&doi=10.1016%2FS2468-1253%2818%2930056-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS2468-1253%2818%2930056-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2468-1253%252818%252930056-6%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%2520prevalence%252C%250Atreatment%252C%2520and%2520prevention%2520of%2520hepatitis%2520B%2520virus%2520infection%2520in%25202016%253A%250Aa%2520modelling%2520study%26jtitle%3DLancet%2520Gastroenterol.%2520Hepatol.%26date%3D2018%26volume%3D3%26spage%3D383%26epage%3D403%26doi%3D10.1016%2FS2468-1253%2818%2930056-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanford, R. E.</span></span> <span> </span><span class="NLM_article-title">Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1128/JVI.67.1.366-372.1993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.67.1.366-372.1993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=8416375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaK3sXlsleitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=366-372&author=C.+Sureauauthor=B.+Guerraauthor=R.+E.+Lanford&title=Role+of+the+large+hepatitis+B+virus+envelope+protein+in+infectivity+of+the+hepatitis+delta+virion&doi=10.1128%2FJVI.67.1.366-372.1993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion</span></div><div class="casAuthors">Sureau, Camille; Guerra, Bernadette; Lanford, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">366-72</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">The hepatitis delta virus (HDV) is coated with large (L), middle (M), and small (S) envelope proteins encoded by coinfecting hepatitis B virus (HBV).  To study the role of the HBV envelope proteins in the assembly and infectivity of HDV, we produced three types of recombinant particles in Huh7 cells by transfection with HBV DNA and HDV cDNA: (i) particles with an envelope contg. the S HBV envelope protein only, (ii) particles with an envelope contg. S and M proteins, and (iii) particles with an envelope contg. S, M, and L proteins.  Although the resulting S-, SM-, and SML-HDV particles contained both hepatitis delta antigen and HDV RNA, only particles coated with all three envelope proteins (SML) showed evidence of infectivity in an in vitro culture system susceptible to HDV infection.  We concluded that the L HBV envelope protein, and more specifically the pre- S1 domain, is important for infectivity of HDV particles and that the M protein, which has been reported to bear a site for binding to polymd. albumin in the pre-S2 domain, is not sufficient for infectivity.  Our data also show that the helper HBV is not required for initiation of HDV infection.  The mechanism by which the L protein may affect HDV infectivity is discussed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiHc4X4_5QV7Vg90H21EOLACvtfcHk0lhS0huUomHK7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsleitA%253D%253D&md5=3e436e69840f20e918c08cfbc7c8418f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1128%2FJVI.67.1.366-372.1993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.67.1.366-372.1993%26sid%3Dliteratum%253Aachs%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DLanford%26aufirst%3DR.%2BE.%26atitle%3DRole%2520of%2520the%2520large%2520hepatitis%2520B%2520virus%2520envelope%2520protein%2520in%2520infectivity%2520of%2520the%2520hepatitis%2520delta%2520virion%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D366%26epage%3D372%26doi%3D10.1128%2FJVI.67.1.366-372.1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanford, R. E.</span></span> <span> </span><span class="NLM_article-title">Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5233</span>– <span class="NLM_lpage">5243</span>, <span class="refDoi"> DOI: 10.1128/JVI.78.10.5233-5243.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.78.10.5233-5243.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15113905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFeqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=5233-5243&author=A.+Barreraauthor=B.+Guerraauthor=H.+Leeauthor=R.+E.+Lanford&title=Analysis+of+host+range+phenotypes+of+primate+hepadnaviruses+by+in+vitro+infections+of+hepatitis+D+virus+pseudotypes&doi=10.1128%2FJVI.78.10.5233-5243.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes</span></div><div class="casAuthors">Barrera, Azeneth; Guerra, Bernadette; Lee, Helen; Lanford, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5233-5243</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) and woolly monkey hepatitis B virus (WMHBV) have natural host ranges that are limited to closely related species.  The barrier for infection of primates seems to be at the adsorption and/or entry steps of the viral replication cycle, since a human hepatoma cell line is permissive for HBV and WMHBV replication following transfection of cloned DNA.  We hypothesized that the HBV and WMHBV envelope proteins contain the principal viral determinants of host range.  As previously shown by using the hepatitis D virus (HDV) system, recombinant HBV-HDV particles were infectious in chimpanzee as well as human hepatocytes.  We extended the HDV system to include HDV particles pseudotyped with the WMHBV envelope.  In agreement with the natural host ranges of HBV and WMHBV, in vitro infections demonstrated that HBV-HDV and WM-HDV particles preferentially infected human and spider monkey cells, resp.  Previous studies have implicated the pre-S1 region of the large (L) envelope protein in receptor binding and host range; therefore, recombinant HDV particles were pseudotyped with the hepadnaviral envelopes contg. chimeric L proteins with the 1st 40 amino acids from the pre-S1 domain exchanged between HBV and WMHBV.  Surprisingly, addn. of the human amino terminus to the WMHBV L protein increased infectivity on spider monkey hepatocytes but did not increase infectivity for human hepatocytes.  Based upon these data, we discuss the possibility that the L protein may be comprised of 2 domains that affect infectivity and that sequences downstream of residue 40 may influence host range and receptor binding or entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN6vnsWRzMALVg90H21EOLACvtfcHk0lhS0huUomHK7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFeqsLY%253D&md5=ace31fcc43643b1889448255c972a2c9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.10.5233-5243.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.10.5233-5243.2004%26sid%3Dliteratum%253Aachs%26aulast%3DBarrera%26aufirst%3DA.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DLanford%26aufirst%3DR.%2BE.%26atitle%3DAnalysis%2520of%2520host%2520range%2520phenotypes%2520of%2520primate%2520hepadnaviruses%2520by%2520in%2520vitro%2520infections%2520of%2520hepatitis%2520D%2520virus%2520pseudotypes%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D5233%26epage%3D5243%26doi%3D10.1128%2FJVI.78.10.5233-5243.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedemeyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, P. M.</span></span> <span> </span><span class="NLM_article-title">Hepatitis delta virus</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(10)61931-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2FS0140-6736%2810%2961931-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=21511329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A280%3ADC%252BC3MnkvF2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=73-85&author=S.+A.+Hughesauthor=H.+Wedemeyerauthor=P.+M.+Harrison&title=Hepatitis+delta+virus&doi=10.1016%2FS0140-6736%2810%2961931-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis delta virus</span></div><div class="casAuthors">Hughes Sarah A; Wedemeyer Heiner; Harrison Phillip M</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9785</span>),
    <span class="NLM_cas:pages">73-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatitis delta virus (HDV) is a small, defective RNA virus that can infect only individuals who have hepatitis B virus (HBV); worldwide more than 15 million people are co-infected.  There are eight reported genotypes of HDV with unexplained variations in their geographical distribution and pathogenicity.  The hepatitis D virion is composed of a coat of HBV envelope proteins surrounding the nucleocapsid, which consists of a single-stranded, circular RNA genome complexed with delta antigen, the viral protein.  HDV is clinically important because although it suppresses HBV replication, it causes severe liver disease with rapid progression to cirrhosis and hepatic decompensation.  The range of clinical presentation is wide, varying from mild disease to fulminant liver failure.  The prevalence of HDV is declining in some endemic areas but increasing in northern and central Europe because of immigration.  Treatment of HDV is with pegylated interferon alfa; however, response rates are poor.  Increased understanding of the molecular virology of HDV will identify novel therapeutic targets for this most severe form of chronic viral hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3jL0e3Tx5HEbxh97K6Vt6fW6udTcc2ebyNtHXZml6Q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnkvF2ksw%253D%253D&md5=0b085e954f1340d10f3965cf975af56e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2961931-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252961931-9%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DS.%2BA.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DHarrison%26aufirst%3DP.%2BM.%26atitle%3DHepatitis%2520delta%2520virus%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D73%26epage%3D85%26doi%3D10.1016%2FS0140-6736%2810%2961931-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span>. <i>Elife</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e00049</span> <span class="refDoi"> DOI: 10.7554/eLife.00049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.7554%2FeLife.00049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=23150796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&author=H.+Yanauthor=G.+Zhongauthor=G.+Xuauthor=W.+Heauthor=Z.+Jingauthor=Z.+Gaoauthor=Y.+Huangauthor=Y.+Qiauthor=B.+Pengauthor=H.+Wangauthor=L.+Fuauthor=M.+Songauthor=P.+Chenauthor=W.+Gaoauthor=B.+Renauthor=Y.+Sunauthor=T.+Caiauthor=X.+Fengauthor=J.+Suiauthor=W.+Li&title=Sodium+taurocholate+cotransporting+polypeptide+is+a+functional+receptor+for+human+hepatitis+B+and+D+virus&doi=10.7554%2FeLife.00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span></div><div class="casAuthors">Yan, Huan; Zhong, Guocai; Xu, Guangwei; He, Wenhui; Jing, Zhiyi; Gao, Zhenchao; Huang, Yi; Qi, Yonghe; Peng, Bo; Wang, Haimin; Fu, Liran; Song, Mei; Chen, Pan; Gao, Wenqing; Ren, Bijie; Sun, Yinyan; Cai, Tao; Feng, Xiaofeng; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e00049, 28 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Human hepatitis B virus (HBV) infection and HBV-related diseases remain a major public health problem.  Individuals coinfected with its satellite hepatitis D virus (HDV) have more severe disease.  Cellular entry of both viruses is mediated by HBV envelope proteins.  The pre-S1 domain of the large envelope protein is a key determinant for receptor(s) binding.  However, the identity of the receptor(s) is unknown.  Here, by using near zero distance photo-crosslinking and tandem affinity purifn., the authors revealed that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the liver.  Silencing NTCP inhibited HBV and HDV infection, while exogenous NTCP expression rendered nonsusceptible hepatocarcinoma cells susceptible to these viral infections.  Moreover, replacing amino acids 157-165 of nonfunctional monkey NTCP with the human counterpart conferred its ability in supporting both viral infections.  The authors' results demonstrate that NTCP is a functional receptor for HBV and HDV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0tqZhmqs37Vg90H21EOLACvtfcHk0ljkR_bRI4zkdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK&md5=7380905d92bd82b9cf3407b7c113bdfb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.7554%2FeLife.00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.00049%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DSodium%2520taurocholate%2520cotransporting%2520polypeptide%2520is%2520a%2520functional%2520receptor%2520for%2520human%2520hepatitis%2520B%2520and%2520D%2520virus%26jtitle%3DElife%26date%3D2012%26volume%3D1%26doi%3D10.7554%2FeLife.00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortune, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qadri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, E.</span></span> <span> </span><span class="NLM_article-title">Multihormonal regulation of hepatic sinusoidal Ntcp gene expression</span>. <i>Am. J. Physiol.: Gastrointest. Liver Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">G782</span>– <span class="NLM_lpage">G794</span>, <span class="refDoi"> DOI: 10.1152/ajpgi.00379.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1152%2Fajpgi.00379.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15361361" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2004&pages=G782-G794&author=F.+R.+Simonauthor=J.+Fortuneauthor=M.+Iwahashiauthor=I.+Qadriauthor=E.+Sutherland&title=Multihormonal+regulation+of+hepatic+sinusoidal+Ntcp+gene+expression&doi=10.1152%2Fajpgi.00379.2003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00379.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00379.2003%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DF.%2BR.%26aulast%3DFortune%26aufirst%3DJ.%26aulast%3DIwahashi%26aufirst%3DM.%26aulast%3DQadri%26aufirst%3DI.%26aulast%3DSutherland%26aufirst%3DE.%26atitle%3DMultihormonal%2520regulation%2520of%2520hepatic%2520sinusoidal%2520Ntcp%2520gene%2520expression%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Gastrointest.%2520Liver%2520Physiol.%26date%3D2004%26volume%3D287%26spage%3DG782%26epage%3DG794%26doi%3D10.1152%2Fajpgi.00379.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span> <span> </span><span class="NLM_article-title">The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation</span>.  <i>Handbook of Experimental Pharmacology</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2011</span>;  <span class="NLM_volume">201</span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">259</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=205-259&author=B.+Stieger&title=Handbook+of+Experimental+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStieger%26aufirst%3DB.%26atitle%3DThe%2520role%2520of%2520the%2520sodium-taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%2520and%2520of%2520the%2520bile%2520salt%2520export%2520pump%2520%2528BSEP%2529%2520in%2520physiology%2520and%2520pathophysiology%2520of%2520bile%2520formation%26btitle%3DHandbook%2520of%2520Experimental%2520Pharmacology%26pub%3DSpringer%26date%3D2011%26volume%3D201%26spage%3D205%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notvall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanford, R. E.</span></span> <span> </span><span class="NLM_article-title">Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">9786</span>– <span class="NLM_lpage">9798</span>, <span class="refDoi"> DOI: 10.1128/JVI.79.15.9786-9798.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.79.15.9786-9798.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=16014940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVels7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=9786-9798&author=A.+Barreraauthor=B.+Guerraauthor=L.+Notvallauthor=R.+E.+Lanford&title=Mapping+of+the+hepatitis+B+virus+pre-S1+domain+involved+in+receptor+recognition&doi=10.1128%2FJVI.79.15.9786-9798.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping of the Hepatitis B virus pre-S1 domain involved in receptor recognition</span></div><div class="casAuthors">Barrera, Azeneth; Guerra, Bernadette; Notvall, Lena; Lanford, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">9786-9798</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) and Woolly monkey hepatitis B virus (WMHBV) are primate hapadnaviruses that display restricted tissue and host tropisms.  Hepatitis D virus (HDV) particles pseudotyped with HBV and WMHBV envelopes (HBV-HDV and WM-HDV) preferentially infect human and spider monkey hepatocytes, resp., thereby confirming host range bias in vitro.  The anal. of chimeric HBV and WMHBV large (L) envelope proteins suggests that the pre-S1 domain may comprise two regions that affect infectivity: one within the amino-terminal 40 amino acids of pre-S1 and one downstream of this region.  In the present study, we further characterized the role of the amino terminus of pre-S1 in infectivity by examg. the ability of synthetic peptides to competitively block HDV infection of primary human and spider monkey hepatocytes.  A synthetic peptide representing the first 45 residues of the pre-S1 domain of the HBV L protein blocked infectivity of HBV-HDV and WM-HDV, with a requirement for myristylation of the amino terminal residue.  Competition studies with truncated peptides suggested that pre-S1 residues 5 to 20 represent the minimal domain for inhibition of HDV infection and, thus, presumably represent the residues involved in virus-host receptor interaction.  Recombinant pre-S1 proteins expressed in insect cells blocked infection with HBV-HDV and WM-HDV at a concn. of 1 nanomolar.  The ability of short pre-S1 peptides to efficiently inhibit HDV infection suggests that they represent suitable ligands for identification of the HBV receptor and that a pre-S1 mimetic may represent a rational therapy for the treatment of HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK-SwGGMbHVLVg90H21EOLACvtfcHk0ljkR_bRI4zkdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVels7c%253D&md5=dd9b37b314fb7c03a21fb27f0427cc09</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.15.9786-9798.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.15.9786-9798.2005%26sid%3Dliteratum%253Aachs%26aulast%3DBarrera%26aufirst%3DA.%26aulast%3DGuerra%26aufirst%3DB.%26aulast%3DNotvall%26aufirst%3DL.%26aulast%3DLanford%26aufirst%3DR.%2BE.%26atitle%3DMapping%2520of%2520the%2520hepatitis%2520B%2520virus%2520pre-S1%2520domain%2520involved%2520in%2520receptor%2520recognition%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D9786%26epage%3D9798%26doi%3D10.1128%2FJVI.79.15.9786-9798.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glebe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoop, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cag, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krass, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulavaite, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasnauskas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlich, W. H.</span></span> <span> </span><span class="NLM_article-title">Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2005.03.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1053%2Fj.gastro.2005.03.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=16012950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVGrsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2005&pages=234-245&author=D.+Glebeauthor=S.+Urbanauthor=E.+V.+Knoopauthor=N.+Cagauthor=P.+Krassauthor=S.+Grunauthor=A.+Bulavaiteauthor=K.+Sasnauskasauthor=W.+H.+Gerlich&title=Mapping+of+the+hepatitis+B+virus+attachment+site+by+use+of+infection-inhibiting+preS1+lipopeptides+and+tupaia+hepatocytes&doi=10.1053%2Fj.gastro.2005.03.090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes</span></div><div class="casAuthors">Glebe, Dieter; Urban, Stephan; Knoop, Eva V.; Cag, Nilguen; Krass, Peter; Grun, Stefanie; Bulavaite, Aiste; Sasnauskas, Kestutis; Gerlich, Wolfram H.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-245</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background & Aims: Studies on the early steps in the life cycle of hepatitis B virus have been hampered by the lack of readily available target cells.  In this study, we mapped a defined virus attachment site to primary hepatocytes that is essential for infection.  Methods: We used purified virus particles from human carrier plasma as an inoculum and primary cultures of tupaia hepatocytes as susceptible target cells and studied the inhibitory effect of amino-terminally acylated preS1-derived lipopeptides on infection interference.  Results: Infectivity of virus could be blocked efficiently in this system by amino-terminally acylated peptides contg. amino acids 2-18 from the preS1 domain.  The addn. of amino acids 28-48 enhanced the inhibitory capacity, whereas amino acids 49-78 did not contribute to inhibition.  Myristoylated preS1 peptides 2-48 bound strongly to tupaia hepatocytes but not to nonhepatic cells or rodent hepatocytes and thereby inhibited infection even at concns. of 1 nmol/L completely.  Particles consisting only of the small hepatitis B surface protein - the active component of current hepatitis B vaccines - did not bind at all to tupaia hepatocytes, but the addn. of the preS1 domain to the particles allowed binding.  Conclusions: The preS1 sequence 2-48 mediates attachment of the virus to its target cells, whereas the small surface protein seems to be involved in other steps.  These findings indicate that the current subunit hepatitis B vaccines may be improved by the addn. of distinct preS1 epitopes.  Moreover, preS1 lipopeptides are promising candidates for specific antiviral therapy against hepatitis B infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocg0MMTWvTnrVg90H21EOLACvtfcHk0lgQVECUQqBcHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVGrsbs%253D&md5=50e06abf7c21964d3ba336db2e48bfd3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2005.03.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2005.03.090%26sid%3Dliteratum%253Aachs%26aulast%3DGlebe%26aufirst%3DD.%26aulast%3DUrban%26aufirst%3DS.%26aulast%3DKnoop%26aufirst%3DE.%2BV.%26aulast%3DCag%26aufirst%3DN.%26aulast%3DKrass%26aufirst%3DP.%26aulast%3DGrun%26aufirst%3DS.%26aulast%3DBulavaite%26aufirst%3DA.%26aulast%3DSasnauskas%26aufirst%3DK.%26aulast%3DGerlich%26aufirst%3DW.%2BH.%26atitle%3DMapping%2520of%2520the%2520hepatitis%2520B%2520virus%2520attachment%2520site%2520by%2520use%2520of%2520infection-inhibiting%2520preS1%2520lipopeptides%2520and%2520tupaia%2520hepatocytes%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D129%26spage%3D234%26epage%3D245%26doi%3D10.1053%2Fj.gastro.2005.03.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lempp, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkongolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stindt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koniger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span> <span> </span><span class="NLM_article-title">Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1083</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2013.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1053%2Fj.gastro.2013.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24361467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslWitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=1070-1083&author=Y.+Niauthor=F.+A.+Lemppauthor=S.+Mehrleauthor=S.+Nkongoloauthor=C.+Kaufmanauthor=M.+Falthauthor=J.+Stindtauthor=C.+Konigerauthor=M.+Nassalauthor=R.+Kubitzauthor=H.+Sultmannauthor=S.+Urban&title=Hepatitis+B+and+D+viruses+exploit+sodium+taurocholate+co-transporting+polypeptide+for+species-specific+entry+into+hepatocytes&doi=10.1053%2Fj.gastro.2013.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes</span></div><div class="casAuthors">Ni, Yi; Lempp, Florian A.; Mehrle, Stefan; Nkongolo, Shirin; Kaufman, Christina; Falth, Maria; Stindt, Jan; Koniger, Christian; Nassal, Michael; Kubitz, Ralf; Sultmann, Holger; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1070-1083.e6</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Hepatitis B and D viruses (HBV and HDV) are human pathogens with restricted host ranges and high selectivity for hepatocytes; the HBV L-envelope protein interacts specifically with a receptor on these cells.  We aimed to identify this receptor and analyze whether it is the recently described sodium-taurocholate co-transporter polypeptide (NTCP), encoded by the SLC10A1 gene.  To identify receptor candidates, we compared gene expression patterns between differentiated HepaRG cells, which express the receptor, and naive cells, which do not.  Receptor candidates were evaluated by small hairpin RNA silencing in HepaRG cells; the ability of receptor expression to confer binding and infection were tested in transduced hepatoma cell lines.  We used interspecies domain swapping to identify motifs for receptor-mediated host discrimination of HBV and HDV binding and infection.  Bioinformatic analyses of comparative expression arrays confirmed that NTCP, which was previously identified through a biochem. approach is a bona fide receptor for HBV and HDV.  NTCPs from rat, mouse, and human bound Myrcludex B, a peptide ligand derived from the HBV L-protein.  Myrcludex B blocked NTCP transport of bile salts; small hairpin RNA-mediated knockdown of NTCP in HepaRG cells prevented their infection by HBV or HDV.  Expression of human but not mouse NTCP in HepG2 and HuH7 cells conferred a limited cell-type-related and virus-dependent susceptibility to infection; these limitations were overcome when cells were cultured with DMSO.  We identified 2 short-sequence motifs in human NTCP that were required for species-specific binding and infection by HBV and HDV.  Human NTCP is a specific receptor for HBV and HDV.  NTCP-expressing cell lines can be efficiently infected with these viruses, and might be used in basic research and high-throughput screening studies.  Mapping of motifs in NTCPs have increased our understanding of the species specificities of HBV and HDV, and could lead to small animal models for studies of viral infection and replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnxfIdRSMiSbVg90H21EOLACvtfcHk0lgQVECUQqBcHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslWitLs%253D&md5=9a6474af0ba645b685289066a35e972c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DY.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DMehrle%26aufirst%3DS.%26aulast%3DNkongolo%26aufirst%3DS.%26aulast%3DKaufman%26aufirst%3DC.%26aulast%3DFalth%26aufirst%3DM.%26aulast%3DStindt%26aufirst%3DJ.%26aulast%3DKoniger%26aufirst%3DC.%26aulast%3DNassal%26aufirst%3DM.%26aulast%3DKubitz%26aufirst%3DR.%26aulast%3DSultmann%26aufirst%3DH.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DHepatitis%2520B%2520and%2520D%2520viruses%2520exploit%2520sodium%2520taurocholate%2520co-transporting%2520polypeptide%2520for%2520species-specific%2520entry%2520into%2520hepatocytes%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D1070%26epage%3D1083%26doi%3D10.1053%2Fj.gastro.2013.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">7977</span>– <span class="NLM_lpage">7991</span>, <span class="refDoi"> DOI: 10.1128/JVI.03540-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.03540-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=23678176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFWjt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=7977-7991&author=H.+Yanauthor=B.+Pengauthor=W.+Heauthor=G.+Zhongauthor=Y.+Qiauthor=B.+Renauthor=Z.+Gaoauthor=Z.+Jingauthor=M.+Songauthor=G.+Xuauthor=J.+Suiauthor=W.+Li&title=Molecular+determinants+of+hepatitis+B+and+D+virus+entry+restriction+in+mouse+sodium+taurocholate+cotransporting+polypeptide&doi=10.1128%2FJVI.03540-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide</span></div><div class="casAuthors">Yan, Huan; Peng, Bo; He, Wenhui; Zhong, Guocai; Qi, Yonghe; Ren, Bijie; Gao, Zhenchao; Jing, Zhiyi; Song, Mei; Xu, Guangwei; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7977-7991</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human hepatitis B virus (HBV) and its satellite virus, hepatitis D virus (HDV), primarily infect humans, chimpanzees, or tree shrews (Tupaia belangeri).  Viral infections in other species are known to be mainly restricted at the entry level since viral replication can be achieved in the cells by transfection of the viral genome.  Sodium taurocholate cotransporting polypeptide (NTCP) is a functional receptor for HBV and HDV, and amino acids 157 to 165 of NTCP are crit. for viral entry and likely limit viral infection of macaques.  However, the mol. determinants for viral entry restriction in mouse NTCP (mNTCP) remain unclear.  In this study, mNTCP was found to be unable to support either HBV or HDV infection, although it can bind to pre-S1 of HBV L protein and is functional in transporting substrate taurocholate; comprehensive swapping and point mutations of human NTCP (hNTCP) and mNTCP revealed mol. determinants restricting mNTCP for viral entry of HBV and HDV.  Remarkably, when mNTCP residues 84 to 87 were substituted by human counterparts, mNTCP can effectively support viral infections.  In addn., a no. of cell lines, regardless of their species or tissue origin, supported HDV infection when transfected with hNTCP or mNTCP with residues 84 to 87 replaced by human counterparts, highlighting the central role of NTCP for viral infections mediated by HBV envelope proteins.  These studies advance our understanding of NTCP-mediated viral entry of HBV and HDV and have important implications for developing the mouse model for their infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo181QjmyElmLVg90H21EOLACvtfcHk0lgQVECUQqBcHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFWjt7zK&md5=59f5669452aad2a667b6dfd1ba54d525</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FJVI.03540-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.03540-12%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DG.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DMolecular%2520determinants%2520of%2520hepatitis%2520B%2520and%2520D%2520virus%2520entry%2520restriction%2520in%2520mouse%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D7977%26epage%3D7991%26doi%3D10.1128%2FJVI.03540-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">3273</span>– <span class="NLM_lpage">3284</span>, <span class="refDoi"> DOI: 10.1128/JVI.03478-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.03478-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24390325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVOqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=3273-3284&author=H.+Yanauthor=B.+Pengauthor=Y.+Liuauthor=G.+Xuauthor=W.+Heauthor=B.+Renauthor=Z.+Jingauthor=J.+Suiauthor=W.+Li&title=Viral+entry+of+hepatitis+B+and+D+viruses+and+bile+salts+transportation+share+common+molecular+determinants+on+sodium+taurocholate+cotransporting+polypeptide&doi=10.1128%2FJVI.03478-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide</span></div><div class="casAuthors">Yan, Huan; Peng, Bo; Liu, Yang; Xu, Guangwei; He, Wenhui; Ren, Bijie; Jing, Zhiyi; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3273-3284, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The liver bile acids transporter sodium taurocholate cotransporting polypeptide (NTCP) is responsible for the majority of sodium-dependent bile salts uptake by hepatocytes.  NTCP also functions as a cellular receptor for viral entry of hepatitis B virus (HBV) and hepatitis D virus (HDV) through a specific interaction between NTCP and the pre-S1 domain of HBV large envelope protein.  However, it remains unknown if these two functions of NTCP are independent or if they interfere with each other.  Here we show that binding of the pre-S1 domain to human NTCP blocks taurocholate uptake by the receptor; conversely, some bile acid substrates of NTCP inhibit HBV and HDV entry.  Mutations of NTCP residues crit. for bile salts binding severely impair viral infection by HDV and HBV; to a lesser extent, the residues important for sodium binding also inhibit viral infection.  The mutation S267F, corresponding to a single nucleotide polymorphism (SNP) found in about 9% of the East Asian population, renders NTCP without either taurocholate transporting activity or the ability to support HBV or HDV infection in cell culture.  These results demonstrate that mol. determinants crit. for HBV and HDV entry overlap with that for bile salts uptake by NTCP, indicating that viral infection may interfere with the normal function of NTCP and bile acids and their derivs. hold the potential for further development into antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsAWAqX4p6L7Vg90H21EOLACvtfcHk0litMkHihl6zqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVOqtr4%253D&md5=22fe09e746ad3f6ee76002a316de82b1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FJVI.03478-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.03478-13%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DViral%2520entry%2520of%2520hepatitis%2520B%2520and%2520D%2520viruses%2520and%2520bile%2520salts%2520transportation%2520share%2520common%2520molecular%2520determinants%2520on%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%26jtitle%3DJ.%2520Virol.%26date%3D2014%26volume%3D88%26spage%3D3273%26epage%3D3284%26doi%3D10.1128%2FJVI.03478-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">König, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geipel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glebe, D.</span></span> <span> </span><span class="NLM_article-title">Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2014.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.jhep.2014.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24845614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A280%3ADC%252BC2cjkslSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=867-875&author=A.+K%C3%B6nigauthor=B.+Doringauthor=C.+Mohrauthor=A.+Geipelauthor=J.+Geyerauthor=D.+Glebe&title=Kinetics+of+the+bile+acid+transporter+and+hepatitis+B+virus+receptor+Na%2B%2Ftaurocholate+cotransporting+polypeptide+%28NTCP%29+in+hepatocytes&doi=10.1016%2Fj.jhep.2014.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes</span></div><div class="casAuthors">Konig Alexander; Mohr Christina; Geipel Andreas; Doring Barbara; Geyer Joachim; Glebe Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">867-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND & AIMS:  The human liver bile acid transporter Na(+)/taurocholate cotransporting polypeptide (NTCP) has recently been identified as liver-specific receptor for infection of hepatitis B virus (HBV), which attaches via the myristoylated preS1 (myr-preS1) peptide domain of its large surface protein to NTCP.  Since binding of the myr-preS1 peptide to NTCP is an initiating step of HBV infection, we investigated if this process interferes with the physiological bile acid transport function of NTCP.  METHODS:  HBV infection, myr-preS1 peptide binding, and bile acid transport assays were performed with primary Tupaia belangeri (PTH) and human (PHH) hepatocytes as well as NTCP-transfected human hepatoma HepG2 cells allowing regulated NTCP expression, in the presence of various bile acids, ezetimibe, and myr-preS1 peptides.  RESULTS:  The myr-preS1 peptide of HBV inhibited bile acid transport in PTH and PHH as well as in NTCP-expressing HEK293 and HepG2 cells.  Inversely, HBV infection of PTH, PHH, and NTCP-transfected HepG2 cells was inhibited in a concentration-dependent manner by taurine and glycine conjugates of cholic acid and ursodeoxycholic acid as well as by ezetimibe.  In NTCP-HepG2 cells and PTH, NTCP expression, NTCP transport function, myr-preS1 peptide binding, and HBV infection followed comparable kinetics.  CONCLUSIONS:  Myr-preS1 virus binding to NTCP, necessary for productive HBV infection, interferes with the physiological bile acid transport function of NTCP.  Therefore, HBV infection via NTCP may be lockable by NTCP substrates and NTCP-inhibiting drugs.  This opens a completely new way for an efficient management of HBV infection by the use of NTCP-directed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQL8uPrQ26gtXtlzo9xastyfW6udTcc2eb7c1Qtr0zwIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjkslSgug%253D%253D&md5=46106af8958ba2cd35a321f29fe58970</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6nig%26aufirst%3DA.%26aulast%3DDoring%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DGeipel%26aufirst%3DA.%26aulast%3DGeyer%26aufirst%3DJ.%26aulast%3DGlebe%26aufirst%3DD.%26atitle%3DKinetics%2520of%2520the%2520bile%2520acid%2520transporter%2520and%2520hepatitis%2520B%2520virus%2520receptor%2520Na%252B%252Ftaurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%2520in%2520hepatocytes%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3D867%26epage%3D875%26doi%3D10.1016%2Fj.jhep.2014.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jen, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-J.</span></span> <span> </span><span class="NLM_article-title">The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1514</span>– <span class="NLM_lpage">1521</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2015-310686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1136%2Fgutjnl-2015-310686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=26642861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSkt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=1514-1521&author=H.-H.+Huauthor=J.+Liuauthor=Y.-L.+Linauthor=W.-S.+Luoauthor=Y.-J.+Chuauthor=C.-L.+Changauthor=C.-L.+Jenauthor=M.-H.+Leeauthor=S.-N.+Luauthor=L.-Y.+Wangauthor=S.-L.+Youauthor=H.-I.+Yangauthor=C.-J.+Chen&title=The+rs2296651+%28S267F%29+variant+on+NTCP+%28SLC10A1%29+is+inversely+associated+with+chronic+hepatitis+B+and+progression+to+cirrhosis+and+hepatocellular+carcinoma+in+patients+with+chronic+hepatitis+B&doi=10.1136%2Fgutjnl-2015-310686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B</span></div><div class="casAuthors">Hu, Hui-Han; Liu, Jessica; Lin, Yu-Ling; Luo, Wun-Sheng; Chu, Yu-Ju; Chang, Chia-Lin; Jen, Chin-Lan; Lee, Mei-Hsuan; Lu, Sheng-Nan; Wang, Li-Yu; You, San-Lin; Yang, Hwai-I.; Chen, Chien-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1514-1521</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective: The sodium taurocholate co-transporting polypeptide (NTCP), encoded by SLC10A1, was recently identified as a receptor for HBV.  We assessed the assocn. of the p.Ser267Phe variant (rs2296651) with chronic hepatitis B (CHB) serostatus, cirrhosis and hepatocellular carcinoma (HCC) in patients with CHB.  Design: The variant was genotyped in 3801 patients with CHB and 3801 matched hepatitis B surface antigen (HBsAg) seroneg. individuals.  ORs with 95% CIs for the variant's assocn. with CHB, cirrhosis and HCC were estd. using logistic regression.  Results: In patients with CHB, the S267F variant was obsd. in 515 (18.5%) controls, 40 (17.2%) cirrhosis only cases, 49 (13.2%) non-cirrhotic HCC cases, and 52 (12.7%) cirrhotic-HCC cases.  After adjustment for known risk factors, S267F was significantly assocd. with decreased risk for cirrhosis (OR 0.65 (95% CI 0.49 to 0.86), p=0.002) and HCC (OR 0.55 (95% CI 0.42 to 0.72), p<0.001).  This assocn. persisted for noncirrhotic and cirrhotic-HCC.  Compared with patients with HBV DNA levels greater than 105 copies/mL who carried the GG genotype, patients who had undetectable HBV DNA and the GA or AA genotypes had a 25-fold decreased risk of developing HCC (OR 0.04 (95% CI 0.02 to 0.11), p<0.001).  The AA genotype was also assocd. with HBsAg seronegativity (OR 0.13 (95% CI 0.05 to 0.34), p<0.001).  Conclusions: The SLC10A1 (NTCP) S267F variant is independently assocd. with decreased risk of cirrhosis and HCC, and resistance to CHB infection.  Together with serum HBV DNA levels, S267F may help to identify patients with CHB with very low risk of HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAZUGcfX19kbVg90H21EOLACvtfcHk0litMkHihl6zqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSkt7s%253D&md5=d3fe750d172588c40910031e38de878e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2015-310686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2015-310686%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.-H.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.-L.%26aulast%3DLuo%26aufirst%3DW.-S.%26aulast%3DChu%26aufirst%3DY.-J.%26aulast%3DChang%26aufirst%3DC.-L.%26aulast%3DJen%26aufirst%3DC.-L.%26aulast%3DLee%26aufirst%3DM.-H.%26aulast%3DLu%26aufirst%3DS.-N.%26aulast%3DWang%26aufirst%3DL.-Y.%26aulast%3DYou%26aufirst%3DS.-L.%26aulast%3DYang%26aufirst%3DH.-I.%26aulast%3DChen%26aufirst%3DC.-J.%26atitle%3DThe%2520rs2296651%2520%2528S267F%2529%2520variant%2520on%2520NTCP%2520%2528SLC10A1%2529%2520is%2520inversely%2520associated%2520with%2520chronic%2520hepatitis%2520B%2520and%2520progression%2520to%2520cirrhosis%2520and%2520hepatocellular%2520carcinoma%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520B%26jtitle%3DGut%26date%3D2016%26volume%3D65%26spage%3D1514%26epage%3D1521%26doi%3D10.1136%2Fgutjnl-2015-310686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. E.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1008</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1021/mp300453k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300453k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1008-1019&author=Z.+Dongauthor=S.+Ekinsauthor=J.+E.+Polli&title=Structure-activity+relationship+for+FDA+approved+drugs+as+inhibitors+of+the+human+sodium+taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1021%2Fmp300453k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship for FDA Approved Drugs As Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP)</span></div><div class="casAuthors">Dong, Zhongqi; Ekins, Sean; Polli, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1008-1019</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hepatic bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP) is less well characterized than its ileal paralog, the apical sodium dependent bile acid transporter (ASBT), in terms of drug inhibition requirements.  The objectives of this study were (a) to identify FDA approved drugs that inhibit human NTCP, (b) to develop pharmacophore and Bayesian computational models for NTCP inhibition, and (c) to compare NTCP and ASBT transport inhibition requirements.  A series of NTCP inhibition studies were performed using FDA approved drugs, in concert with iterative computational model development.  Screening studies identified 27 drugs as novel NTCP inhibitors, including irbesartan (Ki = 11.9 μM) and ezetimibe (Ki = 25.0 μM).  The common feature pharmacophore indicated that two hydrophobes and one hydrogen bond acceptor were important for inhibition of NTCP.  From 72 drugs screened in vitro, a total of 31 drugs inhibited NTCP, while 51 drugs (i.e., more than half) inhibited ASBT.  Hence, while there was inhibitor overlap, ASBT unexpectedly was more permissive to drug inhibition than was NTCP, and this may be related to NTCP possessing fewer pharmacophore features.  Findings reflected that a combination of computational and in vitro approaches enriched the understanding of these poorly characterized transporters and yielded addnl. chem. probes for possible drug-transporter interaction detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbGhpWyONrzbVg90H21EOLACvtfcHk0lg6AnPXHQH8Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCnsL8%253D&md5=0a0e0af7c8d1acb875ef8208c84f13c6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fmp300453k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300453k%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DEkins%26aufirst%3DS.%26aulast%3DPolli%26aufirst%3DJ.%2BE.%26atitle%3DStructure-activity%2520relationship%2520for%2520FDA%2520approved%2520drugs%2520as%2520inhibitors%2520of%2520the%2520human%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D1008%26epage%3D1019%26doi%3D10.1021%2Fmp300453k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nkongolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lempp, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esser-Nobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span> <span> </span><span class="NLM_article-title">Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2013.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.jhep.2013.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24295872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=723-731&author=S.+Nkongoloauthor=Y.+Niauthor=F.+A.+Lemppauthor=C.+Kaufmanauthor=T.+Lindnerauthor=K.+Esser-Nobisauthor=V.+Lohmannauthor=W.+Mierauthor=S.+Mehrleauthor=S.+Urban&title=Cyclosporin+A+inhibits+hepatitis+B+and+hepatitis+D+virus+entry+by+cyclophilin-independent+interference+with+the+NTCP+receptor&doi=10.1016%2Fj.jhep.2013.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor</span></div><div class="casAuthors">Nkongolo, Shirin; Ni, Yi; Lempp, Florian A.; Kaufman, Christina; Lindner, Thomas; Esser-Nobis, Katharina; Lohmann, Volker; Mier, Walter; Mehrle, Stefan; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">723-731</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic hepatitis B and hepatitis D are global health problems caused by the human hepatitis B and hepatitis D virus.  The myristoylated preS1 domain of the large envelope protein mediates specific binding to hepatocytes by sodium taurocholate co-transporting polypeptide (NTCP).  NTCP is a bile salt transporter known to be inhibited by cyclosporin A.  This study aimed to characterize the effect of cyclosporin A on HBV/HDV infection.  HepaRG cells, primary human hepatocytes, and susceptible NTCP-expressing hepatoma cell lines were applied for infection expts.  The mode of action of cyclosporin A was studied by comparing the effect of different inhibitors, cyclophilin A/B/C-silenced cell lines as well as NTCP variants and mutants.  Bile salt transporter and HBV receptor functions were investigated by taurocholate uptake and quantification of HBVpreS binding.Cyclosporin A inhibited hepatitis B and D virus infections during and - less pronounced - prior to virus inoculation.  Binding of HBVpreS to NTCP was blocked by cyclosporin A concns. at 8 μM.  An NTCP variant deficient in HBVpreS binding but competent for bile salt transport showed resistance to cyclosporin A.  Silencing of cyclophilins A/B/C did not abrogate transporter and receptor inhibition.  In contrast, tacrolimus, a cyclophilin-independent calcineurin inhibitor, was inactive.HBV and HDV entry via sodium taurocholate co-transporting polypeptide is inhibited by cyclosporin A.  The interaction between the drug and the viral receptor is direct and overlaps with a functional binding site of the preS1 domain, which mediates viral entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTAVAhQe6_ErVg90H21EOLACvtfcHk0lj2gwKs8qD0RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlagtw%253D%253D&md5=d8c7e3698ac926cd5c06a9e7e2c4717b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DNkongolo%26aufirst%3DS.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DKaufman%26aufirst%3DC.%26aulast%3DLindner%26aufirst%3DT.%26aulast%3DEsser-Nobis%26aufirst%3DK.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DMehrle%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DCyclosporin%2520A%2520inhibits%2520hepatitis%2520B%2520and%2520hepatitis%2520D%2520virus%2520entry%2520by%2520cyclophilin-independent%2520interference%2520with%2520the%2520NTCP%2520receptor%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D723%26epage%3D731%26doi%3D10.1016%2Fj.jhep.2013.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borroto-Esoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span> <span> </span><span class="NLM_article-title">Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1726</span>– <span class="NLM_lpage">1737</span>, <span class="refDoi"> DOI: 10.1002/hep.26982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1002%2Fhep.26982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24375637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1726-1737&author=K.+Watashiauthor=A.+Sluderauthor=T.+Daitoauthor=S.+Matsunagaauthor=A.+Ryoauthor=S.+Nagamoriauthor=M.+Iwamotoauthor=S.+Nakajimaauthor=S.+Tsukudaauthor=K.+Borroto-Esodaauthor=M.+Sugiyamaauthor=Y.+Tanakaauthor=Y.+Kanaiauthor=H.+Kusuharaauthor=M.+Mizokamiauthor=T.+Wakita&title=Cyclosporin+A+and+its+analogs+inhibit+hepatitis+B+virus+entry+into+cultured+hepatocytes+through+targeting+a+membrane+transporter%2C+sodium+taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1002%2Fhep.26982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)</span></div><div class="casAuthors">Watashi, Koichi; Sluder, Ann; Daito, Takuji; Matsunaga, Satoko; Ryo, Akihide; Nagamori, Shushi; Iwamoto, Masashi; Nakajima, Syo; Tsukuda, Senko; Borroto-Esoda, Katyna; Sugiyama, Masaya; Tanaka, Yasuhito; Kanai, Yoshikatsu; Kusuhara, Hiroyuki; Mizokami, Masashi; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1726-1737</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide.  Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clin. available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other targets.  Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes.  The anti-HBV effect of CsA was independent of binding to cyclophilin and calcineurin.  Rather, blockade of HBV infection correlated with the ability to inhibit the transporter activity of sodium taurocholate cotransporting polypeptide (NTCP).  We also found that HBV infection-susceptible cells, differentiated HepaRG cells and primary human hepatocytes expressed NTCP, while nonsusceptible cell lines did not.  A series of compds. targeting NTCP could inhibit HBV infection.  CsA inhibited the binding between NTCP and large envelope protein in vitro.  Evaluation of CsA analogs identified a compd. with higher anti-HBV potency, having a median inhibitory concn. <0.2 μM.  Conclusion: This study provides a proof of concept for the novel strategy to identify anti-HBV agents by targeting the candidate HBV receptor, NTCP, using CsA as a structural platform. (Hepatol. 2014;59:1726-1737).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRV21kvExmObVg90H21EOLACvtfcHk0lj2gwKs8qD0RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFCltro%253D&md5=d83ae63fbe3e8b827f9fbf5f6601b316</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fhep.26982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26982%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DSluder%26aufirst%3DA.%26aulast%3DDaito%26aufirst%3DT.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DNagamori%26aufirst%3DS.%26aulast%3DIwamoto%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DTsukuda%26aufirst%3DS.%26aulast%3DBorroto-Esoda%26aufirst%3DK.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DCyclosporin%2520A%2520and%2520its%2520analogs%2520inhibit%2520hepatitis%2520B%2520virus%2520entry%2520into%2520cultured%2520hepatocytes%2520through%2520targeting%2520a%2520membrane%2520transporter%252C%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D1726%26epage%3D1737%26doi%3D10.1002%2Fhep.26982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanchet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, P.</span></span> <span> </span><span class="NLM_article-title">Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2014.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.antiviral.2014.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=24717262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=111-115&author=M.+Blanchetauthor=C.+Sureauauthor=P.+Labonte&title=Use+of+FDA+approved+therapeutics+with+hNTCP+metabolic+inhibitory+properties+to+impair+the+HDV+lifecycle&doi=10.1016%2Fj.antiviral.2014.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle</span></div><div class="casAuthors">Blanchet, Matthieu; Sureau, Camille; Labonte, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-115</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Worldwide there are approx. 240 million individuals chronically infected with the hepatitis B virus (HBV), including 15-20 million coinfected with the hepatitis delta virus (HDV).  Treatments available today are not fully efficient and often assocd. to important side effects and development of drug resistance.  Targeting the HBV/HDV entry step using preS1-specific lipopeptides appears as a promising strategy to block viral entry for both HBV and HDV (Gripon et al., 2005; Petersen et al., 2008).  Recently, the human Sodium Taurocholate Cotransporting Polypeptide (hNTCP) has been identified as a functional, preS1-specific receptor for HBV and HDV.  This groundbreaking discovery has opened a very promising avenue for the treatment of chronic HBV and HDV infections.  Here we investigated the ability of FDA approved therapeutics with documented inhibitory effect on hNTCP cellular function to impair viral entry using a HDV in vitro infection model based on a hNTCP-expressing Huh7 cell line.  We demonstrate the potential of three FDA approved mols., irbesartan, ezetimibe, and ritonavir, to alter HDV infection in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5uuuK9vPHVbVg90H21EOLACvtfcHk0lj2gwKs8qD0RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSrsLc%253D&md5=abe5262a9fa3fc4daaff030ae1a080c1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchet%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DLabonte%26aufirst%3DP.%26atitle%3DUse%2520of%2520FDA%2520approved%2520therapeutics%2520with%2520hNTCP%2520metabolic%2520inhibitory%2520properties%2520to%2520impair%2520the%2520HDV%2520lifecycle%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D106%26spage%3D111%26epage%3D115%26doi%3D10.1016%2Fj.antiviral.2014.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucifora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protzer, U.</span></span> <span> </span><span class="NLM_article-title">Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2012.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.antiviral.2012.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=23266293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=195-197&author=J.+Luciforaauthor=K.+Esserauthor=U.+Protzer&title=Ezetimibe+blocks+hepatitis+B+virus+infection+after+virus+uptake+into+hepatocytes&doi=10.1016%2Fj.antiviral.2012.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes</span></div><div class="casAuthors">Lucifora, Julie; Esser, Knud; Protzer, Ulrike</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-197</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Current treatment of chronic hepatitis B virus (HBV) infection mainly targets viral replication in hepatocytes and leads to curing only in exceptional cases.  Despite their potential to improve therapeutic success, no drugs interfering with early infection steps of the hepatotropic pathogen HBV are available to date.  Recently, entry of the hepatitis C virus (HCV) was shown to occur along hepatic cholesterol uptake pathways and ezetimibe, a drug which blocks this lipid transport, was shown to inhibit HCV infection.  We here investigated the effect of ezetimibe on HBV infection using differentiated HepaRG cells as a cell-culture infection model.  Treatment with ezetimibe inhibited establishment of intrahepatic cccDNA and expression of viral replication markers when cells were infected with HBV virions, while we obsd. no effect when the HBV viral genome was transduced via an adenoviral vector.  Our data suggest that modulating hepatic cholesterol uptake by ezetimibe inhibits early HBV infection and that ezetimibe sensitive lipid transport pathways represent new targets for antiviral therapy in HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNJ1wQJ_RUkbVg90H21EOLACvtfcHk0lgSTs--sz2-DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSrsrw%253D&md5=dcfca7855b8cacdad584203e23690f85</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2012.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2012.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DEsser%26aufirst%3DK.%26aulast%3DProtzer%26aufirst%3DU.%26atitle%3DEzetimibe%2520blocks%2520hepatitis%2520B%2520virus%2520infection%2520after%2520virus%2520uptake%2520into%2520hepatocytes%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D97%26spage%3D195%26epage%3D197%26doi%3D10.1016%2Fj.antiviral.2012.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veloso
Alves Pereira, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprinzl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlaphoff, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vondran, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarrazin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manns, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto Marques Souza de Oliveira, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodeik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Hahn, T.</span></span> <span> </span><span class="NLM_article-title">Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP)</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0117152</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0117152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1371%2Fjournal.pone.0117152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=25646622" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=I.+Veloso%0AAlves+Pereiraauthor=B.+Buchmannauthor=L.+Sandmannauthor=K.+Sprinzlauthor=V.+Schlaphoffauthor=K.+Dohnerauthor=F.+Vondranauthor=C.+Sarrazinauthor=M.+P.+Mannsauthor=C.+Pinto+Marques+Souza+de+Oliveiraauthor=B.+Sodeikauthor=S.+Ciesekauthor=T.+von+Hahn&title=Primary+biliary+acids+inhibit+hepatitis+D+virus+%28HDV%29+entry+into+human+hepatoma+cells+expressing+the+sodium-taurocholate+cotransporting+polypeptide+%28NTCP%29&doi=10.1371%2Fjournal.pone.0117152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0117152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0117152%26sid%3Dliteratum%253Aachs%26aulast%3DVeloso%2BAlves%2BPereira%26aufirst%3DI.%26aulast%3DBuchmann%26aufirst%3DB.%26aulast%3DSandmann%26aufirst%3DL.%26aulast%3DSprinzl%26aufirst%3DK.%26aulast%3DSchlaphoff%26aufirst%3DV.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DVondran%26aufirst%3DF.%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DManns%26aufirst%3DM.%2BP.%26aulast%3DPinto%2BMarques%2BSouza%2Bde%2BOliveira%26aufirst%3DC.%26aulast%3DSodeik%26aufirst%3DB.%26aulast%3DCiesek%26aufirst%3DS.%26aulast%3Dvon%2BHahn%26aufirst%3DT.%26atitle%3DPrimary%2520biliary%2520acids%2520inhibit%2520hepatitis%2520D%2520virus%2520%2528HDV%2529%2520entry%2520into%2520human%2520hepatoma%2520cells%2520expressing%2520the%2520sodium-taurocholate%2520cotransporting%2520polypeptide%2520%2528NTCP%2529%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0117152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucifora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knolle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkirane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durantel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosset, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick-Marchand, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barre-Sinoussi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delfraissy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoulim, F.</span></span> <span> </span><span class="NLM_article-title">Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1314</span>– <span class="NLM_lpage">1326</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2014-308943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1136%2Fgutjnl-2014-308943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=25670809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVCrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1314-1326&author=M.+B.+Zeiselauthor=J.+Luciforaauthor=W.+S.+Masonauthor=C.+Sureauauthor=J.+Beckauthor=M.+Levreroauthor=M.+Kannauthor=P.+A.+Knolleauthor=M.+Benkiraneauthor=D.+Durantelauthor=M.+L.+Michelauthor=B.+Autranauthor=F.+L.+Cossetauthor=H.+Strick-Marchandauthor=C.+Trepoauthor=J.+H.+Kaoauthor=F.+Carratauthor=K.+Lacombeauthor=R.+F.+Schinaziauthor=F.+Barre-Sinoussiauthor=J.+F.+Delfraissyauthor=F.+Zoulim&title=Towards+an+HBV+cure%3A+state-of-the-art+and+unresolved+questions%2D%2Dreport+of+the+ANRS+workshop+on+HBV+cure&doi=10.1136%2Fgutjnl-2014-308943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure</span></div><div class="casAuthors">Zeisel, Mirjam B.; Lucifora, Julie; Mason, William S.; Sureau, Camille; Beck, Jurgen; Levrero, Massimo; Kann, Michael; Knolle, Percy A.; Benkirane, Monsef; Durantel, David; Michel, Marie-Louise; Autran, Brigitte; Cosset, Francois-Loic; Strick-Marchand, Helene; Trepo, Christian; Kao, Jia-Horng; Carrat, Fabrice; Lacombe, Karine; Schinazi, Raymond F.; Barre-Sinoussi, Francoise; Delfraissy, Jean-Francois; Zoulim, Fabien</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1314-1326</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma.  Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide.  Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons.  In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' program, a scientific workshop was held in Paris in June 2014 to define the state-ofthe- art and unanswered questions regarding HBV pathobiol., and to develop a concerted strategy towards an HBV cure.  This review summarizes our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq3d3BmB6kC7Vg90H21EOLACvtfcHk0lgSTs--sz2-DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVCrt7g%253D&md5=3fb4876ea829381ac9fbf8f9f3deeda7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2014-308943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2014-308943%26sid%3Dliteratum%253Aachs%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DW.%2BS.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DLevrero%26aufirst%3DM.%26aulast%3DKann%26aufirst%3DM.%26aulast%3DKnolle%26aufirst%3DP.%2BA.%26aulast%3DBenkirane%26aufirst%3DM.%26aulast%3DDurantel%26aufirst%3DD.%26aulast%3DMichel%26aufirst%3DM.%2BL.%26aulast%3DAutran%26aufirst%3DB.%26aulast%3DCosset%26aufirst%3DF.%2BL.%26aulast%3DStrick-Marchand%26aufirst%3DH.%26aulast%3DTrepo%26aufirst%3DC.%26aulast%3DKao%26aufirst%3DJ.%2BH.%26aulast%3DCarrat%26aufirst%3DF.%26aulast%3DLacombe%26aufirst%3DK.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DBarre-Sinoussi%26aufirst%3DF.%26aulast%3DDelfraissy%26aufirst%3DJ.%2BF.%26aulast%3DZoulim%26aufirst%3DF.%26atitle%3DTowards%2520an%2520HBV%2520cure%253A%2520state-of-the-art%2520and%2520unresolved%2520questions--report%2520of%2520the%2520ANRS%2520workshop%2520on%2520HBV%2520cure%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D1314%26epage%3D1326%26doi%3D10.1136%2Fgutjnl-2014-308943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gripon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span> <span> </span><span class="NLM_article-title">Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1613</span>– <span class="NLM_lpage">1622</span>, <span class="refDoi"> DOI: 10.1128/JVI.79.3.1613-1622.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.79.3.1613-1622.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15650187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=1613-1622&author=P.+Griponauthor=I.+Cannieauthor=S.+Urban&title=Efficient+inhibition+of+hepatitis+B+virus+infection+by+acylated+peptides+derived+from+the+large+viral+surface+protein&doi=10.1128%2FJVI.79.3.1613-1622.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein</span></div><div class="casAuthors">Gripon, Philippe; Cannie, Isabelle; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1613-1622</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The lack of an appropriate in vitro infection system for the major human pathogen hepatitis B virus (HBV) has prevented a mol. understanding of the early infection events of HBV.  We used the novel HBV-infectible cell line HepaRG and primary human hepatocytes to investigate the interference of infection by HBV envelope protein-derived peptides.  We found that a peptide consisting of the authentically myristoylated N-terminal 47 amino acids of the pre-S1 domain of the large viral envelope protein (L protein) specifically prevented HBV infection, with a 50% inhibitory concn. (IC50) of 8 nM.  The replacement of myristic acid with other hydrophobic moieties resulted in changes in the inhibitory activity, most notably by a decrease in the IC50 to picomolar concns. for longer unbranched fatty acids.  The obstruction of HepaRG cell susceptibility to HBV infection after short preincubation times with the peptides suggested that the peptides efficiently target and inactivate a receptor at the hepatocyte surface.  Our data both shed light on the mol. mechanism of HBV entry into hepatocytes and provide a basis for the development of potent hepadnaviral entry inhibitors as a novel therapeutic concept for the treatment of hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ35R_8zOmS7Vg90H21EOLACvtfcHk0lgg3NAPPfaiyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjtb8%253D&md5=519a08a82ce4de9e5db5692cf2a5ae80</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.3.1613-1622.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.3.1613-1622.2005%26sid%3Dliteratum%253Aachs%26aulast%3DGripon%26aufirst%3DP.%26aulast%3DCannie%26aufirst%3DI.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DEfficient%2520inhibition%2520of%2520hepatitis%2520B%2520virus%2520infection%2520by%2520acylated%2520peptides%2520derived%2520from%2520the%2520large%2520viral%2520surface%2520protein%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D1613%26epage%3D1622%26doi%3D10.1128%2FJVI.79.3.1613-1622.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allweiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warlich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutgehetmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandri, M.</span></span> <span> </span><span class="NLM_article-title">The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.jhep.2012.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=23246506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFyqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=861-867&author=T.+Volzauthor=L.+Allweissauthor=M.+M.+Benauthor=M.+Warlichauthor=A.+W.+Lohseauthor=J.+M.+Pollokauthor=A.+Alexandrovauthor=S.+Urbanauthor=J.+Petersenauthor=M.+Lutgehetmannauthor=M.+Dandri&title=The+entry+inhibitor+Myrcludex-B+efficiently+blocks+intrahepatic+virus+spreading+in+humanized+mice+previously+infected+with+hepatitis+B+virus&doi=10.1016%2Fj.jhep.2012.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus</span></div><div class="casAuthors">Volz, Tassilo; Allweiss, Lena; Ben Mbarek, Mounira; Warlich, Michael; Lohse, Ansgar W.; Pollok, Joerg M.; Alexandrov, Alexander; Urban, Stephan; Petersen, Joerg; Luetgehetmann, Marc; Dandri, Maura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">861-867</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Currently approved antivirals rarely cure hepatitis B virus (HBV) infection.  Therefore addnl. therapeutic strategies interfering with other viral replication steps are needed.  Using synthetic lipopeptides derived from the HBV envelope protein, we previously demonstrated prevention of de novo HBV infection in vivo.  We aimed at investigating the ability of the lipopeptide Myrcludex-B to block HBV spreading post-infection.uPA/SCID mice reconstituted with human hepatocytes were infected with HBV.  Daily s.c. Myrcludex-B administration was initiated either 3 days, 3 wk or 8 wk post HBV inoculation.  Viral loads were quantitated in serum and liver, and visualized by immunohistochem.Myrcludex-B efficiently prevented viral spreading from the initially infected human hepatocytes, as demonstrated by the lack of increase in viremia, antigen levels and amt. of HBcAg-pos. human hepatocytes detd. 6 wk after treatment.  Myrcludex-B efficiently blocked HBV dissemination also when treatment was started in the ramp-up phase of infection, in mice displaying moderate levels of circulating virions (median 3 × 106 HBV DNA copies/mL).  Notably, after 6 wk of treatment, not only the amt. of HBcAg-pos. hepatocytes, but also intrahepatic cccDNA loads, remained comparable to values found in mice sacrificed 3 wk post-infection.  In none of the exptl. settings, drug administration affected human hepatocyte half-life or altered virion productivity.Myrcludex-B efficiently not only prevented HBV spreading from infected human hepatocytes in vivo, but also hindered amplification of the cccDNA pool in initially infected hepatocytes.  Administration of an entry inhibitor, possibly used in combination with current HBV drugs, may improve patients' treatment outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa56-oby3iE7Vg90H21EOLACvtfcHk0lgg3NAPPfaiyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFyqsb8%253D&md5=308396c033ffd1f57f2ded28890c173a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DVolz%26aufirst%3DT.%26aulast%3DAllweiss%26aufirst%3DL.%26aulast%3DBen%26aufirst%3DM.%2BM.%26aulast%3DWarlich%26aufirst%3DM.%26aulast%3DLohse%26aufirst%3DA.%2BW.%26aulast%3DPollok%26aufirst%3DJ.%2BM.%26aulast%3DAlexandrov%26aufirst%3DA.%26aulast%3DUrban%26aufirst%3DS.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DLutgehetmann%26aufirst%3DM.%26aulast%3DDandri%26aufirst%3DM.%26atitle%3DThe%2520entry%2520inhibitor%2520Myrcludex-B%2520efficiently%2520blocks%2520intrahepatic%2520virus%2520spreading%2520in%2520humanized%2520mice%2520previously%2520infected%2520with%2520hepatitis%2520B%2520virus%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D861%26epage%3D867%26doi%3D10.1016%2Fj.jhep.2012.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogomolov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voronkova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macievich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrachenkova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lempp, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedemeyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haefeli, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, S.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">490</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2016.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.jhep.2016.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=27132170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVynsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=490-498&author=P.+Bogomolovauthor=A.+Alexandrovauthor=N.+Voronkovaauthor=M.+Macievichauthor=K.+Kokinaauthor=M.+Petrachenkovaauthor=T.+Lehrauthor=F.+A.+Lemppauthor=H.+Wedemeyerauthor=M.+Haagauthor=M.+Schwabauthor=W.+E.+Haefeliauthor=A.+Blankauthor=S.+Urban&title=Treatment+of+chronic+hepatitis+D+with+the+entry+inhibitor+myrcludex+B%3A+First+results+of+a+phase+Ib%2FIIa+study&doi=10.1016%2Fj.jhep.2016.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study</span></div><div class="casAuthors">Bogomolov, Pavel; Alexandrov, Alexander; Voronkova, Natalia; Macievich, Maria; Kokina, Ksenia; Petrachenkova, Maria; Lehr, Thorsten; Lempp, Florian A.; Wedemeyer, Heiner; Haag, Mathias; Schwab, Matthias; Haefeli, Walter E.; Blank, Antje; Urban, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">490-498</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The therapeutic option for patients with chronic hepatitis delta virus infection (CHD) is limited to interferon alpha with rare curative outcome.  Myrcludex B is a first-in-class entry inhibitor inactivating the hepatitis B virus (HBV) and hepatitis D virus (HDV) receptor sodium taurocholate co-transporting polypeptide.  We report the interim results of a pilot trial on chronically infected HDV patients treated with myrcludex B, or pegylated interferon alpha (PegIFNα-2a) or their combination.  Twenty-four patients with CHD infection were equally randomized (1:1:1) to receive myrcludex B, or PegIFNα-2a or their combination.  Patients were evaluated for virol. and biochem. response and tolerability of the study drugs at weeks 12 and 24.  Myrcludex B was well tolerated and no serious adverse event occurred.  Although hepatitis B surface antigen levels remained unchanged, HDV RNA significantly declined at week 24 in all cohorts.  HDV RNA became neg. in two patients each in the Myrcludex B and PegIFNα-2a cohorts, and in five patients of the Myrcludex B + PegIFNα-2a cohort.  ALT decreased significantly in the Myrcludex B cohort (six of eight patients), and HBV DNA was significantly reduced at week 24 in the Myrcludex B + PegIFNα-2a cohort.  Virus kinetic modeling suggested a strong synergistic effect of myrcludex B and PegIFNα-2a on both HDV and HBV.  Myrcludex B showed a strong effect on HDV RNA serum levels and induced ALT normalization under monotherapy.  Synergistic antiviral effects on HDV RNA and HBV DNA in the Myr-IFN cohort indicated a benefit of the combination of entry inhibition with PegIFNα-2a to treat CHD patients.  Myrcludex B is a new drug to treat hepatitis B and D infection.  After 24 wk of treatment with myrcludex B and/or pegylated interferon α-2a, HDV RNA, a relevant marker for hepatitis D infection, decreased in all patients with chronic hepatitis B and D.  Two of eight patients which received either myrcludex B or pegylated interferon α-2a, became neg. for HDV RNA, and five of seven patients who received both drugs at the same time became neg.  The drug was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo29Ewz7ZuCMrVg90H21EOLACvtfcHk0lgg3NAPPfaiyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVynsbrE&md5=9b31bd4df1423aa2da1e49d41a89192a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DBogomolov%26aufirst%3DP.%26aulast%3DAlexandrov%26aufirst%3DA.%26aulast%3DVoronkova%26aufirst%3DN.%26aulast%3DMacievich%26aufirst%3DM.%26aulast%3DKokina%26aufirst%3DK.%26aulast%3DPetrachenkova%26aufirst%3DM.%26aulast%3DLehr%26aufirst%3DT.%26aulast%3DLempp%26aufirst%3DF.%2BA.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DHaag%26aufirst%3DM.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26aulast%3DBlank%26aufirst%3DA.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DTreatment%2520of%2520chronic%2520hepatitis%2520D%2520with%2520the%2520entry%2520inhibitor%2520myrcludex%2520B%253A%2520First%2520results%2520of%2520a%2520phase%2520Ib%252FIIa%2520study%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D65%26spage%3D490%26epage%3D498%26doi%3D10.1016%2Fj.jhep.2016.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rüegger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loosli, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguenin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiquerez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Wartburg, A.</span></span> <span> </span><span class="NLM_article-title">[Cyclosporin A, a Peptide Metabolite from <i>Trichoderma polysporum</i> (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity]</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1092</span>, <span class="refDoi"> DOI: 10.1002/hlca.19760590412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1002%2Fhlca.19760590412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=950308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaE28Xkt12ksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1976&pages=1075-1092&author=A.+R%C3%BCeggerauthor=M.+Kuhnauthor=H.+Lichtiauthor=H.+R.+Loosliauthor=R.+Hugueninauthor=C.+Quiquerezauthor=A.+von+Wartburg&title=%5BCyclosporin+A%2C+a+Peptide+Metabolite+from+Trichoderma+polysporum+%28Link+ex+Pers.%29+Rifai%2C+with+a+remarkable+immunosuppressive+activity%5D&doi=10.1002%2Fhlca.19760590412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclosporin A, a peptide metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with immunosuppressive activity</span></div><div class="casAuthors">Ruegger, Arthur; Kuhn, Max; Lichti, Heinz; Loosli, Hans R.; Huguenin, Rene; Quiquerez, Charles; Von Wartburg, Albert</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1075-92</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    </div><div class="casAbstract">Cyclosporin A (I), the main component of T. polysporum Rifai known to possess immunosuppressive and antiinflammatory activity, was isolated from this organism and the amino acid structure of the cyclic peptide I was detd.  Some properties of the minor component cyclosporin C were also detd.  I contained 11 amino acids, as detd. by hydrolysis, including a new C9 amino acid.  The amino acid sequence of the iso-cyclosporin A, a basic rearrangement product formed from I by N,O-acyl migration, was detd., and some evidence for the configuration about the double bond of the new C9 amino acid [(2S,3R,4R)-2-methylamino-3-hydroxy-4-methyl-6-octenoic acid] is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9ZhJk4jT_abVg90H21EOLACvtfcHk0ljBOGoyjH_kpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28Xkt12ksro%253D&md5=a83026035f18d748aa3ca23b99aab69d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19760590412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19760590412%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25BCegger%26aufirst%3DA.%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DLichti%26aufirst%3DH.%26aulast%3DLoosli%26aufirst%3DH.%2BR.%26aulast%3DHuguenin%26aufirst%3DR.%26aulast%3DQuiquerez%26aufirst%3DC.%26aulast%3Dvon%2BWartburg%26aufirst%3DA.%26atitle%3D%255BCyclosporin%2520A%252C%2520a%2520Peptide%2520Metabolite%2520from%2520Trichoderma%2520polysporum%2520%2528Link%2520ex%2520Pers.%2529%2520Rifai%252C%2520with%2520a%2520remarkable%2520immunosuppressive%2520activity%255D%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1976%26volume%3D59%26spage%3D1075%26epage%3D1092%26doi%3D10.1002%2Fhlca.19760590412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagenbuch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, P. J.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1326</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1172/JCI117091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1172%2FJCI117091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=8132774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFKqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1994&pages=1326-1331&author=B.+Hagenbuchauthor=P.+J.+Meier&title=Molecular+cloning%2C+chromosomal+localization%2C+and+functional+characterization+of+a+human+liver+Na%2B%2Fbile+acid+cotransporter&doi=10.1172%2FJCI117091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter</span></div><div class="casAuthors">Hagenbuch, Bruno; Meier, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1326-31</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">A cDNA probe from a cloned rat liver Na+/taurocholate-cotransporting polypeptide (Ntcp) was used to screen a human liver cDNA library.  A 1599-bp cDNA clone that encodes a human Na+/taurocholate cotransporting polypeptide (NTCP) was isolated.  The human NTCP consists of 349 amino acids (calcd. mol. mass of 38 kDa) and exhibits 77% amino acid homol. with the rat Ntcp.  In vitro translation expts. indicate that the protein is glycosylated and has a mol. wt. similar to the rat Ntcp.  Injection of in vitro transcribed cRNA into Xenopus laevis oocytes resulted in the expression of Na+-dependent taurocholate uptake.  Satn. kinetics indicated that the human NTCP has a higher affinity for taurocholate (apparent Km = 6 μM) than the previously cloned rat protein (apparent Km = 25 μM).  NTCP-mediated taurocholate uptake into oocytes was inhibited by all major bile acid derivs. (100 μM), bumetanide (500 μM), and bromosulfophthalein (100 μM).  Southern blot anal. of genomic DNA from a panel of human/hamster somatic cell hybrids mapped the human NTCP gene to chromosome 14.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqmQsr-mlVh7Vg90H21EOLACvtfcHk0ljBOGoyjH_kpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFKqtLk%253D&md5=1e49aa2044dce90f56b3671d4cca53c4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1172%2FJCI117091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI117091%26sid%3Dliteratum%253Aachs%26aulast%3DHagenbuch%26aufirst%3DB.%26aulast%3DMeier%26aufirst%3DP.%2BJ.%26atitle%3DMolecular%2520cloning%252C%2520chromosomal%2520localization%252C%2520and%2520functional%2520characterization%2520of%2520a%2520human%2520liver%2520Na%252B%252Fbile%2520acid%2520cotransporter%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1994%26volume%3D93%26spage%3D1326%26epage%3D1331%26doi%3D10.1172%2FJCI117091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leake, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvetkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roden, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walubo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, G. R.</span></span> <span> </span><span class="NLM_article-title">Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">1204</span>– <span class="NLM_lpage">1209</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10565843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaK1MXnslyns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=1999&pages=1204-1209&author=R.+B.+Kimauthor=B.+Leakeauthor=M.+Cvetkovicauthor=M.+M.+Rodenauthor=J.+Nadeauauthor=A.+Waluboauthor=G.+R.+Wilkinson&title=Modulation+by+drugs+of+human+hepatic+sodium-dependent+bile+acid+transporter+%28sodium+taurocholate+cotransporting+polypeptide%29+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity</span></div><div class="casAuthors">Kim, Richard B.; Leake, Brenda; Cvetkovic, Mirjana; Roden, Mark M.; Nadeau, Jessica; Walubo, Andrew; Wilkinson, Grant R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1204-1209</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Adequate bile flow, maintained in part by the efficient enterohepatic recirculation of bile acids, is crit. for normal liver function.  One important component of this process is the uptake of bile acids from the portal circulation into hepatocytes by the bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP).  Thus, the expression and functional activity of this transporter may affect the rate of bile acid removal from the portal circulation.  Accordingly, we assessed NTCP mRNA expression from human livers using a sensitive RNase protection assay.  In addn., the ability of various bile acids and drugs to inhibit NTCP activity was detd. using a recombinant vaccinia expression system.  A 40-fold interindividual variability was found in NTCP mRNA levels detd. in eight liver samples of disease-free donors.  Expressed NTCP exhibited high-affinity, sodium-dependent uptake of taurocholate, and as expected, this was markedly inhibited by bile acids and org. anions.  A no. of drugs, including peptidomimetic renin inhibitors, propranolol, cyclosporin, and progesterone, were found to be potent inhibitors, whereas antiarrhythmic agents, including bupivacaine, lidocaine, and quinidine, were found to enhance NTCP activity.  Accordingly, these results indicate that large interindividual variability exists in NTCP mRNA level and that a no. of drugs currently in clin. use have the potential to interact with and alter NTCP activity, thereby affecting hepatic bile acid uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNsDZlZNuqb7Vg90H21EOLACvtfcHk0ljBOGoyjH_kpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnslyns7g%253D&md5=7e3f384ab1fe72b2bd2162c47fd7be42</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DLeake%26aufirst%3DB.%26aulast%3DCvetkovic%26aufirst%3DM.%26aulast%3DRoden%26aufirst%3DM.%2BM.%26aulast%3DNadeau%26aufirst%3DJ.%26aulast%3DWalubo%26aufirst%3DA.%26aulast%3DWilkinson%26aufirst%3DG.%2BR.%26atitle%3DModulation%2520by%2520drugs%2520of%2520human%2520hepatic%2520sodium-dependent%2520bile%2520acid%2520transporter%2520%2528sodium%2520taurocholate%2520cotransporting%2520polypeptide%2529%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D291%26spage%3D1204%26epage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span> <span> </span><span class="NLM_article-title">The role of the HBV envelope proteins in the HDV replication cycle</span>. In  <i>Current Topics in Microbiology and Immunology</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2006</span>; Vol.  <span class="NLM_volume">307</span>, pp  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">131</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=113-131&author=C.+Sureau&title=Current+Topics+in+Microbiology+and+Immunology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSureau%26aufirst%3DC.%26atitle%3DThe%2520role%2520of%2520the%2520HBV%2520envelope%2520proteins%2520in%2520the%2520HDV%2520replication%2520cycle%26btitle%3DCurrent%2520Topics%2520in%2520Microbiology%2520and%2520Immunology%26pub%3DSpringer%26date%3D2006%26volume%3D307%26spage%3D113%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e1004840</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1004840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1371%2Fjournal.ppat.1004840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=25902143" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&author=W.+Heauthor=B.+Renauthor=F.+Maoauthor=Z.+Jingauthor=Y.+Liauthor=Y.+Liuauthor=B.+Pengauthor=H.+Yanauthor=Y.+Qiauthor=Y.+Sunauthor=J.+T.+Guoauthor=J.+Suiauthor=F.+Wangauthor=W.+Li&title=Hepatitis+D+Virus+Infection+of+Mice+Expressing+Human+Sodium+Taurocholate+Co-transporting+Polypeptide&doi=10.1371%2Fjournal.ppat.1004840"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004840%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DHepatitis%2520D%2520Virus%2520Infection%2520of%2520Mice%2520Expressing%2520Human%2520Sodium%2520Taurocholate%2520Co-transporting%2520Polypeptide%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26doi%3D10.1371%2Fjournal.ppat.1004840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">8866</span>– <span class="NLM_lpage">8874</span>, <span class="refDoi"> DOI: 10.1128/JVI.00901-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1128%2FJVI.00901-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=27466423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWkt7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=8866-8874&author=W.+Heauthor=Z.+Caoauthor=F.+Maoauthor=B.+Renauthor=Y.+Liauthor=D.+Liauthor=H.+Liauthor=B.+Pengauthor=H.+Yanauthor=Y.+Qiauthor=Y.+Sunauthor=F.+Wangauthor=J.+Suiauthor=W.+Li&title=Modification+of+Three+Amino+Acids+in+Sodium+Taurocholate+Cotransporting+Polypeptide+Renders+Mice+Susceptible+to+Infection+with+Hepatitis+D+Virus+In+Vivo&doi=10.1128%2FJVI.00901-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of three amino acids in sodium taurocholate cotransporting polypeptide renders mice susceptible to infection with hepatitis d virus in vivo</span></div><div class="casAuthors">He, Wenhui; Cao, Zhiliang; Mao, Fengfeng; Ren, Bijie; Li, Yunfei; Li, Dan; Li, Huiyu; Peng, Bo; Yan, Huan; Qi, Yonghe; Sun, Yinyan; Wang, Fengchao; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8866-8874</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Sodium taurocholate cotransporting polypeptide (NTCP) was identified as a functional receptor for hepatitis D virus (HDV) and its helper hepatitis B virus (HBV).  In cultured cell lines, HDV infection through mouse NTCP is restricted by residues 84 to 87 of the receptor.  This study shows that mice with these three amino acids altered their corresponding human residues (H84R, T86K, and S87N) in endogenous mouse NTCP support de novo HDV infection in vivo.  HDV infection was documented by the presence of replicative forms of HDV RNA and HDV proteins in liver cells at day 6 after viral inoculation.  Monoclonal antibody specifically binding to the motif centered on K86 in NTCP partially inhibited HDV infection.  These studies demonstrated specific interaction between the receptor and the viral envelopes in vivo and established a novel mouse model with minimal genetic manipulation for studying HDV infection.  The model will also be useful for evaluating entry inhibitors against HDV and its helper HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdRCyblqT1HrVg90H21EOLACvtfcHk0li7A5nQfa-MTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWkt7zE&md5=a465c633d4933e7be3979253bceb8d12</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FJVI.00901-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00901-16%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DW.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DRen%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DModification%2520of%2520Three%2520Amino%2520Acids%2520in%2520Sodium%2520Taurocholate%2520Cotransporting%2520Polypeptide%2520Renders%2520Mice%2520Susceptible%2520to%2520Infection%2520with%2520Hepatitis%2520D%2520Virus%2520In%2520Vivo%26jtitle%3DJ.%2520Virol.%26date%3D2016%26volume%3D90%26spage%3D8866%26epage%3D8874%26doi%3D10.1128%2FJVI.00901-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Morais, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2004.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.cbi.2004.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15535988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2004&pages=179-187&author=S.+D.+Campbellauthor=S.+M.+de+Moraisauthor=J.+J.+Xu&title=Inhibition+of+human+organic+anion+transporting+polypeptide+OATP+1B1+as+a+mechanism+of+drug-induced+hyperbilirubinemia&doi=10.1016%2Fj.cbi.2004.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia</span></div><div class="casAuthors">Campbell, Scott D.; de Morais, Sonia M.; Xu, Jinghai J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-187</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">OATP1B1 (a.k.a. OATP-C, OATP2, LST-1, or SLC21A6) is a liver-specific org. anion uptake transporter and has been shown to be a higher affinity bilirubin uptake transporter than OATP1B3.  Using human embryonic kidney (HEK 293) cells stably transfected with OATP1B1, we have studied the effects of indinavir, saquinavir, cyclosporin A, and rifamycin SV on human OATP1B1 transport function.  These drugs are potent inhibitors of OATP1B1 transport activity in vitro.  We further provide evidence that the calcd. fraction of OATP1B1 inhibited at the clin. exposure level correlated very well with the obsd. hyperbilirubinemia outcome for these drugs in humans.  Our data support the hypothesis that inhibition of OATP1B1 is an important mechanism for drug-induced unconjugated hyperbilirubinemia.  Inhibition of OATPs may be an important mechanism in drug-drug and drug-endogenous substance interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE5V-CJDYQ9LVg90H21EOLACvtfcHk0li7A5nQfa-MTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKnsb4%253D&md5=de2b3edf235c967aba77a5e94d0679dc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2004.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2004.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DS.%2BD.%26aulast%3Dde%2BMorais%26aufirst%3DS.%2BM.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26atitle%3DInhibition%2520of%2520human%2520organic%2520anion%2520transporting%2520polypeptide%2520OATP%25201B1%2520as%2520a%2520mechanism%2520of%2520drug-induced%2520hyperbilirubinemia%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2004%26volume%3D150%26spage%3D179%26epage%3D187%26doi%3D10.1016%2Fj.cbi.2004.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.041921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1124%2Fjpet.102.041921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=12538813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2003&pages=610-616&author=Y.+Shitaraauthor=T.+Itohauthor=H.+Satoauthor=A.+P.+Liauthor=Y.+Sugiyama&title=Inhibition+of+transporter-mediated+hepatic+uptake+as+a+mechanism+for+drug-drug+interaction+between+cerivastatin+and+cyclosporin+A&doi=10.1124%2Fjpet.102.041921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A</span></div><div class="casAuthors">Shitara, Yoshihisa; Itoh, Tomoo; Sato, Hitoshi; Li, Albert P.; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">610-616</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The mechanism involved in the clin. relevant drug-drug interaction (DDI) between cerivastatin (CER) and cyclosporin A (CsA) has not yet been clarified.  In the present study, we examd. the possible roles of transporter-mediated hepatic uptake in this DDI.  The uptake of [14C]CER into human hepatocytes prepd. from three different donors was examd.  Kinetic analyses revealed Km values for the uptake of [14C]CER within the range of 3 to 18 μM, suggesting that more than 70% of the total uptake at therapeutic CER concns. was accounted for by a saturable process, i.e., transporter-mediated uptake.  This uptake was inhibited by CsA with Ki values of 0.3 to 0.7 μM.  The uptake of [14C]CER was also examd. in human org. anion transporting polypeptide-2 (OATP2)-expressing Madin-Darby canine kidney cells (MDCKII).  Saturable OATP2-mediated uptake of [14C]CER was obsd. and was also inhibited by CsA, with a Ki value of 0.2 μM.  These results suggest that the DDI between CER and CsA involves the inhibition of transporter-mediated uptake of CER and, at least in part, its OATP2-mediated uptake.  The effect of CsA on the in vitro metab. of [14C]CER was also examd.  The metab. of [14C]CER was inhibited by CsA with an IC50 value of more than 30 μM.  From these results, we conclude that the DDI between CER and CsA is mainly due to the inhibition of transporter (at least partly OATP2)-mediated uptake in the liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi5U1KGJaCCbVg90H21EOLACvtfcHk0li7A5nQfa-MTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVCguw%253D%253D&md5=36a4960df1b5b369b52fe9d00226c317</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.041921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.041921%26sid%3Dliteratum%253Aachs%26aulast%3DShitara%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DA.%2BP.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DInhibition%2520of%2520transporter-mediated%2520hepatic%2520uptake%2520as%2520a%2520mechanism%2520for%2520drug-drug%2520interaction%2520between%2520cerivastatin%2520and%2520cyclosporin%2520A%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D304%26spage%3D610%26epage%3D616%26doi%3D10.1124%2Fjpet.102.041921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarcho, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windass, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneck, D. W.</span></span> <span> </span><span class="NLM_article-title">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2004.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2Fj.clpt.2004.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=15289793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Ogu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=167-177&author=S.+G.+Simonsonauthor=A.+Razaauthor=P.+D.+Martinauthor=P.+D.+Mitchellauthor=J.+A.+Jarchoauthor=C.+D.+Brownauthor=A.+S.+Windassauthor=D.+W.+Schneck&title=Rosuvastatin+pharmacokinetics+in+heart+transplant+recipients+administered+an+antirejection+regimen+including+cyclosporine&doi=10.1016%2Fj.clpt.2004.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine</span></div><div class="casAuthors">Simonson, Steven G.; Raza, Ali; Martin, Paul D.; Mitchell, Patrick D.; Jarcho, John A.; Brown, Colin D. A.; Windass, Amy S.; Schneck, Dennis W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-177</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Cyclosporine (INN, ciclosporin) increases the systemic exposure of all statins.  Therefore rosuvastatin pharmacokinetic parameters were assessed in an open-label trial involving stable heart transplant recipients (≥6 mo after transplant) on an antirejection regimen including cyclosporine.  Rosuvastatin has been shown to be a substrate for the human liver transporter org. anion transporting polypeptide C (OATP-C).  Inhibition of this transporter could increase plasma concns. of rosuvastatin.  Therefore the effect of cyclosporine on rosuvastatin uptake by cells expressing OATP-C was also examd.  Methods: Ten subjects were assessed while taking 10 mg rosuvastatin for 10 days; 5 of these were then assessed while taking 20 mg rosuvastatin for 10 days.  Rosuvastatin steady-state area under the plasma concn.-time curve from time 0 to 24 h [AUC(0-24)] and max. obsd. plasma concn. (Cmax) were compared with values in controls (historical data from 21 healthy volunteers taking 10 mg rosuvastatin).  Rosuvastatin uptake by OATP-C-transfected Xenopus oocytes was also studied by use of radiolabeled rosuvastatin with and without cyclosporine.  Results: In transplant recipients taking 10 mg rosuvastatin, geometric mean values and percent coeff. of variation for steady-state AUC(0-24) and Cmax were 284 ng · h/mL (31.3%) and 48.7 ng/mL (47.2%), resp.  In controls, these values were 40.1 ng · h/mL (39.4%) and 4.58 ng/mL (46.9%), resp.  Compared with control values, AUC(0-24) and Cmax were increased 7.1-fold and 10.6-fold, resp., in transplant recipients.  In transplant recipients taking 20 mg rosuvastatin, these parameters increased less than dose-proportionally.  Rosuvastatin had no effect on cyclosporine blood concns.  The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (assocn. const., 8.5 ± 1.1 μmol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition const., 2.2 ± 0.4 μmol/L when the rosuvastatin concn. was 5 μmol/L).  Conclusions: Rosuvastatin exposure was significantly increased in transplant recipients on an antirejection regimen including cyclosporine.  Cyclosporine inhibition of OATP-C-mediated rosuvastatin hepatic uptake may be the mechanism of the drug-drug interaction.  Coadministration of rosuvastatin with cyclosporine needs to be undertaken with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqigXZ0UMAaibVg90H21EOLACvtfcHk0ljKsZ9tjwnjEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Ogu78%253D&md5=9da8626f6ed97a135c4e13ce9d02e9ad</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2004.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2004.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DSimonson%26aufirst%3DS.%2BG.%26aulast%3DRaza%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DP.%2BD.%26aulast%3DMitchell%26aufirst%3DP.%2BD.%26aulast%3DJarcho%26aufirst%3DJ.%2BA.%26aulast%3DBrown%26aufirst%3DC.%2BD.%26aulast%3DWindass%26aufirst%3DA.%2BS.%26aulast%3DSchneck%26aufirst%3DD.%2BW.%26atitle%3DRosuvastatin%2520pharmacokinetics%2520in%2520heart%2520transplant%2520recipients%2520administered%2520an%2520antirejection%2520regimen%2520including%2520cyclosporine%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D76%26spage%3D167%26epage%3D177%26doi%3D10.1016%2Fj.clpt.2004.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulcher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span> <span> </span><span class="NLM_article-title">Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory</span>. <i>Immunol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1046/j.1440-1711.1999.00870.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1046%2Fj.1440-1711.1999.00870.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10571678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhsVCgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1999&pages=559-564&author=D.+Fulcherauthor=S.+Wong&title=Carboxyfluorescein+succinimidyl+ester-based+proliferative+assays+for+assessment+of+T+cell+function+in+the+diagnostic+laboratory&doi=10.1046%2Fj.1440-1711.1999.00870.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory</span></div><div class="casAuthors">Fulcher, D. A.; Wong, S. W. J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology and Cell Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">559-564</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Immune deficiency diseases are often accompanied by abnormalities in one or both arms of the specific immune system.  Impairment can often be detected as a decrease in the no. of T or B lymphocytes or their products in the circulation, but questions are often asked as to the functional capabilities of T lymphocytes in patients with recurrent infections.  Function of T cells has traditionally been measured by their uptake of [3H]-thymidine following stimulation with antigen or mitogen in vitro.  However, the ability of carboxyfluorescein succinimidyl ester (CFSE) to label lymphocytes intracellularly and track their mitotic activity by progressive two-fold redn. in fluorescence intensity prompted an alternative methodol. based on flow cytometry, an approach which has the advantage of allowing specific gating on particular T cell subsets and simultaneous assessment of activation markers.  This method was therefore evaluated for T cell responses to mitogen and antigen.  Phytohemagglutinin-induced blast transformation of CFSE-labeled T cells was reflected by an increase in forward and orthogonal light scatter and a progressive two-fold decrease in CFSE fluorescence intensity.  These changes allowed the derivation of various measures of mitotic activity, which correlated well with [3H]-thymidine uptake.  Patients with T cell functional deficiencies showed impairment in their responses by both assays, whereas the CFSE-based assay demonstrated that impaired blastogenesis was not simply due to depressed T cell nos.  Concomitant measurement of the activation markers CD69 and CD25 showed that CD69 was rapidly expressed on non-mitotic cells and that this expression was progressively dild. with subsequent rounds of cell division.  In contrast, CD25 expression was unaffected by cell cycle, but was expressed in proportion to the PHA dose.  Antigen-specific responsiveness to Candida was also assessed using a CFSE-based assay.  Initial gating on the relatively minor population of T cells that underwent blast transformation demonstrated progressive twofold dilns. of CFSE intensity in responsive cells.  These normal Candida responses, found in patients who had recovered from Candida infection, contrasted with those who had not been infected with Candida or who had chronic recurrent infection, in whom neither blast transformation nor significant mitosis could be detected.  Again, there was good correlation with [3H]-thymidine uptake.  The CFSE-based assays are equiv. to traditional measures of mitogen- and antigen-specific T cell responsiveness in the diagnostic lab. and have significant advantages in terms of decreased labour intensiveness, avoidance of radioactivity, the ability to gate on a specific population of lymphocytes and the concomitant measurement of activation markers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppDhcdtAHXHLVg90H21EOLACvtfcHk0ljKsZ9tjwnjEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhsVCgtw%253D%253D&md5=731619a7c5bf8b5a5f6b9e153fa9b9eb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1046%2Fj.1440-1711.1999.00870.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1440-1711.1999.00870.x%26sid%3Dliteratum%253Aachs%26aulast%3DFulcher%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DS.%26atitle%3DCarboxyfluorescein%2520succinimidyl%2520ester-based%2520proliferative%2520assays%2520for%2520assessment%2520of%2520T%2520cell%2520function%2520in%2520the%2520diagnostic%2520laboratory%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D1999%26volume%3D77%26spage%3D559%26epage%3D564%26doi%3D10.1046%2Fj.1440-1711.1999.00870.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clipstone, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentino, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span> <span> </span><span class="NLM_article-title">Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">26431</span>– <span class="NLM_lpage">26437</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=10.1016%2FS0021-9258%2818%2947212-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=7523407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;key=1%3ACAS%3A528%3ADyaK2cXmt1Wgurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=26431-26437&author=N.+A.+Clipstoneauthor=D.+F.+Fiorentinoauthor=G.+R.+Crabtree&title=Molecular+analysis+of+the+interaction+of+calcineurin+with+drug-immunophilin+complexes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes</span></div><div class="casAuthors">Clipstone, Neil A.; Fiorentino, David F.; Crabtree, Gerald R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">26431-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The calcium/calmodulin-regulated phosphatase calcineurin (CN) is the site of action of the immunosuppressive drugs cyclosporin A (CsA) and FK506.  CN has recently been established as a key signaling enzyme in the T cell signal transduction cascade and an important regulator of transcription factors such as NF-AT and OAP/Oct-1, which are involved in the expression of a no. of important T cell early genes.  CsA and FK506 act by forming complexes with their resp. intracellular receptors cyclophilin and FKBP (immunophilins), which can then bind to CN, inhibiting its enzymic activity and thereby preventing early gene expression.  CN is comprised of two subunits: a 59-kDa catalytic subunit (CNA), which contains a calmodulin binding domain and autoinhibitory region, and a 19-kDa intrinsic calcium binding regulatory subunit (CNB).  In this study, the authors have utilized a series of deletion mutants of the CNA subunit to investigate the subunit and mol. requirements that govern the interaction of CN with drug-immunophilin complexes.  The calmodulin binding and autoinhibitory domains of the CNA subunit were dispensable for the binding to CN to drug-immunophilin complexes.  In contrast, the authors found that the regulatory CNB subunit appears to play an obligatory role in this interaction and have defined an amino acid sequence of the CNA subunit which forms the binding site for CNB.  Although necessary, the CNB subunit per se is not sufficient to mediate an interaction with drug-immunophilin complexes; amino acid residues of the the CNA subunit, specifically a region located within the putative catalytic domain, are also required for the interaction of CN with both FKBP·FK506 and cyclophilin A·CsA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0S9tu36BQBbVg90H21EOLACvtfcHk0ljKsZ9tjwnjEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmt1Wgurc%253D&md5=371ff859936ccfc9176428443b9ab7c5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2947212-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252947212-2%26sid%3Dliteratum%253Aachs%26aulast%3DClipstone%26aufirst%3DN.%2BA.%26aulast%3DFiorentino%26aufirst%3DD.%2BF.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26atitle%3DMolecular%2520analysis%2520of%2520the%2520interaction%2520of%2520calcineurin%2520with%2520drug-immunophilin%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D26431%26epage%3D26437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01484">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_53654"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01484?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01484</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Concentration in plasma of preliminary pharmacokinetics experiment (PO) data of the selected compounds; plasma protein binding study of the compound <b>27A</b>; 2D-NMR analysis of <b>27A</b> and <b>27B</b>; inhibition of HBV infection by <b>27A</b> and <b>27B</b> on primary human hepatocytes (PHH); fluorescence intensity analysis of <a id="rightTab-" class=" internalNav" href="#fig4">Figure <a id="rightTab-" class=" internalNav" href="#fig4">4</a></a>B,C; treatment of C57B/L mice by <b>27A</b> of indicated dosage (<i>n</i> = 5 for each group) for 14 days; inhibition of HBV virus infection of HepG2-NTCP cells by 27A and Alisporivir; synthesis of mercapto heterocyclic and aromatic intermediates (1–28); and <sup>1</sup>H and <sup>13</sup>C NMR spectra of compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_001.pdf">jm0c01484_si_001.pdf (3.67 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01484/suppl_file/jm0c01484_si_002.csv">jm0c01484_si_002.csv (14.43 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01484&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01484%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01484" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998168292e2308","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
